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Older people are at an increased risk of experiencing medication related harm (MRH), but it is not 
clear which older people are at greatest risk.  Multivariable risk prediction models target 
interventions at patients stratified by their risk of developing a specific outcome over time.  An 
MRH risk prediction model could prioritise care for high-risk older patients at the point of discharge 
- a time of heightened patient vulnerability.  The overall aim of this thesis was to examine the 
possibility of identifying older patients at risk of MRH following discharge from hospital.   
To achieve this, three distinct studies were conducted; Study 1 was a systematic review of MRH 
risk prediction models which informed the development of a conceptual framework and the design 
of Study 2.  Study 2 involved conducting a prospective cohort study to determine the incidence, 
and describe the characteristics, of MRH in an older population discharged from a United 
Kingdom (UK) teaching hospital.  Patients discharged from acute care were recruited and followed 
up for 8 weeks.  A review of any re-admission, General Practice (GP) notes, and a patient 
telephone interview were used to determine if MRH had occurred.  Likelihood, preventability, 
severity and the medicine(s) involved were determined.  MRH was defined as harm from 
medicines due to an adverse drug reaction or failure to receive a medicine (including non-
adherence).  Study 3 identified variables associated with MRH focussing on physiological and 
psychosocial domains.  
Following an extensive literature search of over 13,000 articles, Study 1 identified only five risk 
prediction models of modest quality, all focussing on adverse drug reactions (ADRs), mainly 
drawing on physiological variables to predict medication harm and none related to the post-
discharge period.  Four had undertaken some validation but displayed only modest performance 
(Area Under Receiver Operator Curve (AUROC) 0.62-0.73), rendering them unsuitable for routine 
clinical use.  This systematic review and a review of the wider literature around MRH led to the 
design of a conceptual framework, drawing together physiological and psychosocial variables and 
highlighting commonalities between MRH and frailty to build a theoretical model of the factors 
involved in medication harm.  
The prospective cohort study recruited 396 patients during their in-patient stay in the older 
persons’ unit, (mean age 83±7 years, Charlson comorbidity index (CCI) 2.16±1.63, mean Barthel 
index 13.24±4.56, 55% received a package of care) and highlighted that two in five frail patients 
experienced MRH, 88% of which required treatment modification and more than half were 
preventable. Approximately a third required re-admission. Non-adherence contributed to 
approximately one third of the MRH incidents. Medicines acting on the central nervous system 
were responsible for the majority of MRH (25%).   
Physiological and psychosocial variables were associated with MRH at a univariate level: number 
of medicines (odds ratio (OR) 1.10 [95% confidence interval (CI) 1.05-1.16, p<0.0001]), 
antithrombotics (OR 1.71 [95%CI 1.12-2.60, p0.01]), antihypertensives (OR 1.55 [95%CI 1.03-
2.33, p0.04]), MUST score (OR 1.92 [95%CI 1.12-3.29, p0.02]), and hand grip strength (men) 
(OR 0.93 [95%CI 0.89-0.98]).   
A higher than expected re-admission rate was reported; 156 patients (39%) were re-admitted, 67 
with MRH. Sub-analysis revealed a mean time to event of 48.9 days (95% CI 47.3-50.6) and when 
compared to those not re-admitted, identified additional variables associated with MRH: use of a 
multi-compartment compliance aid (MCA) (chi square 9.76, p 0.002), CCI (hazard ratio (HR) 1.14 
[95% CI 1.01-1.29, p0.03]) and depression (HR 1.04 [95% CI 1.01-1.08, p0.02]). Number of 
medicines was also significant (HR 1.10 [95% CI 1.05-1.15, p<0.01]) and was the only variable 
to retain significance upon multivariate analysis.  There was little difference between patients re-
admitted with MRH and patients re-admitted without MRH with only number of medicines reaching 
statistical significance (OR 1.08 [95% CI 1.01-1.17, p0.04]).  All re-admitted patients were frail. 
The heterogeneity of an older population, due to advancing age and frailty, makes the 
identification of a small number of highly predictive variables challenging and may limit the 
usefulness of pursing the traditional path of risk prediction modelling.  The study population were 
frail and given the high prevalence of low reserve, the significance of the number of medicines 
may represent both a greater illness burden, and increased likelihood of exposure to potential 
medicine related insult thus an increased risk of MRH.  This study suggests that MRH is similar 
to geriatric syndromes; it is multifactorial, occurs when there is an accumulation of deficits across 
multiple systems, and renders the patient vulnerable to situational challenges.  In light of this, 
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energies may be better expended exploring the clinical utility of a frailty index to stratify the risk 
of MRH in this complex population.  
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Chapter 1 Introduction  
“Res eadem vulnus opemque feret”.1  The same medicine will both harm and cure me.  This 
paradoxical outcome of taking medicines has long been recognised, and while the severity of 
such harm may vary, it is responsible for a significant proportion of hospital admissions in older 
adults.2  In a globally ageing population, as the prevalence of multimorbidity increases and the 
number of prescribed medicines grows it is essential that we investigate this risk, with the aim of 
identifying patients most likely to suffer harm from their medicines.  Cases can then be prioritised, 
and interventions targeted to reduce the burden of medication related harm (MRH) for both 
patients and the healthcare system. 
 
1.1 Definitions and terminology 
When conducting research in the area of MRH it is necessary to consider the different definitions 
and terminology used.  Described as a Tower of Babel of terminology3, a multitude of terms have 
emerged, many with overlapping yet conflicting jurisdictions.  It is therefore important to 
understand the meaning of these terms to allow accurate comparison of the literature. 
 
1.1.1 Drug related problems 
Drug (or medication) related problem (DRP) is perhaps the broadest of terms and is often used 
interchangeably with adverse drug events (ADEs).  Defined by one group as “a circumstance 
related to the patient’s use of a drug that actually or potentially prevents the patient from gaining 
the intended benefit of the drug”, there are at least 14 different classification systems.4  These 
systems focus on: drug choice problems (errors, substitutions, discontinuations/omissions, use of 
unnecessary drugs); dosing problems (dose changes, cancellations, omissions); drug use 
problems (lack of knowledge, lack of understanding, non-adherence); interactions and adverse 
drug reactions.5  For example, the Swedish-developed Westerlund System4, which 
accommodates over-the-counter (OTC) and herbal medicines, consists of the following 13 
categories: 1. uncertainty about the aim of the drug; 2. drug duplication; 3. interaction; 4. 
contraindication; 5. therapy failure; 6. adverse reaction; 7. underuse of drug; 8. overuse of drug; 
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9. inappropriate time for drug intake/wrong dosage interval; 10. problem administering drug; 11. 
difficulty opening container; 12. inappropriate storage of drug and 13. other. 
 
1.1.2 Adverse drug events 
ADEs are commonly defined as “an injury resulting from medical intervention relating to the 
drug”6.  This includes harm caused by the drug (adverse drug reactions and overdoses) and harm 
from the use of the drug (including dose reductions and discontinuation of drug therapy).  This 
term is often applied in the literature when reductions or discontinuations are deemed 
inappropriate, and so ADE has become closely associated with medication errors.7 
 
1.1.3 Adverse drug reactions 
Frequently, and incorrectly, ADE and ADR are used synonymously.  ADR, as defined by the World 
Health Organisation (WHO) refers to “a response to a drug that is noxious and unintended and 
occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease or for 
modification of physiological functions”.8  This was later refined by Edward and Aronson to 
improve its utility in clinical practice through the inclusion of medication error.  They defined an 
ADR as “an appreciably harmful or unpleasant reaction, resulting from an intervention related to 
the use of a medicinal product, which predicts hazard from future administration and warrants 
prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the 
product”9.  According to this definition all ADRs are considered to be ADEs and some of these 
will be due to a medication error.   
 
1.1.4 Medication error 
Medication errors are described as “preventable events that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of the healthcare 
professional, patient or consumer”.7  They can occur during any stage of the medication journey 
including compounding, prescribing, dispensing or administration.  Medication errors do not harm 




Nebeker and colleagues7 provide a useful diagrammatic summary of the terminology used to 
describe different types of harm from medicines, and the relationship between them (see Figure 
1.1).   
 
Figure 1.1 Relationship between the types of harm from medicines (adapted from Nebeker et al.7) 
 
1.1.5 Medication related harm 
This thesis defines and uses the term medication related harm (MRH) as an umbrella term when 
referring to harm from medicines in general and as the specific outcome measure used in the 
prospective cohort study described in Chapter 4.  Agreed by an international, multidisciplinary 
expert panel, MRH incorporates ADRs and failure to receive medicines (including due to failure 
in the supply chain and non-adherence).  This term was derived to more accurately reflect the 
challenges presented to older adults when prescribed medicines, and was measurable given the 
resources available.  Its derivation is described in more detail in Chapter 4.  Importantly, it does 
not relate to medication errors which account for a very small proportion of harm10 and has its 
own body of literature.  
 
1.2 The size of the problem 
There is great variation in the reported incidence and prevalence of MRH, much of which may be 
attributed to the outcome measured (usually either an adverse drug event (ADE) or an adverse 
drug reaction (ADR)), the setting (inpatient or community) and the population studied (often all 




In a recent review of observational studies from across Europe, 16 papers reporting the rate of 
adult inpatient ADR (including ADEs and DRPs) were identified.11  Three focussed specifically on 
older adults.  A median ADR rate of 11.9% (range1.7-81.3%) was reported for the 13 studies that 
were not restricted by age.  The study with the highest incidence was conducted in Norway across 
5 different centres over a 6-month period and recruited 827 patients from internal medicine and 
rheumatology departments who were assessed for DRPs through intensive chart review.  The 
high incidence reported is likely to reflect the broad outcome measure of DRP which included 
“need for laboratory test” and “therapy discussions”.  DRPs related to ADRs were experienced in 
7.8% of patients which may be a more valuable comparator and is consistent with several other 
European studies which measured ADRs specifically.12–14  All three studies focussing on older 
adults measured ADR as defined by the WHO8, the incidence of which ranged from 11.5-
60.7%.15–17  Two further studies in patients over the age of 65 years, which weren’t included in 
the review as the data were collected or the paper was published outwith the defined time period, 
reported ADR rates of 6.5%18 and 12.5%19.  This large variation in incidence in studies using the 
same outcome measure is possibly due to different methods of identification of ADR and 
differences in the populations studied.   
   
1.2.2 Community 
Few studies have explored the prevalence of MRH occurring in the community.  Only two, in 
patients over the age of 18 years, were identified in a review of the European literature which 
focused on studies published since January 2000.11  Investigating ADEs in Swedish adults, these 
were two large population-based studies, conducted by the same research group in Sweden.  
ADEs were identified via self-reporting in one study and through review of patient medical records 
in the other.  The reported ADE rate was 19.4% (95% CI 18.5-20.3%) and 12.0% (95% CI 11.1-
12.9%) respectively.20,21  The lower prevalence reported via medical record review is consistent 
with previous studies.22  The population differences may explain some of this variance, for 
example, the self-reporting population were older, mean age 53.2±18.2 years compared to 
48.9±19.0 years for the medical records review population, however the outcome data source will 
have also influenced the prevalence. 
24 
 
1.2.2.1 Post-discharge  
A sub-set of the community-based literature are those studies which investigate post-discharge 
MRH.  Representing a discrete population, these studies explore MRH in patients during a time 
of heightened vulnerability following admission to hospital.23   
A review of articles reporting DRPs in patients over the age of 60 years old discharged from 
hospital and interventions to reduce them, published between January 1998 and December 2009, 
identified 23 papers meeting the inclusion criteria.  Fourteen were cross-sectional or cohort 
studies reporting the prevalence and incidence of DRPs, and nine were quasi-experimental or 
clinical trials reporting the outcomes of an intervention.  The majority were conducted in the United 
States (US); one was conducted in the United Kingdom, however only data relating to the 
intervention was reported.  The review authors concluded that differences in study design, 
outcome measures and patient populations limits comparisons and results in a wide-ranging 
prevalence (14-46%).24  The quality of the studies was also questioned with over half (56.5%) 
subject to selection bias due to a small sample size (the number of participants ranged from 68-
808).  The highest quality studies were clinical trials and cohort studies, which met 82% and 70% 
of the quality criteria respectively.  The clinical trials focussed on post-discharge interventions and 
did not report the incidence of DRPs, and only two of the cohort studies reported the incidence of 
DRPs and are summarised in Table 1.125,26.  The other two cohort studies reported the incidence 
of non-adherence (30.6% of patients were under-adherent and 18.4% were over-adherent during 
the two weeks following discharge)27, and the incidence of medicine modifications in the month 
after discharge (37.5±25.4%)28.  Additional studies regarding post-discharge MRH that were not 
included in the review, because they did not meet the inclusion criteria or were published after 
the review period, are also described in Table 1.1.     
25 
 















Ellitt,  201029 
(Australia) 
GP practices  
(36 months) 
Retrospective cohort. Patients 
discharged home from Cardiology 
unit with at least one cardiac drug 
and had a HMR on GP system.  





NR Blinded research 








about indication 32%; 
potential interaction 









Prospective cohort. Patients 
discharged from medical or surgical 
wards following 48-hour minimum 
stay with at least 2 of 10 frailty 
criteria 
> 65 years 
Mean age: NR 
46.4% >75 years 
(n=808) 
 
1 year Blinded geriatrician and 
geropharmacist pairs 
using Naranjo algorithm 
ADR 33% (1.92 events per 
1000 person-days 
follow up) 






Prospective cohort. Patients 
discharged home from medical 
wards.  Consent via telephone 2 
weeks after discharge. Electronic 
medical records review and patient 
telephone survey 
Not specified 
Mean age: 57 
years 
(n=400) 
2 weeks (up to 
5 weeks) 
2 hospital doctors.  No 
standardised assessment 
used 
ADE n=45 (11%) 
• 27% preventable 


























Prospective cohort.  All hospital 
referrals from primary care who had 
a follow up with the referring GP 
within 30 days of discharge.  GP 
reported suspected ADR 
Not specified 




follow up visits) 
30 days Consulting GP, reviewed 
by study GP and hospital 
doctor, classified by 
representative of local 
drug monitoring centre 







admission of a 
pre-admission 
drug 
n=29 (1.3% of 30- 
day follow up; 0.4% 
of all admissions) 
• 59% preventable  
• 20% ADR re-
admission 




Prospective cohort. Patients 
discharged from hospital and 
receiving home health care 
≥ 65 years 
Mean age: 80.0± 
7.3 years 
(n=256) 









A sub-section of the literature relating to post-discharge MRH focuses on re-admissions due to 
MRH.14,32,33  Hauviller and colleagues’33 study, conducted in an older population, was a 
retrospective case note review of patients over the age of 65 years old diagnosed with an ADR 
on their “index” admission to a Parisian teaching hospital and re-admitted with an ADR during the 
one year follow up.  ADRs were initially identified using International Classification of Disease 10th 
revision (ICD-10) codes and confirmed through a review of the medical notes.  The reported rate 
of ADR related re-admission was 8.7%.  
Overall, few studies have investigated post-discharge MRH, none in older adults in the UK.  The 
incidence of post-discharge MRH varies significantly from 1.3-93% and is largely dependent upon 
the definition of MRH used and the method used to identify harm.  
 
1.2.3 Hospitalisation 
The exact prevalence of medication related hospitalisation varies (from 0.1-54%) due to 
significant heterogeneity in study design, as outlined by Leendertse and colleagues in a literature 
review of hospitalisation secondary to medication related harm.34  Whilst acknowledging this 
variability, a review of the literature over the past 45 years (summarised in Table 1.2) and recent 
analysis of Hospital Episodes Statistics (HES) data35 would suggest that the prevalence of ADR 
related hospitalisation has not improved, and is approximately 5%.  Recent studies from the UK 
suggest higher rates of 6.5% and 8.8%.2,36
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Table 1.2 Summary of selected literature describing the prevalence of hospitalisation secondary to ADRs 
Study (year) Aim Databases 
searched 
Exclusion criteria ADR definition No. of studies, 
setting, location 



















IPA, Web of 
Science 
(up to Sept 
2010) 
• Non-English language 
• Not original research 




• Paediatrics or ICU focus 
• Only life-threatening/fatal 
ADRs 
• ADR reported exclusively 
via spontaneous reporting 
or diagnostic codes 
• No assessment or recording 
of preventable ADR or 
preventability 
• Studies where Type A 
ADRs presumed 
preventable 
WHO or Edward & 
Aronson (deviation from 
exact wording accepted 
as long as functional 
meaning maintained) 
n=22 (14 outpatients, 6 
inpatients, 2 both) 
• Europe (12) 
• USA and Canada (4)  
• Iran (3) 
• Australia (2) 
• India (1) 
All admissions 
• n=48797 emergency 
visits/hospitalisations 
• 2% PADRs (95% CI 1.2-3.2%) 





Table 1.2 cont. Summary of selected literature describing the prevalence of hospitalisation secondary to ADRs 
Study (year) Aim Databases 
searched 
Exclusion criteria ADR definition No. of studies, 
setting, location 















(up to Aug 
2007) 
• Specific conditions or 
specific type of ADR 
investigated 
• Retrospective design 
• Insufficient data for 
evaluation of ADR incidence 
• Non-standard ADR definition 
WHO or definition 
mapped directly to WHO 
n=25 
• Europe (17) 
• Asia (3) 
• Australia (2) 
• USA (2) 
• South America (1) 
All admissions 
• n=106586  
• 2143 associated with ADRs 
• Median 5.3% (IQR 2.7-9.0%) 
• Range 0.16-15.7% 
 
All adults (excluding <16 years old) 
• 620/11477 (median 6.3% [IQR 3.9-
9.0%]) admissions associated with 
ADRs 
 
Over 60 years 
• 201/2029 (median 10.7% [IQR 9.6-






Table 1.2 cont. Summary of selected literature describing the prevalence of hospitalisation secondary to ADRs 
Study (year) Aim Databases 
searched 
Exclusion criteria ADR definition No. of studies, 
setting, location 













(up to Apr 
2001) 
 
• Illicit drug use, drug/alcohol 
abuse 
• DRPs during admission 
WHO n=68 
• Australia (15) 
• Croatia (1) 
• Denmark (4) 
• France (3) 
• Iran (1) 
• Israel (3) 
• Italy (2) 
• Lebanon (1) 
• S. Africa (1) 
• Spain (3) 
• Sweden (1) 
• Switzerland (1) 
• Taiwan (1) 
• USA (25) 
• Canada (2) 
• Netherlands (2) 
• UK (2) 
All admissions 
• n=123794 admission  
• 6071 associated with ADRs 
• Mean 4.9±0.1% 
• Range 0.2-41.3% 
 
Adults <65 years old  
• 4082/116241 (mean 4.1± 0.1% [95% 
CI 0.2-35.1%]) admissions 
associated with ADRs 
 
Adults >65 years old  
• 1251/7553 (mean 16.6±0.8% [95% 
CI 6.6-41.3%]) admissions 
associated with ADRs 
 
>65 years v <65 years significant when 





Table 1.2 cont. Summary of selected literature describing the prevalence of hospitalisation secondary to ADRs 
Study (year) Aim Databases 
searched 
Exclusion criteria ADR definition No. of studies, 
setting, location 




















Events caused by 
administration errors, non-
compliance, overdose, drug 
abuse, therapeutic failure, 
deliberate or accidental self-
harm with drugs 
WHO n=69 
• North America (29) 
• Europe (31) 
• Australia/NZ (7) 
• Middle East (3) 
• Far East (3) 
• South Africa (1) 
• India (1) 
 
All causing and during admission  
• n=412909 patients 
• 6072 associated with ADRs 
• Mean 6.7% (95% CI 6.6-6.8) 
 
ADRs causing admission only  
• 133471 admissions 





















• Specific conditions or 
type/drug exposure 
• Insufficient data to evaluate 
ADR incidence 
• Possible ADRs (defined by 
Karch and Lasagna) 
• Non-US studies 
• Retrospective studies 
• No English translation 
 
WHO n=39 (USA only) 
 
All admission  
• n=45770 admission 
• serious 4.7% of 28017 (95% CI 3.1-
6.2%) 






Table 1.2 cont. Summary of selected literature describing the prevalence of hospitalisation secondary to ADRs 
Study (year) Aim Databases 
searched 
Exclusion criteria ADR definition No. of studies, 
setting, location 















• Non-English language 
• Admission due to 
overdose/intentional 
poisoning, attempted 
suicide, drug abuse or 
intoxication 
Definition by Cluff - any 
unintended/undesired 







n=37 (49 reports of 
ADR related admission 
rates) 
• North America (30) 
• Europe (10) 
• Asia (5) 
• Australasia (2) 
• Africa (2) 
 




• n=69187 admissions 
• 2897 (4.2% [range 0.2-21.7%]), 
(median 4.9% [IQR 2.9-6.7%]), 
(mean 5.5±4.1%) due to ADR 
• Meta-analytic average 5.1% (95% CI 
4.4-5.8%) 
• Study sample size 41-11891 
(median 714 [IQR 275-1245]), 
(mean 1412±2233) 
• 25% had more than one ADR 
ADR: adverse drug reaction; CI: confidence interval; CINAHL: Cumulative Index to Nursing and Allied Health Literature; ICU: intensive care unit; IPA: International Pharmaceutical Abstracts; NZ: New 




1.2.4 Impact of MRH 
Irrespective of the variation in the overall incidence and prevalence of MRH and associated 
inconsistency in terminology, it is universally reported that older adults are more likely to 
experience serious harm from their medicines resulting in hospital admission than younger 
adults.2,36,38,39,43  As the largest consumers of healthcare and most rapidly growing section of 
society, tackling MRH in older adults is a national priority. The 2013 report from the House of 
Lords Select Committee on Public Health and Demographic Change, Ready for Ageing, 
concluded that the current healthcare system is not delivering “good enough healthcare and is 
inefficient.  The Government and our society are woefully underprepared for the rapid ageing of 
the UK population”.44 
This demographic transition is a global phenomenon describing the shift from high fertility, high 
mortality to low fertility, low mortality.  Consequently, the global population is ageing.  By 2050, 
there will be over 2 billion people over the age of 60 in the world.45  At present,  one person in six 
in the UK is over the age of 65 years.46  Whilst improvements in healthcare and social 
development have supported an increased life expectancy, lifestyle changes involving high 
dietary intake of fats, sugars and salt, smoking and alcohol consumption have resulted in an 
increase in chronic disease.47  Over 50% more people will be living with three or more long-term 
conditions (LTCs) in England in 2018 compared to 2008.44  An analysis conducted in Scotland 
using data from 2007 identified that most people over the age of 65 years were multimorbid (see 
Figure 1.2).  Interestingly, in absolute terms more people under the age of 65 years old were 
multimorbid than those over 65 years old, however older people had more comorbidities on 
average.48  This observation has implications for the delivery of care to older people in the future 






Figure 1.2 Number of chronic disorders by age group (Barnett et al. Epidemiology of multimorbidity and 
implications for health care, research and medical education: a cross-sectional study48) 
 
The fragmented care that is associated with multimorbidity can increase an individual’s risk of 
experiencing harm.49  Often seen by a specialist for each condition, in addition to their GP, older 
patients frequently have multiple healthcare professionals responsible for the prescribing of their 
medicines which has been demonstrated to increase their risk of MRH.26  Moreover, each 
condition is likely to have its own specific guideline outlining the recommended pharmacological 
management which leads to complex polypharmacy that is difficult to manage and potentially 
harmful.50   
 
1.3 Risk of medication related harm 
The increased incidence of MRH experienced by older adults is likely to be multifactorial, with age 
related changes in physiology, compounded by chronic disease, affecting drug pharmacology.  
Furthermore, the aforementioned polypharmacy driven by guideline based prescribing and 




1.3.1 Changes in drug pharmacology 
The physiological changes that occur in old age can impact on drug pharmacokinetics and 
pharmacodynamics (Table 1.3 and Table 1.4) resulting in an increased susceptibility to 
medication related harm due to unpredictable and enhanced effects.51  It is also important to 
consider the impact of co-morbidities and polypharmacy causing drug-disease and drug-drug 
interactions which alter drug pharmacokinetics, for example heart failure which may result in a 
reduction in drug absorption due to mucosal oedema as well as changes in renal clearance, due 
to changes in renal blood flow.   
 
Table 1.3 Examples of age-related physiological changes and the impact on drug pharmacokinetics 
Physiological change Impact on pharmacokinetics Drug example 
Changes to active transport Reduced absorption of some drugs 
through active transport 
Vitamin B12, iron, calcium 
Reduced dopa-
decarboxylase in gastric 
mucosa 
Increased absorption of levodopa Levodopa 
Reduced liver mass and liver 
blood flow 
Increased bioavailability of drugs 
with extensive first-pass metabolism 
Propranolol, labetalol 
Reduced activation of pro-drugs 
activated in the liver 
Enalapril, perindopril 
Reduced clearance of drugs with 
high hepatic extraction ratio 
Glyceryl trinitrate, propranolol 
Relative reduction in total 
body water 
Reduced volume of distribution and 
increased serum concentrations of 
water-soluble drugs 
Gentamicin, digoxin 
Relative increase in body fat Increased volume of distribution and 
longer half-life of lipid-soluble drugs 
Diazepam, lidocaine 
Reduced serum albumin 
concentration* 
Reduced protein binding so 
increased concentration of free 
(active) drug 
Warfarin 
Reduction in glomerular 
filtration rate 
Reduced drug clearance of renally 
excreted drugs 
Water-soluble antibiotics, 
diuretics, digoxin, lithium, 
NSAIDS 
Adapted from Alder et al.51 





Table 1.4 Examples of age-related changes in drug pharmacodynamics 
Drug Pharmacodynamic effect Age-related change 
Diazepam Sedation, postural sway Increased 
Diltiazem Antihypertensive effect Increased 
Acute PR interval prolongation Reduced  
Furosemide Peak diuretic response Reduced 
Isoprenaline Chronotropic effect Reduced 
Morphine Analgesic effect Increased 
Respiratory depression Unchanged 
Temazepam Postural sway Increased 
Warfarin Anticoagulant effect Increased 
Adapted from Alder et al.51 
 
1.3.2 Polypharmacy 
As already outlined, increasing multimorbidity is associated with an increasing number of 
prescribed medicines resulting in the publication of major policy documents from across the 
United Kingdom, including: The King’s Fund, Polypharmacy and medicines optimisation52; the All 
Wales Medicines Strategy Group, Polypharmacy – Guidance for prescribing in frail adults53 and; 
National Health Service (NHS) Scotland: Polypharmacy guidance.54  Over the course of a decade 
the number of items prescribed in the general population increased by 53.8% from 11.9 (2001) to 
18.3 (2011)55, with a particularly high proportion (16.4%) of patients (in 2010) over the age of 65 
years old receiving 10 or more medicines56.  This figure may have increased over the past seven 
years and so a simple drug count, whilst easily identifiable in clinical practice, can become quickly 
outdated.  It has therefore become common practice to think of polypharmacy in terms of the 
number of inappropriate medicines prescribed based on specific criteria such as Beer’s57 or the 
Screening Tool of Older People’s potentially inappropriate Prescriptions (STOPP) and the 
Screening Tool to Alert doctors to the Right Treatment (START)58.  Polypharmacy, whether 
measured by medicine count or specific criteria is consistently associated with a higher rate of 
MRH.12,14,59–64 
 
1.3.3 Drug classes 
Certain drug classes seem to be more frequently associated with MRH irrespective of the study 
setting, for example drugs used in cardiovascular disease (including anticoagulants) accounted 
for 47% of ADRs 30 days post-discharge, and central nervous system (CNS) drugs (including 
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psychoactive drugs and opioids) for 20%.31  A systematic review of studies investigating hospital 
admissions associated with ADRs in adults identified 10 studies, 8 of which reported the types of 
medicines.  Cardiovascular medicines (45.7%), non-steroidal anti-inflammatory drugs (NSAIDs) 
(14.6%) and central nervous system agents (9.7%) were the groups of medicines most commonly 
involved in adult ADR, and also when a sub-analysis of the studies involving only older adults 
was conducted.  
 
1.3.4 Non-adherence 
Adherence to long term treatments is estimated to be around 50%65 and is associated with poor 
health outcomes, accounting for between one and two thirds of hospital admissions in the USA66.  
A study, by Col and colleagues, of 315 patients over the age of 65 years admitted consecutively 
to acute care, identified that 89 (28.2%) admissions were medicines related, 36 (11.4%) of which 
were due to non-adherence.  Non-adherence was defined as “any nontrivial deviation from the 
prescribed medication regimen (as judged by the research team). It includes dosage errors 
(underuse and overuse), interruption of treatment, failure to take drugs at specified times, taking 
them at incorrect intervals, and/or the addition of other drugs.”  Factors significantly associated 
with non-adherence were living alone, using two or more “when required” medicines, having no 
assistance with their medicine and using multiple pharmacies.67  Published in 1990, it is likely that 
this is a conservative estimate of harm due to non-adherence due the study population differing 
to today’s older population.  The mean number of medicines was 4, far less than that reported in 
more recent observational studies.68  This is important because in older adults non-adherence is 
often thought to be unintentional due to poor cognition for example but in reality half of all non-
adherence in older adults is intentional71 with one of the driving factors being polypharmacy and 
regimen complexity69.   
Given the awareness of the risk factors described, what has been done already to reduce the 




1.4 Reducing medication related harm 
A large proportion of MRH is reported to be preventable26 which has resulted in the development 
of various strategies aiming to reduce the incidence, including the concept of medicines 
optimisation.  Defined as “a person-centred approach to safe and effective medicines use, to 
ensure people obtain the best possible outcomes from their medicines”72, it recognises the 
potential for poor medicines related outcomes and proposes processes such as medicines 
reconciliation (MR) and medicines reviews to overcome them. 
  
1.4.1 Medicines reconciliation 
Launched in 2004 as part of the US Institute of Healthcare Improvements “100,000 Lives 
Campaign”, MR is a process that aims to reduce harm caused by medication errors during the 
transition of care.73  A key component of the National Institute for Health and Care Excellence 
(NICE) Medicines Optimisation guidelines72, this process has been fully adopted by secondary 
care in the UK.  Within 24 hours of admission all patients have their pre-admission medicines list 
reviewed against their current medicines list and any discrepancies rectified.  “Medicines” include 
over-the-counter and herbal medicines.  This process should be repeated when a patient transfers 
within the hospital and also into primary care following discharge from hospital.   There does not 
however appear to have been the same uptake in primary care74, even though there is evidence 
to suggest it can reduce post-hospital healthcare utilisation due to ADEs75.   
 
1.4.2 Medicines reviews 
In the UK, medicines reviews have been part of the General Medical Service contract76 and an 
advanced service within the Pharmacy contract77 for over a decade.  They exist at four levels: 
Level 0 – Ad hoc (an unstructured, opportunistic review); Level 1 – Prescription review (a technical 
review of a list of patients’ medicines); Level 2 – Treatment review (a review of medicines with 
the patient’s full notes) and; Level 3 – Clinical medication review (a review of the patient, illnesses 
and drug treatment during a consultation).78  As experts in medicines, pharmacists are ideally 
placed within the multi-disciplinary team to review medicines with the aim of preventing harm.  
Indeed, a recent study demonstrated that their presence on the general medical ward round 
resulted in a reduction of preventable ADEs from 26.5 to 5.7 per 1000 hospital days.79  In primary 
39 
 
care, many community pharmacists offer the medicines use review (MUR) service which aims to 
identify any problems or information needs that a patient has with regards to their medicines80, 
but the impact of these reviews on MRH is unclear.    Recognised as a priority group, older patients 
recently discharged from hospital are a target group for MURs but the uptake of the service has 
been varied and data to suggest benefit is limited.81  Recently, as part of the General Practice 
Forward Review 201682 in England, additional funds have been made available to general 
practices to employ clinical pharmacists as core members of their workforce.  Part of their role 
will be to support patients with long term conditions using multiple medicines, which will include 
medicines reviews.  Whilst initial outcomes of the evaluations appear positive, including 
pharmacists supporting medicines optimisation and the management of the long term 
conditions82, the impact on MRH is unknown.  
 
1.4.3 Prescribing indicators 
Another systems based approach to reducing MRH is through the application of a list of implicit 
or explicit prescribing indicators, such as the Medicines Appropriateness Index83 or the 
STOPP/START criteria58 where pharmacological appropriateness is monitored.  Although an 
association between ADRs and the prevalence of prescribing potentially inappropriate medicines 
has been demonstrated, the ability to predict the risk of a future event has not yet been confirmed.  
A large public health database review conducted in the USA identified that “high-risk medicines”, 
as definited by the Beer’s Criteria, contributed to a small proportion of emergency hospital 
admission due to an adverse drug event.  Beer’s Criteria medicines were associated with only 
6.6% of admissions, over half of which were due to digoxin.43  Furthermore, this focus on specific 
medicines often restricts, due to formulary and licensing issues, the use of such prescribing 
indicators in an international context.  A further limitation of such an approach is that they are 
time-consuming to use in routine care and can be viewed, due to the focus on medicines, as one 
dimensional.  From the literature, MRH appears to be a multi-dimensional challenge, comprising 




Table 1.5 Examples of medicines related risk variables for MRH (ADR or ADE) in >60 year olds 






Number of medicines 
Polypharmacy26,64,84–86 Polypharmacy26,64,84–86 Polypharmacy25,87 
≥518,64, ≥788, ≥1230 medicines ≥518,64, ≥7 88, ≥1230 medicines  
Individual medicines 
Warfarin26 Warfarin26 Warfarin87 
Digoxin85,89 Digoxin89 Digoxin87 
  Theophylline26  
Classes of medicines 
ACE inhibitors85,89 Antibiotics64 Alzheimer’s treatments64 
Antibiotics64,85 Anticoagulants26 (a)88 Anticholinergics26  
Antihypertensives85,88  Antipsychotics64,88 Anticonvulsants87 
Anticoagulants26,64 (a)88 Antidepressants64,89 Antigout64 
Anticonvulsants64 Beer’s criteria86 Antihistamines64 
Antipsychotics64,88 Hypnotics/sedatives (d)26 Antineoplastics64 
Antidepressants64,88,89  Hypoglycaemic agents85 Antipakinsonians64 
Beer’s criteria86 Nutrients/supplement (d)64 Antipsychotics26 
Benzodiazepines 26  Beer’s criteria87 
Beta-blockers85  Benzodiazepines87 
Cardiovascular64  Cholesterol-lowering64 
Hypnotics/sedatives64 (d)26   Diuretics64 (loop diuretics87) 
Hypoglycaemic agents64,85,89  Gastrointestinal64 
Muscle relaxants64  High-risk non-Beer’s87 
Non-aspirin NSAIDs26  Hypoglycaemic agents87 
Nutrients/supplement (d)64  Non-opthalmic topicals64 
Opioid analgesics85  Non-opioid analgesics64 
Tricyclic antidepressants26  Opioid analgesics26,64 
  Opthalmics64  
  Osteoporosis64 
  Respiratory64 
  Steroids26,64 
  Thyroid64  
Other 
New medicine25,87 New medicine25 MR on admission32 
Previous ADR18,89 Previous ADR18 Previous ADR26,86 
Multiple prescribers26   






Table 1.6 Examples of clinical related risk variables for MRH (ADR or ADE) in >60 year olds 
Clinical related risk variables 
Significant (univariate) Significant (multivariate) Not significant 
Co-morbidities 
CVD88 (d)89 CKD (c)18 CCF33,87 
Respiratory disease88 CCF18 CKD26,33,64,86,87 
Recent VTE (a)88 Liver disease18 Dementia18,26,33,64,86 
CKD (c)18 Experiences angina (d)89 Anaemia18 
CCF18 Experiences COPD89 Diabetes18,33 
Liver disease18 GI problems89 COPD18 (lung disease33) 
Diabetes85,89 Hyperlipidaemia85 Depression18,25 
Endocrine disorders89 Fall (d)64 Falls18,86 
Haematological disorders89 Neoplasm33 Liver disease33,64,86 
Hyperlipidaemia85  BMI18 
Infection (d)89  PVD33 
PUD89  Stroke33 
Osteoarthritis/arthritis85  Paraplegia33 
Neoplasm33  Connective tissue disease33 
Metastatic cancer33  Acute MI33 
Biochemistry 
Abnormal potassium89 Abnormal potassium89 Albumin <3.5g/dl18 
High WBC85 High WBC85  
Collective co-morbidities 
No. of co-morbidities86, ≥418 ≥4 co-morbidities18 No. of co-morbidities26,87 (d)88 
High CIRS index64  Physical co-morbidity84 
CCI ≥564 or ≥133   Psychiatric co-morbidity84 
  Geriatric conditions87 
Reason for admission 
Bleeding (including rectal)89   
Dehydration89   
Dizziness/vertigo89   
GI disorder89   
Hyper/hypoglycaemia89   
Abnormal glucose89   
Chest pain (d)89   
(a): within past 3 months; (c): eGFR<60ml/min; (d): reduced risk; BMI: body mass index; CCF: congestive cardiac 
failure; CCI: Charlson comorbidity index; CIRS: cumulative index rating scale; CKD: chronic kidney disease; COPD: 
chronic obstructive pulmonary disease; CVD: cardiovascular disease; GI: gastrointestinal; GI disorders 
:gastrointestinal disorders (nausea, vomiting, diarrhoea); Geriatric conditions: cognitive impairment, depression, visual 
impairment, incontinence, constipation, falls, gait instability; MI: myocardial infarction; PVD: peripheral vascular 





Table 1.7 Examples of social (and other) related risk variables for MRH (ADR or ADE) in >60 year olds 
Social (and other) risk variables 
Significant (univariate) Significant (multivariate) Not significant 
Length of stay85,86 Length of stay85 Outpatient geriatric clinic visits in 
previous year84 
New resident64 New resident64 Primary care visits in previous 
year84 
Thinks drug were responsible for 
admission89 
Thinks drug were responsible for 
admission89 
A&E attendances in previous 
year84 
Medicine cost67 Type of insurance67 Hospitalisation in previous year84 
Pharmacy consultation32 Pharmacy consultation32 Days to re-admission32 
No. of pharmacies used67  IADLs disability18,25,64,86,87 
Discharge counselling on side 
effects (d)30 




Age(d)33 Age32 Age18,25,64,84,86,87,89 (>75 years26) 
MMSE25 MMSE25 Marital status84 
Gender25 Gender25 Gender33,64,86,88,89 
Missed follow up32 Missed follow up32 Ethnicity87 
  Self-reported health score25,87 
  Smoker18,89 
  ETOH consumption25,86 
  Level of education32,86 
  Lives alone25 
A&E: accident and emergency; (d): reduced risk; ETOH: alcohol; IADLS: instrumental activities of daily living; MMSE: 
mini mental state examination 
 
1.4.4 Identification of high-risk patients 
Other approaches in health care have overcome the multi-dimensional nature of clinical risk. In 
these approaches predicting the risk of developing specific conditions is a routine component of 
everyday medicine, for example, the European Society of Cardiology CHA2DS2VASc score for 
determining stroke risk in patients with atrial fibrillation.90  Preceded by CHADS2, this updated 
score more accurately identifies those at low stroke risk through inclusion of non-clinical risk 
factors (gender and age ranges), in addition to medical co-morbidities such as heart failure, 
hypertension and previous stroke.  With a healthcare system under increasing financial pressure 
it is perhaps understandable that risk prediction models are generating increasing interest91, 
however the surge of risk prediction research has been described as “low quality, low impact”.92  
A quality risk stratification model could assist in case prioritisation, supporting clinicians and 
patients to make informed decisions about treatments, and deliver a more efficient healthcare 
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service.  Where current systems only look at the medicines aspect of risk, a risk prediction model 
may be able to map the complex interplay between clinical, social and medicine related variables, 
and stratify an individual’s risk of a future adverse drug event.   
Experts in the field define risk prediction, or prognostic modelling, as “the probability/risk of an 
individual developing a particular state of health (outcome) over a specific period of time, based 
on his or her clinical and non-clinical profile”.93  Clinical profile may include such things as renal 
function or number of medicines, but from a review of the variables it seems that these alone do 
not produce accurate enough predictions.  The non-clinical aspect of the patient profile seems to 
be understudied in this population and may be the missing element when trying to accurately 
identify those at risk of MRH, especially during the post-discharge period.  It is necessary to 
consider the whole individual when prognosticating93 and all the complexities that are associated 
with that individual, especially in a complex older population and so aspects such as social 
support or adherence may be worth further investigation.  A quality prediction model, that 
incorporates the intricacies of MRH in older adults, should accurately identify patients at high-risk 
of harm.  
 
1.5 Conclusion 
Older adults have a high-risk of MRH due to the physiological changes that occur with ageing and 
the consequential altered drug handling, in conjunction with high levels of multimorbidity and 
associated polypharmacy.  During acute illness, and following discharge from hospital, older 
adults are particularly vulnerable to the potential harmful effects of their medicines.  Yet the post-
discharge period is a stage of the patient journey that has received little attention from 
researchers.  Several systems based approaches aimed at optimising medicines use have been 
developed with limited success, and with the unprecedented growth in the number of multimorbid 
older people in our society the practical utility of these time-consuming interventions is 
questionable.  Risk stratification is a potential solution to targeting interventions at those who are 
at highest risk of harm thereby improving the efficiency of the healthcare service, however further 
research is required to determine if it is possible to identify older patients at risk of MRH following 
an acute hospital episode.  This forms the main aim of this thesis which is outlined in more detail 
in Chapter 2.  
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Chapter 2 Thesis overview 
2.1 Importance of this work 
Evidence from the literature demonstrates that clinicians are being presented with an increasingly 
complex ageing population.  The majority of people over the age of 65 years old live with multiple 
chronic conditions for which they receive a complicated array of medicines, the consequences of 
which in the older inpatient population has been extensively described.  Similarly, hospitalisation 
of older adults due to their medicines is well documented.  An area which has received little 
attention are the weeks immediately after discharge from hospital following an acute admission, 
during which time individuals may be described as having “post-hospital syndrome”23.  Defined 
as “an acquired, transient condition of generalised risk”23, post-hospital syndrome describes the 
depletion of homeostatic reserves due to the stress of the hospital admission, as much as the 
impact of the original acute illness, resulting in an increased vulnerability to harm.  Factors relating 
to a depleted physiological reserve as a consequence of hospital admission may therefore 
contribute to the risk of MRH through, for example, altered drug handling or a limited capacity to 
cope with the pharmacological effects of a new medicine.  Moreover, depletion of psychosocial 
reserves is also likely to play a significant role in post-discharge MRH, however the impact of this 
group of factors, for example mood or package of care, is poorly understood.   
The lack of evidence around the post-discharge period poses a problem when attempting to 
design and deliver interventions to advance the care of older adults.  This research will help to 
quantify the harm older adults experience from their medicines when they leave hospital but, more 
importantly, it will assist in the identification of those most at risk of harm so that interventions can 
be targeted.  During a time of increasing financial pressures in the National Health Service (NHS), 
the ability to allocate resources to those most at risk of harm would benefit both the patients and 
the organisation.  Through a series of studies outlined in this chapter, this thesis will further our 
understanding of medication related harm (MRH) in older adults and so assist in the improvement 





2.2 Research aim and objectives 
This thesis aims to examine the possibility of identifying older patients at risk of medication related 
harm following discharge from hospital.  It will do this by: 
1. Systematic review of the literature to identify, and assess the quality of, validated 
medication risk prediction models to determine their potential benefit to the care of older 
people  
2. Exploration of medication related harm experienced by older adults following discharge 
from an acute inpatient episode in a UK hospital 
3. Exploration of the relationships between physiological and psychosocial variables and 
the risk of post-discharge medication related harm.  
 
2.3 Description of thesis chapters 
The first chapter of this thesis summarises the findings of the literature around MRH.  In particular, 
it highlights the multiple definitions and methods of measurement used in this research area, and 
the consequential variation in the reported incidence.  The risk factors associated with, and the 
consequences of, MRH in older adults are discussed in the context of an ageing, multimorbid 
population and a health service under growing pressures to increase efficiency.  Current 
approaches, and their limitations, to managing the risk of harm from medicines in older adults are 
described.  Potential future strategies in the form of risk stratification are outlined with a focus on 
the post-discharge period, a high-risk time in the patient journey which has been seldom studied 
in the UK.   
The following section provides a brief outline of the three studies conducted (Figure 2.1) as part 





Figure 2.1 Overview of research presented in this thesis 
   
Chapter 3 provides a detailed outline of the key stages of developing, validating, measuring the 
impact and implementation of a quality risk prediction model.  Through a systematic review of the 
literature (Study 1), the chapter then identifies existing MRH risk prediction models and assesses 
their quality.  This study was published in Clinical Interventions in Aging (Stevenson JM et al. 
Predicting adverse drug reactions in older adults; a systematic review of the risk prediction 
models. Clin Interv Aging. 2014 Sep; 1581 - see Appendix A).  This study was designed to identify 
prediction models but through a detailed critique of the studies it also informed the design of Study 
2 and the development of a conceptual framework, presented at the end of the chapter.  The 
conceptual framework outlines the complexity of MRH in an older population and reflects upon 
the parallels with frailty and the need to consider a broad range of variables in order to identify 
those at risk.  
Chapter 4 provides detail of the findings of an observational study (Study 2) undertaken to gain 
an understanding of the incidence, severity, preventability and causality of post-discharge MRH.  
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The body systems affected and most common type of medicines involved in MRH were reported 
along with the proportion of harm that was due to an ADR, non-adherence or a combination of 
both.  Healthcare utilisation was also measured.  The full protocol for this study was published in 
BMC Geriatrics (Stevenson JM et al. Protocol for a Prospective (P) study to develop a model to 
stratify the risk (RI) of medication (M) related harm in hospitalized elderly (E) patients in the UK 
(The PRIME study). BMC Geriatr. 2016;16:22 – see Appendix B).  The study identified a frail 
population and a higher than anticipated re-admission rate which directed subsequent analysis in 
Study 3.  
Chapter 5, using data collected in Study 2, explores the relationships between a range of variables 
and post-discharge MRH.  In Study 3, previously studied variables, along with variables 
suggested through the conceptual framework, are analysed and the findings discussed.  Due to 
the high re-admission rate, a sub-analysis of re-admissions was conducted with the aim of 
identifying variables that would predict re-admission due to MRH.       
A final discussion, summarising the findings of this research in the context of the current published 
literature is provided in the last chapter, Chapter 6.  Recommendations for practices and further 
work are also outlined.    
 
2.4 The research team 
The main research team consisted of five members; two principal investigators, the principal 
researcher (Jennifer Stevenson), a research pharmacist and research nurse.  The principal 
researcher was responsible for the study design, training of staff and day to day research co-
ordination, overseen by the principal investigators.   
In Study 1 the principal researcher designed and ran the search strategy for the systematic 
review.  Titles and abstracts were independently reviewed by the principal researcher and a 
medicines information specialist pharmacist and papers to be included agreed through 
discussion.  Data were extracted from the studies meeting the inclusion criteria by the principal 
researcher and confirmed by two independent reviewers (a medicines information specialist and 
a professor of medical statistics).  The quality assessment of the included studies was conducted 
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by the principal researcher and medicines information specialist and confirmed by experts in 
medical literature review and clinical geriatrics.     
Recruitment of patients to the observational study (Study 2) was conducted mainly by the 
research nurse, with the support of the research pharmacist, both under the supervision of the 
principal researcher.  Follow up was conducted by the principal researcher with the support of the 
research pharmacist.  Classification and categorisation of MRH was conducted by the principal 
researcher and principal investigators. 
2.5 The PRIME Study 
This thesis focusses on a sample of patients recruited from one hospital, St. Thomas’ Hospital, 
participating in a larger multi-centre study, the PRIME Study.  The PRIME Study, with the aim of 
developing a risk prediction model to identify older patients at risk of MRH in the 8-week period 
following hospital discharge, was conducted in 5 teaching hospitals in the South East of England.  
A sample size calculation, based on the nomogram designed by Carley and colleagues94 and 
Buderer95, estimated 1500 patients would be required to achieve a sensitivity of 80% with a 95% 
confidence interval width of 5%, based on a MRH prevalence of 30%.  Furthermore, this would 
allow a maximum 45 variables to be tested for inclusion in the risk prediction model whilst 
adhering to the commonly applied 10 events per variable rule of risk prediction modelling96–98.  
The PRIME Study monitoring committee identified that the St. Thomas’ cohort had a re-admission 
rate almost three times higher than the other sites in the PRIME Study and so a sub-analysis of 
this population was conducted.  This thesis reports the results of this sub-analysis.  
The principal researcher (Jennifer Stevenson) developed the study documentation, including 
patient information leaflets (see Appendix E and Appendix F), consent forms (see Appendix G 





Chapter 3 Systematic review 
3.1 Introduction 
Predicting the risk of developing specific conditions is already a routine component of everyday 
medicine, for example the European Society of Cardiology CHA2DS2-VASc score for determining 
stroke risk in patients with atrial fibrillation.90  More generally, with a focus on long-term conditions 
(LTCs), risk prediction models, for example the John Hopkins University Applied Clinical Guideline 
System, have been adopted by the Primary Care Sector of the NHS99,100 to identify patients at 
risk of hospital admission.  It is perhaps understandable that prediction models that quantify the 
risk of ADRs occurring in older patients are generating increasing interest as readmissions are 
more frequent, and are associated with financial consequences.101  The 2013 report from the 
House of Lords Select Committee on Public Health and Demographic Change, Ready for Ageing, 
concluded that the current healthcare system is not delivering “good enough healthcare and is 
inefficient.  The Government and our society are woefully underprepared for the rapid ageing of 
UK population”.  The committee called for the provision of better healthcare in a more efficient 
manner.44 
In the UK, one person in six is over the age of 65 years.46  The King’s Fund has projected that 
there will be over 50% more people with three or more LTCs in England in 2018 compared to 
2008.44  As a direct result, there is likely to be an increase in the number of medicines prescribed 
to treat LTCs leading to polypharmacy, a frequently reported risk factor for ADRs.12,14,61–64  We 
also know that the changes in drug pharmacokinetic and pharmacodynamic properties that occur 
with ageing often lead to an increased susceptibility to ADRs.102  Therefore, given the awareness 
of potential risk factors, the ability to stratify a patient’s risk of suffering an ADR is attractive.  Risk 
stratification could assist in case prioritisation, supporting clinicians and patients to make informed 
decisions about treatments and deliver a more efficient healthcare service.   
To predict risk in the clinical setting accurately, a quality risk prediction model should be the result 
of four key stages, namely: development, validation, impact and implementation.91,93,103,104  A 




Table 3.1 Description of stages of multivariable prognostic research  
Stage Description of stage Importance 
Development • Identification of the important predictors. 
• Assignment of relative weights to each predictor. 
• Estimation of model’s predictive ability (calibration and 
discrimination). 
• Estimation of potential for optimism using internal 
validation techniques. 
• Adjustment of model for overfitting, if necessary. 
Identification of 
variables, in a 
combination, that 
accurately identify 
those at risk of the 
outcome.  
Validation • Testing the model’s predictive performance (calibration 
and discrimination) in new participants. 
• Can be narrow – using participants from same 
institution, measured in the same way and by the same 
researchers at a later time (internal validation), or in 
another single institution by different researchers using 
slightly different definitions and data collection methods 
(external validation). 
• Can be broad – using participants from various other 
institutions or using wider inclusion criteria. 
Gives understanding 
about the model’s 
ability to perform in a 
different patient group 
from that of the 
development 
population. 
Impact • Quantifying whether the use of a prognostic model in 
the clinical setting by practicing healthcare 
professionals truly improves decision making and 
patient outcomes. 
• Can be narrow – within same institution etc. 
• Can be broad – in a different institution etc.  
Demonstration of 
model’s value within 
the healthcare setting. 
Implementation • Applicable when a model is consistently accurate in 
diverse populations. 
• Demonstration of superior ability to discriminate in 
comparison to routine care (ideally conducted during 
development phase). 
• Assessment of face validity and user-friendliness. 
Support routine 
application in clinical 
care setting. 
Adapted from Moons and colleagues93 and Toll and colleagues91 
 
It is recognised that many risk prediction models are often only the product of the first two stages, 
the methods and outcomes of which are frequently poorly reported.91,104–106  Furthermore, to be 
of practical use, these models should ideally use clearly defined, easily obtainable data, have 
good predictive power, be tested in a large sample representative of the target population and 
have high reliability and face validity.91 
The ideal study design is summarised in Table 3.2, with key aspects explained in more detail in 
the following paragraphs.107–110 
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Risk factors of interest, also referred to as candidate predictor variables, may include 
demographics e.g. age or gender, blood biochemistry, clinical diagnoses, the results of genomic 
investigations amongst many other possible variables.  Candidate predictor variables should be 
identified through a review of the literature and expert opinion.  Univariate analysis of variables 
collected from the development cohort may be used to identify candidate predictor variables 
however, using this method alone may result in a sufficiently accurate model within the study 
population but poor performance when applied elsewhere.  Where this occurs, the model may be 
said to be overfitted to the development population and will likely have poor generalisability.  
Furthermore, candidate predictor variables should be clearly defined to allow replication of the 
study in external populations by other investigators.111   
Outcomes must also be clearly defined and a standardised method of measurement utilised.  This 
is especially important when considering the area of MRH where multiple definitions exist for ADR 
and are often used interchangeably with ADE. 
The design should ideally be a longitudinal prospective cohort study to ensure that all predictors 
and outcomes are captured and thus limiting missing data.  Whilst retrospective data sets may 
be used, there is often a challenge with incomplete data and variation in predictor and outcome 
measurement.  Where a prospective method is applied, investigators should be blinded to the 








Study design Prospective: allows optimal collection of potential candidate variables; smaller dataset 
often generated. 
Retrospective: enables use of large previously collected datasets; quality of candidate 
variable data may be compromised due to missing data which rarely occurs at random. 
Prospective, n=690, all exclusions were for appropriate reasons 
85 




Inclusion and exclusion criteria should be clearly described to allow full assessment of 
patient population studied. 
Any systematic variation in recruitment of patients should be viewed with caution due to 
risk of sampling bias.  
There is no pre-determined satisfactory number for loss to follow up however it should 
be considered that missing data impacts on the statistical power of study. 
Interview data were only collected for half of the patients during 
the development phase.  Patients not wishing to participate in 




Variables and their measurement should be clearly defined to allow replication. 
Investigators should be blind to the outcome to reduce the risk of bias.  
Continuous variables should be assessed for conformity to linear gradient. Not 
necessary for dichotomous variables however, dichotomisation of continuous variables 
not recommended as impacts on statistical power of study. 
Correlation (test for collinearity) between risk variables should be examined and 
reported. 
Unclear how key variables e.g. liver disease, were defined.  To 
replicate, study investigators would be required to apply own 









Outcome Method of measuring outcome:  must be reproducible and, where assessment scales 
are applied these should be validated to increase accuracy and reproducibility of the 
measurement.   Dichotomisation of continuous outcomes is not recommended as it can 
affect statistical power. 
Investigators generated own causality assessment of unknown 
validity.88 
Applied widely used, validated causality assessment (Naranjo 
algorithm).112 
Statistical power Sample size is calculated based on number of outcome events per variable, where ten 
events per variable is often recommended.  A high number of variables and a rare 
outcome can result in over-fitting of model, causing poor generalisability. 
Reported 86 ADRs in a sample of 690 patients and assessed 34 




Independent variable selection should be described clearly and can be based on the 
literature and/or statistical association as determined by univariate analysis with 
outcome variable. Selection based upon univariate analysis alone increases likelihood 
of developing an over-fitted model.   Inclusion of variables applicable to over 5% of 
population may help exclude artefact variables. 
Fitting procedure (entering of variables into model) should be explicitly stated, including 
removal criteria. 
Variables were entered into multivariate analysis if p<0.05 after 
univariate analysis or p<0.25 for variables identified from other 
studies.  Liver disease was removed as applied to <5% of 
population. Backward elimination and forward selection were 











In both development and validation phases, assessment of discrimination and 
calibration should be reported to determine how well the model distinguishes those who 
have an ADR from those who have not and how close the prediction is to the observed 
outcome for that risk group. 
AUROC >0.7 is often deemed acceptable, but this alone is not sufficient to determine 
the clinical usefulness of the model. 
Assessment of the generalisability of the model is important to determine the accuracy 
of predictions in another population and is recommended prior to routine clinical 
application.  Internal validation, by methods such as bootstrapping (data resampling) or 
split-sample, assesses how well predictors correspond to the outcome but lead to 
optimistic estimates of model performance.  External validation is more rigorous and 
enables assessment of accuracy when the model is applied by investigators not 
involved in the development of the model. 
Discrimination (AUROC1) and calibration (Hosmer-Lemeshow) 
reported in the development and validation phases.85 
Trivalle applied bootstrapping.88 
Onder applied external validation whereby the model was 
applied by investigators not in involved in the development of the 
model and in a different geographical location.112 
ADR: adverse drug reaction; AUROC: area under receiver operator curve 
aCriteria derived from the published literature.107–110  
                                                     
1 Area under the receiver operator curve (AUROC) is a measure of how accurately a model can separate those with and without the outcome of interest i.e. discrimination.  An area equal to 1 demonstrates 




To undertake a systematic review to identify, and assess the quality of, validated medication risk 
prediction models to determine their potential benefit to the care of older people.  
 
3.3 Objectives 
1. To design and apply a search strategy to relevant healthcare literature databases to 
identify existing validated medication risk prediction models 
2. To systematically exclude papers which fail to meet the inclusion criteria 
3. To measure the quality of study design and reporting against standard assessment 
guidelines 
4. To identify the most statistically robust model(s) for use in routine clinical practice 
5. To identify variables for potential inclusion in future risk prediction models. 
 
3.4 Method 
3.4.1 Information sources and search strategy 
A systematic search for published material was performed, using a cut-off of 30th November 
2012.  Standard databases (Embase, Medline, Cochrane Library, British Nursing Index (BNI), 
CINAHL, National Electronic Library for Medicines (NeLM), IPA) were searched to identify 
relevant studies as well as those associated with policy documents and unpublished work 
(Department of Health, King’s Fund, Worldcat, Open Grey, Google Scholar).  In addition, for the 
key studies identified, the bibliographies and citations were reviewed, along with an author search, 
to identify any additional published studies. The search strategy was verified by two independent 
information specialists from the Regional Medicines Information Centre, Guy’s and St. Thomas’ 
NHS Foundation Trust (GSTFT). 
Search strategies were developed for each database in line with their specific requirements and 
used standard terms based around three key concepts, namely; older people, medication-related 
problems and clinical prediction models. The full Embase search strategy is outlined. There were 




3.4.2 Embase search strategy 
Risk Tool 
1. risk assessment.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
2. exp prediction/ 
3. exp scoring system/ 
4. exp clinical assessment tool/ 
5. exp risk factor/ 
6. exp risk management/ 
7. exp decision support system/ 
8. risk stratification.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
9. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 
Medication related problem 
10. exp adverse drug reaction/ 
11. adverse drug event*.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
12. adverse drug reaction*.mp. [mp=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
13. medication related problem*.mp. [mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
14. drug related problem*.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
15. exp medication therapy management/ 
16. drug/ae [Adverse Drug Reaction] 
17. exp polypharmacy/ 
18. exp medication error/ae, pc [Adverse Drug Reaction, Prevention] 
19. inappropriate prescri*.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
20. (readmission and drugs).mp. [mp=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
21. patient compliance.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
22. 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 
Elderly 
23. aged/ 
24. exp aging/ 
25. exp elderly care/ 
26. older people.mp. 
27. older person.mp. 
28. aged over 80.mp. 
29. 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29  
Combined terms  




3.4.3 Inclusion criteria and selection  
Two researchers (the principal researcher and a Medicines Information Specialist) independently 
screened titles and abstracts and, where necessary, full texts to identify those that potentially 
satisfied the following inclusion criteria: 
• Included a majority of patients over the age of 65 years 
• Patients who experienced an adverse drug event (ADE) or adverse drug reaction (ADR) 
but excluding medication errors 
• The risk prediction model followed a multivariable approach in design and analysis 
• The model had been validated, either internally or externally 
 
3.4.4 Search update 
The original search was performed on 30th November 2012.  To ensure the inclusion of more 
recent publications in this review, an update search was conducted on 27th October 2016.  Given 
the large number of titles identified through an unavoidably broad initial search strategy, a 
pragmatic approach was taken for the update search whereby titles and abstracts of papers citing 
any of the four studies included in the systematic review were assessed against the original 
inclusion criteria.  The development of a new model should consider any existing models in that 
field113, and so this method should allow identification of any models published in this area since 
the original search.   
 
3.4.5 Data Extraction 
Data were extracted to provide detail of the population characteristics, study design, process of 
model development and validation, and performance of the model as presented in Table 3.4 and 
Table 3.5.  This was confirmed by a Medicines Information Specialist, GSTFT, and a statistical 
expert, King’s College London (KCL), and any disagreement resolved through discussion.   
 
3.4.6 Quality assessment  
All papers were initially reviewed using a “gold standard” approach for developing and testing 
clinical prediction models to satisfy a range of criteria representing 4 stages: development 
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(identification of candidate predictor variables and model design), validation (testing the 
performance of the model), impact (measurement of usefulness in the clinical setting) and 
implementation (widespread acceptance and adoption in clinical practice).91  
As no standardised quality assessment for risk prediction models was available at the time, each 
study was analysed using criteria derived from the published literature107–110 as outlined in Table 
3.2.  Candidate predictor variables were grouped into 3 categories to allow comparison between 
studies; social factors (e.g. function), medical factors (e.g. co-morbidities) and medication factors 
(e.g. class of medicine).  The event rate was calculated as a percentage ADR/ADE rate where it 
was not reported by the authors in this form.  The overall performance of the models was 
determined by a review of their accuracy, discrimination and calibration. 
  
3.5 Results 
A total of 13423 titles were identified from the literature as potentially relevant, of which only 549 
were associated with adverse outcomes of medicines use. The majority of these (535) were 
excluded on review of the abstract, as they were not associated with the design of a risk prediction 
model, many being observational in nature (Figure 3.1). Full papers were requested for the 
remaining 14 articles for further scrutiny against the inclusion criteria and four met the inclusion 
criteria and were subjected to a full evaluation.85,88,89,112   
The update search generated one title satisfying the inclusion criteria which had already been 
identified in the original search of the grey literature.  This publication19 uses the data from 
Tangiisuran’s thesis85 and upon evaluation, this recent publication provided no additional 





Figure 3.1 PRISMA flow diagram describing paper inclusion for systematic review (original search date 30th 
November 2012) 
 
3.5.1 Excluded papers 
Although the 535 articles excluded were associated with describing the adverse outcomes of 
medicines, none went on to design a risk prediction model.  These articles could be further 
categorised into three sub-groups. The first sub-group (325 studies) involved observational 
studies reporting the incidence of, and factors associated with, ADRs or ADEs.  In some 
instances, these described the patient population associated with the four studies which met the 
inclusion criteria.114,115  The second sub-group (63 studies) included those where quality 
prescribing indicators had been developed.  These were usually in the form of a list of potentially 
inappropriate medicines often associated with common conditions seen in older people, for 
example Beers’ criteria57,116–118, STOPP/START criteria119, and the MAI83.  The final sub-group 
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(147 studies) was where the prescribing indicators were applied within a clinical setting to 
determine any association between the prescribing of inappropriate medicines and adverse 
outcomes. 
 
3.5.2 Included papers 
All four studies included in the systematic were conducted in Western Europe over the past twenty 
years with the intention of identifying older inpatients at risk of ADRs (Table 3.3).  Two studies85,112 
assigned names to their models. 








McElnay89 1997 UK Inpatient None given 
Tangiisuran85 2009 UK Inpatient Brighton ADR Risk (BADRI) model  
Onder112 2010 Italy Inpatient GerontoNet ADR risk score 
Trivalle88 2011 France Inpatient None given 
 
3.5.2.1 Population characteristics 
The population characteristics of the studies included in the systematic review are summarised 
in Table 3.4.  The development phase datasets were generated across a range of care settings 
(acute, community and rehabilitation hospitals).  Two of the four studies represented the oldest 
old (aged over 80 years).85,88  Only one study, Tangiisuran, reported on the ethnic profile of the 
study population.85  
Comorbidities, where reported, were dominated by diseases of the cardiovascular system, 
including hypertension, cerebrovascular disease and coronary heart disease. Also included were 
diabetes, COPD, musculoskeletal, gastrointestinal, genitourinary and neurological conditions.  
The mean number of drugs prescribed (range 4.3-9.4 per patient) increased as publication date 
became more recent.  Medical and medication factors were considered in all studies.  Social or 
patient factors, e.g. patient functionality, were reported by Onder112, Tangiisuran85 and McElnay89 
and were measured using different methods.  Examples of these factors include: Onder112 and 
Tangiisuran85 captured activities of daily living using the Katz Index120 and Barthel Index121 
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respectively; McElnay89 explored “healthcare behavioural factors” including whether the patient 
thought that the drug was responsible for the admission to hospital.   
The primary outcome in all of the studies was ADR, based on the WHO definition, “a response to 
a drug which is noxious and unintended, and which occurs at doses normally used in man for the 
prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function.”8  
One study used ADE synonymously88 and another included ineffective treatment, for example 
due to non-compliance, in an extended definition89.  The proportion of patients who experienced 
an ADR/ADE ranged from 6.5% - 39%, with gastrointestinal, cardiovascular, and nervous systems 
the most frequently affected.  This range is likely to be reflective of variation in the study design.  
It would be expected that a broader definition of ADR, such as that used by Trivalle88, would 
produce a larger rate of events (39%).  Conversely, a more focussed definition, as used by 
Tangiisuran85 and Onder112, would produce a lower rate of events (12.5% and 6.5% respectively).  
Furthermore, the retrospective study design applied by Onder and colleagues may explain the 
comparatively low outcome rate reported.112  A systematic review of the prevalence of ADRs in 
older patients in the acute setting found the prevalence of ADRs to be lower in studies with a 
retrospective design.122  Medications most frequently associated with ADRs/ADEs included 
psychotropics, anticoagulants and analgesics.  The risks associated with the use of psychotropic 
and anticoagulant medications in older adults is well documented.123,124  Analgesics, as described 
by Tangiisuran, included both opioid and non-steroidal anti-inflammatory drugs (NSAIDs), 
whereas Trivalle did not include (NSAIDs).  Nevertheless, both groups of drugs are commonly 
identified as being potentially problematic in older adults due to side effects such as sedation and 
constipation in the case of opioids125 and gastrointestinal, renal and cardiovascular adverse 









Author Development Validation 
Population and 
setting 







Drug associated with 
primary outcome (%) 
Systems affected by ADR 
(%) 










Age: 65-98 years  
Location: Acute 
hospital (UK) 
Year: NR (published 
in 1997) 
Gender: F 50%, 
Ethnicity: NR 









- ADR and 
adherence 
Digoxin (NR) 
ACE inhibitors (NR) 
Antidepressants (NR) 
Insulin (NR) 
NR n = 204 (number ADRs unknown) 














Age:  85±7.9 years  
Location: Acute 
hospital (UK) 
Year: 2007 & 2008 
Gender: F 61%, 
Ethnicity: White 
n = 690 
















n = 483 (56 suffered ADR) 
Number of drugs 11.0±7.0 
Cohort similar - from 4 European 







Table 3.4 cont. Summary of patient population characteristics of included studies 
Author Development Validation 
Population and 
setting 







Drug associated with 
primary outcome (%) 
Systems affected by ADR 
(%) 









Age: 78±7.2 years  




n = 5936 
HTN (24)a  



















n = 483 (56 suffered ADR) 
Number of drugs 11.0±7.0 
Cohort similar - from 4 European 
countries (UK, Belgium, Italy and 
Netherlands). 
Secondary Study60  
n = 513 (135 ADRs)  
Number of drugs 7 (IQR 7-10) 

















Drug associated with 
primary outcome (%) 
Systems affected by ADR 
(%) 













Year: NR  
Gender: F 72%, 
Ethnicity: NR 
n = 576 
CV (72), MSK 






















n = NR 
Validation cohort similar to 
developmental cohort 
ACE: Angiotensin Converting Enzyme; ADE: Adverse Drug Event; ADR: Adverse Drug Reaction; CHD: Coronary Heart Disease; COPD: Chronic Obstructive Pulmonary Disease; CV: Cardiovascular; F: 
female; GI: Gastrointestinal; GU: Genitourinary;  HTN: Hypertension; MSK: Musculoskeletal; NR: Not recorded;  NSAIDs: Non-Steroidal Anti-Inflammatory drugs; SD: Standard Deviation;  
aData extracted from the Gruppo Italiano di Farmacoepidemiologis nell Anziano (GIFA) study114 
65 
 
3.5.2.2 Quality assessment  
None of the four models meeting the inclusion criteria satisfied all four key stages in the creation 
of a quality risk prediction model. Whilst all models included the development and validation 
phases, none addressed the impact and implementation phases, although it is possible that this 
work may be in progress and the findings have not, as yet, been published.  However, given the 
time elapsed since development of the model and personal communication with Tangiisuran and 
Onder, it would seem unlikely that the impact and implementation of the models, in their current 
form, will be conducted.   
 
3.5.2.3 Model development 
3.5.2.3.1 Study design 
For participant sampling in the development phase all, except Onder112, used a prospective case-
cohort design method, where events accrued over the study period (Table 3.5). Onder and 
colleagues112 drew their data from a previously established historical database. Data were 
extracted over a 3-year period in this study in comparison to the studies with a prospective design, 
where data extraction varied between one and six months, depending on study design.  
Prospective study design is beneficial as it allows optimal collection of potential candidate 
variables; this is because standardised measurements of variables can be applied and the 
likelihood of missing data can be minimised.  The use of a retrospective dataset does not allow 
for this level of detail and relies upon data collected previously, often for another reason.  
Consequently, it is not possible to extract or confirm some aspects of the data resulting in 
uncertainty with regards to definitions of variables and the reason for any missing data.  Patient 
medical notes, in-patient charts and electronic records were reviewed in the prospective 
studies.85,88,89  In addition, McElnay89 asked patients directly about aspects of their medicines 
while Trivalle88 used patient self-reporting of any medication-related problems as a trigger for 
further analysis.  The validation phase was conducted prospectively for all studies except 




Table 3.5 Summary of quality assessment of included studies 
Standard criteria McElnay89  Tangiisuran85 Onder
112  Trivalle88  
Study design  Prospective cohort (development 
and validation) 
Prospective cohort (development 
and validation) 
Retrospective cohort (development) 
Prospective (validation) 
Prospective cohort (development)  






















- Non-elective admissions to 
medical, surgical, cardiac and 
geriatric wards in a single 
hospital 
- > 65 years old and taking 
medicines 
Validation 
-  as above 
Yes  
Development 
- Non-elective admission to Care 
of the Elderly wards in a teaching 
hospital 
- > 80 years old  
Validation  
- admitted to 1 of 4 European 
hospitals  




- Community and teaching hospital 
admissions  
- ≥ 65 years old and taking medicines  
Validation  




- Consecutive admissions to 16 
geriatric rehabilitation centres  
Validation 







Data only collected from patients 
recruited who underwent 
interview (50% development, 
42% validation) 
Yes  
All patients excluded were for 
appropriate reasons 
Unsure 
An unknown number of patients were 
excluded due to incomplete data   
61 cancer patients excluded 
Unsure 
Data from 71 patients were 
excluded (either were part of an 
intervention arm or were not 
present for study duration) 
Acceptably 
low loss to 
follow up 
Yes 
Data from all interviewed patients 
were used 
Yes  
No patients lost to follow up 
Yes 
No patients lost to follow up 
Yes  
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2 of 7 identified variables were 
not easily quantifiable (GI 
problems, patient thinks drugs 
responsible for hospital 
admission) 
Partly  
Data on 17 potential variables 
assessed. Not clear how co-
morbidity, liver disease, previous 
history of ADR or known allergy to 
medication were defined 
Partly   
Trained physicians completed 
questionnaires but unclear how 
variables were defined (comorbidities, 
liver disease, ADR history) or 
consistently applied 
Partly 
Where candidate predictors were 
reported they could be clearly 
described.  Potential candidate 
predictors which were not 





Data collected prospectively 
Yes 
Data collected prospectively 
Partly 
Blinding is not reported for the 
development phase.  Physicians 
collecting data for the validation 
phase were blinded. 
Yes 






Not reported Not reported 
 
Yes  





Outlined in method but not 
mentioned in results. 
Partly  
Outlined in method but not 
mentioned in results. 
Not reported Yes 
High correlation risk factors were 
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Data from patient records and 
interviews 
ADE as defined by: 
- ADR (measured using modified 
Naranjo scale) 
- Adherence (self-report) 
Partly  
Medical information and 
healthcare staff reviewed daily 
using standardised checklist. 
Suspected ADRs assessed for 
causality, preventability and 
severity using Naranjo algorithm, 
Hallas criteria and a confidence in 
causality likert scale. 
Partly 
Wards visited daily and nursing and 
medical records examined daily. 
Causality was assessed based on 
Naranjo algorithm. 
Partly 
A combination of approaches 
used to identify ADEs: self-
generated standardised 32 item 
checklist was completed by 
nursing staff, incident reporting 
and weekly chart review. Four 
criteria were used to assign 

















Unable to determine exact 
number but <10. 
No  
86 ADRs/34 candidate predictor 
variables = 2.5  
Yes 
Unable to determine exact number 
but >10. 
Unsure 































Screened in univariate analysis 
and entered into model if p<0.25.  
Applicable to >5% of population. 
 
Yes 
Screened in univariate analysis 
and entered into model if p<0.05.  
Variables identified from other 
studies entered into model if 
p<0.25. 
Applicable to >5% of population. 
Yes 
Screened in univariate analysis and 




Screened in univariate analysis 
and entered into model if p<0.05. 
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Stepwise backward elimination 
procedures (using maximum 
likelihood method).  
Preliminary removal of variables 
at p=0.15 then p=0.05. 
Yes 
Multivariate logistic regression - 
using backward elimination 
procedure and forward selection. 
Removal criteria p = 0.10. 
Partly  
Stepwise logistic regression. 
Added and retained variables if p≤0.1. 
Method elimination and retention 
unclear. 
Partly  
Stepwise logistic regression. 
Retained variables if p<0.05. 




















Discrimination as AUROC 
reported with CI 
Calibration as Hosmer-Lemeshow 
and Nagelkerke R2 
Sensitivity and specificity 
reported. 
Partly 
Discrimination as AUROC reported 
with CI 
Sensitivity and specificity reported 
No 





3.5.2.3.2 Participant recruitment 
Recruitment of participants, the criteria for inclusion and exclusion and any loss to follow up were 
clearly described in all studies but reporting of patient selection was poor.  Data were only 
collected through interview for 50% and 42% of patients in the development and validation phases 
respectively in the study by McElnay.89  Patients who were not interviewed either refused, or had 
already been discharged, or were too ill.89  Trivalle88 excluded patients who were not present for 
the study duration or were recruited to the intervention arm of another linked study.  Twenty seven 
percent of the study population were excluded in the study by Tangiisuran85: 111 (43%) were 
under 65 years old and; 145 (57%) either died, the medical notes were unavailable or they were 
discharged within 24 hours of admission or during the weekend.  An unknown number of patients 
were excluded from Onder112 due to incomplete data.  It is extensively reported that missing data 
rarely occurs completely at random and exclusion of participants with incomplete data can affect 
statistical power and introduce bias109 e.g. the relationship between the candidate predictor 
variables and the outcome is different between participants with complete and incomplete data.   
 
3.5.2.3.3 Candidate predictors variables 
Candidate predictor variables (the risk factors being investigated in the study) were, in general, 
handled poorly.  In all studies the description of the variables was inadequate; where Trivalle88 
did not report the potential candidate variables, McElnay89, Tangiisuran85 and Onder112 used 
variables with unclear definitions, e.g. previous ADR.  Despite being labelled as a “bad idea”127, 
dichotomisation of continuous candidate predictor variables (e.g. ≥4 comorbidities, >8 
medications, previous ADR) was common practice, and may explain the failure to consider 
conformity with the linear gradient in all but the Trivalle study88.  Interactions between independent 
variables, that is where one independent variable’s relationship with the outcome is changed by 
the presence of another independent variable, should be considered when developing a risk 
prediction model.  Where significant interactions exist there may be overfitting of the model and 
ultimately poor generalisability.128  Interactions were poorly addressed in all studies.  Insufficient 
detail in the results made it difficult to establish if tests mentioned in the methods had been 
implemented, e.g. McElnay89 reported testing for interactions and collinearity but this was not 
followed through to the results.  Predictor variable measurement was blinded for outcome in the 
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development phase of three85,88,89 of the four studies given the nature of their prospective design.  
Onder112 did not mention blinding.   
 
3.5.2.3.4 Outcome 
The occurrence of an ADE/ADR was the primary outcome measure for all studies.  Each study 
used different procedures to identify, categorise and confirm the primary outcome.  Tangiisuran, 
who was the primary researcher (a pharmacist), identified cases and discussed all suspected 
ADRs with the attending hospital physician.  These were then confirmed by a physician, 
independent of the study.  All ADR cases, and 45 non-ADR cases were then reviewed, 
categorised and confirmed by another independent reviewer and agreement with the primary 
researcher on classification reached through discussion.85  Trivalle followed a similar method 
whereby nurses (alongside the study investigators) initially identified potential ADEs which were 
subsequently reviewed on a monthly basis by a team of pharmacists and physicians.  It is unclear 
if this group was independent of the study.  Finally, a select group of reviewers (from the research 
team) reviewed and classified all medicines related incidents.88  Onder only reported that the initial 
identification of an ADR was conducted by the study physician112 and McElnay did not report any 
part of the procedure used for identification, categorisation or confirmation of ADRs89.  A multiple 
step approach to determining the occurrence of ADEs/ADRs is important to ensure validity and 
reliability of the results.  In addition, a validated assessment of causality, in the form of the Naranjo 
algorithm129 or Hallas criteria130, was adopted by all but Trivalle88, who developed their own 
unvalidated checklist.   The outcome was recorded in the form of continuous categorical data, i.e. 
unlikely, possible, probable, definite, which was then collapsed to produce a binary outcome.  For 
example, Tangiisuran85 combined possible, probable and definite as a positive outcome, i.e. the 
participant had suffered an ADR.   Such an approach can affect the statistical power of the 
research109 however, it may be necessary due to a small number of events or when it is difficult 
to categorically state that the event was due to a specific medicine.  The latter often being the 
case when investigating harm due to medicines in an older population who may present with 




Blinding to the outcome occurred in all four studies during the validation phase due to the 
prospective nature (three studies)85,89,112 and the use of bootstrapping, computer simulated re-
sampling technique (one study)88.   
 
3.5.2.3.5 Statistical power 
The poor description of potential candidate predictor variables makes it impossible to determine 
if the studies were adequately powered.  It is commonly understood that study sample size is 
based on the number of outcome events per variable, where ten events per variable is often 
recommended (however sometimes a lower rate may be appropriate).96–98,131  That is, for every 
candidate predictor variable considered in a development study, not just those considered or 
included for multivariable analysis, there should be 10 events.  Van Smeaden and colleagues 
recently called into question this rule and describe the evidence to support its use as “weak”.132  
It is worth noting however, that a high number of variables and a rare outcome can result in over-
fitting of the model (Type I error), thus reducing reliability and reproducibility, leading to poor 
generalisability.  Under-fitting (Type II error) where important variables are omitted and 
paradoxical fitting (Type III error) where variables are given an “incorrect direction of association” 
can also result from an inadequate event per variable ratio.97  Trivalle88 did not report the 
candidate predictor variables and, Tangiisuran85 and McElnay89 failed to reach the recommended 
10 events per variables.  Onder112 had approximately 17 events per variable.   
 
3.5.2.3.6 Selection of predictor variables 
The method of selecting predictor variables for inclusion within the multivariable analysis, also 
known as the fitting procedure or model selection, was described in all four studies (Table 3.5).  
Tangiisuran85 provided the most detailed description of the methods used to select candidate 
predictor variables, whilst Trivalle88 provided the least.  Although there is no standardised method 
for selecting candidate predictor variables for multivariate analysis, it is recognised that selection 
through univariate analysis alone may result in an over-fitted model with spurious predictions.  
Mixed methods, for example using the literature or expert opinion, and univariate analysis, are 
recommended for variable selection as demonstrated by Tangiisuran.85  Inclusion of candidate 
predictors prevalent in at least 5% of the population can also improve the applicability of the final 
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model.85,88,89  In addition there is no set significance level for retaining a variable in the model and 
so it can vary, for example Onder112 set p≥0.1, McElnay89 set p<0.25.  A set statistical significance 
is used in variable selection merely as an objective variable selection method.  Furthermore, when 
selecting variables it is important to consider cost, accessibility in relation to additive predictive 
value and clinical relevance.  
 
3.5.2.4 Model performance and validation 
Assessment of the performance of the model allows an understanding of how well the predictions 
from the model match the observed values.  Two common forms of performance assessment are 
discrimination and calibration, where discrimination is the ability to separate those with, or without, 
the outcome of interest while calibration is the agreement between the predicted outcome and 
the observed outcome.  The AUROC is commonly reported for discrimination where a value of 
>0.7 may be deemed acceptable, but this alone is not sufficient to determine the clinical 
usefulness of the model.109  AUROC was reported by three of the four studies with values ranging 
between 0.70-0.74 for the development phase (see Table 3.6), which involves estimating model 
values in an initial dataset.  Calibration is assessed using two statistical tests, Hosmer-Lemeshow 
test133 and Nagelkerke R2134.  Calibration was only reported by Tangiisuran; for which Hosmer-
Lemeshow was satisfactory but Nagelkerke was low which is suggestive of a small effect size.85  
Sensitivity and specificity were reported by Tangiisuran85, Onder112 and McElnay89 (see Table 
3.6).  Tangiisuran85 reported the highest sensitivity (80%)858483, in comparison to Onder112 
reporting 68% and McElnay89 40.5%.  With regards to specificity, Onder112 reported the highest 
(65%), with McElnay89 reporting 69% and Tangiisruan85 55%.  
All models underwent the subsequent stage of validation using a second dataset of patients, 
which should be conducted prior to the application of a model in the clinical setting.93  Internal 
validation was reported by McElnay89 and Trivalle88 in the form of two approaches: ‘split sample’ 
(separate evaluation in a second dataset) and ‘bootstrapping’ (sampling within a dataset).  Whilst 
the latter can be useful in testing how well the predictors correspond to the outcome in the 
development population, it fails to assess the generalisability of the model.  Good generalisability 
is important if a model is to be of benefit outside of the population in which it was derived.  Internal 
validation, in the same sample, tends to lead to optimistic estimates of a model’s performance, 
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due to the ignoring of sample to sample variation.  External validation is the most rigorous form 
of validation and was performed by both Onder112 and Tangiisuran85, in the same multi-site 
European prospective cohort.  In addition, a research group from Ireland60 subsequently applied 
the model developed by Onder112 in their local population, providing additional external validation.  
The characteristics of the validation populations are described in detail in Table 3.4.  The number 
of patients involved in the external validation ranged from 204 to 483.  AUROC in the validation 
phase ranged from 0.62-0.73.   
 
3.5.2.5 Score development 
Predictor variables within the final models (Table 3.6) were attributed a points-based score, using 
different methods in three of the four models, as a simplification for practical application.  McElnay 
and colleagues89 did not proceed to this stage due to the poor performance of their model.  The 
methods used by Onder112 and Tangiisuran85 are outlined, with Tangiisuran arguably using the 
more robust approach to score development.  The score developed by Onder112 was on a points-
based system where a predictor variable with an OR in the range 1.00-1.99 was assigned 1 point 
for individuals with that predictor present; for predictors with OR in the range 2.00-2.99, 2 points; 
predictors with OR 3.00-3.99, 3 points; and for predictors with OR in the range 4.00-4.99, 4 points.  
There was no assessment to determine if any of the predictive ability was lost in this simplification.  
Tangiisuran85 assigned one point to each predictor variable based on the variable coefficient 
being of the same magnitude.  It is unclear how Trivalle88 assigned the values to each predictor 




Table 3.6 Summary of final ADR prediction models and scoring 
 
  














Prescribed digoxin 0.69 1.99 (1.05-2.33)  
Gastrointestinal problems 0.77 2.16 (1.13-4.15)  
Abnormal potassium 0.95 2.57 (1.35-4.91)  
Thinks drugs responsible 1.44 4.21 (2.18-8.14)  
Experiences angina -1.79 0.16 (0.07-0.42)  
Experiences COAD 0.88 2.41 (1.06-5.44)  













Hyperlipidaemia 1.20 3.32 (1.81-6.07) 1 External (n=483) 
Sensitivity 80.0% 
Specificity 55.0% 
AUROC 0.73 (95% CI 0.66-0.80) 
Number of drugs ≥8 1.20 3.30 (1.93-5.65) 1 
Length of stay ≥12 days 0.82 2.27 (1.35-3.83) 1 
Hypoglycaemic agents 0.65 1.91 (1.04-3.49) 1 
High admission WBC count 0.44 1.55 (0.94-2.55) 1 












Number of drugs NR 1.90 (1.60-2.30) - Internal (bootstrap) 
AUROC 0.70 (95% CI 0.65-0.74) 0-6   0 
7-9   6 
10-12   12 
≥13   18 
Antipsychotic treatment  2.50 (1.50-4.10) 9 
Recent anticoagulant  2.00 (1.10-1.37) 7 
ADR: Adverse Drug Reaction; AUROC: Area Under Receiver Operator Curve; CI: Confidence Interval; COAD: Chronic Obstructive Airways Disease; eGFR: estimated glomerular filtration rate; OR: 
Odds ratio; WBC: White Blood Cell; NR: Not Reported  
 
  
Table 3.6 cont. Summary of final ADR prediction models and scoring 


















AUROC 0.623 (95% CI 0.570-0.676) 
Heart failure  1.79 (1.39-2.30) 1 
Liver disease  1.36 (1.06-1.74) 1 
Number of drugs <5  1 Reference - 
Number of drugs 5-7  1.90 (1.35-2.68) 1 
Number of drugs ≥8  4.07 (2.93-5.65) 4 
Previous ADR  2.41 (1.79-3.23) 2 
Renal failure (eGFR <60ml/min)  1.21 (0.96-1.51) 1 
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3.5.2.6 Impact and implementation 
The impact and implementation of these models have not, as yet, been assessed - perhaps due 
to their poor to modest performance.  McElnay89 recognised the limitation of the level of 
performance and both Tangiisuran85 and Onder112 call for further external validation of their risk 
models.  However, Trivalle88 concluded that their Geriatric Risk Score could be applied in clinical 
practice alongside other prognostic and diagnostic tools such as the Mini Mental State Exam.   
The challenges of using unclear definitions with certain variables as highlighted by O’Connor60 in 
the application of Onder’s risk model should be heeded as similar difficulties are likely to arise 
when applying Tangiisuran85, Trivalle88 and McElnay89 given the poorly defined predictor variables 
outlined earlier.  The use of variables such as length of stay would also make prospective risk 
stratification, e.g. at the point of admission, impossible.    
 
3.6 Discussion 
This review suggests that the four models identified, which were designed to predict the risk of 
older patients suffering an adverse drug reaction, are not yet suitable for use in routine clinical 
practice. While two (Tangiisuran85 and Onder112) had been externally validated, their ability to 
discriminate between those who had experienced an ADR and those who had not was only 
modest, AUROC 0.73 and 0.70 respectively.  In practice this could result in failure to identify 
patients at high-risk of experiencing an ADR for more intensive review.  Furthermore, none were 
subjected to the investigational rigour required when producing a risk prediction model, in 
particular none reported the findings of impact and implementation stages thereby widening the 
gap between research potential and clinical application.135   
All four studies had limitations commonly found in this research field.  While three of the studies 
failed to provide sufficient information relating to events per variable ratio131, one was insufficiently 
powered85 so that the risk of a Type II error (false negative finding) is more likely.136  In addition, 
all studies dichotomised predictor variables (for example when categorising the number of 
medicines) and outcomes (for example collapsing an ADR causality interval scale) despite this 
practice being sub-optimal.137  This approach to data handling reduces the confidence in the 
findings due to the risk of Type I errors (false positive findings).136  The use of unrepresentative 
samples and the issue of how missing data were managed were also problematic regardless of 
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the retrospective or prospective design.  There was often a lack of reporting of all candidate 
predictor variables which hinders replication by others, and consequently the assessment of 
generalisability, and confirmation of genuine predictor variables through external validation.138,139   
Although research investigating medication risk in older adults is growing, as evidenced by the 
over 500 titles identified in the initial search, almost all were associated with other approaches to 
managing risk and a substantial proportion were observational.  This poses the question how do 
we move forward with research in this area?  There appear to be two main challenges.  Firstly, 
when conducting literature searches in both risk prediction and ADR studies, a broad search 
strategy must be adopted to ensure that all studies are identified.   Secondly, in order to identify 
genuine predictor variables consideration must be given to the care setting, the characteristics of 
the population to be studied (for example frail older adults), clarity of outcome definitions (ADR 
versus ADE) and the sample size.  These challenges have been recognised by the Cochrane 
Prognosis Methods Group and the Prognosis Research Strategy (PROGRESS) partnership, who 
have developed a number of recommendations to assist investigators in combating the range of 
challenges.  A Medline search filter has been created to assist in the identification of relevant 
literature135,136,140–142 and since this review was conducted reporting guidelines have been 
developed for authors to apply to their protocols and manuscripts when designing or publishing 
risk prediction research (Transparent Reporting of a multivariable prediction model for Individual 
Prognosis Or Diagnosis – TRIPOD - guidelines).143  
Weaknesses are evident in the models identified however they do make an important contribution 
to the future development of risk prediction models in this field.  Application of these models to 
large datasets, through close collaboration as illustrated by the pan-European work of Onder and 
colleagues113,141 may help identify genuine predictor variables and generate a generalisable 
inpatient model.   
 
3.6.1 Limitations 
A limitation of this systematic review is that we could not assess for publication bias using 
conventional methods such as funnel plots due to the small number of studies available.144  It 
should be highlighted however, that publication bias is likely to be present as suggested by the 
strong body of evidence generated by work in the cancer risk prediction field.68  Registration of 
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risk prediction research, as is increasingly being championed for all clinical trials 
(www.alltrials.net), should go some way to reduce future reporting bias.141  A further limitation is 
that, in the absence of a consensus guideline, this systematic review adapted three sets of 
recognised standards for reporting risk prediction research.  The rationale for this approach was 
to reduce the likelihood of any important quality measures being excluded.   
 
3.6.2 Further ADR risk prediction models 
After the completion of the updated systematic review (October 2016), Nair and colleagues 
published the Prediction of Hospitalization due to Adverse Drug Reactions in Elderly Community 
Dwelling patients (The PADR-EC score).68  The model was developed to predict the risk of 
community patients being admitted to hospital due to ADRs.  Participants were recruited 
prospectively upon admission to hospital for acute, unplanned care.  It was reported that 39.6% 
(n=503) of the study population were excluded: 130 (25.8%) were unwilling to consent and 373 
(74.2%) were unable to be interviewed.  A summary of the population characteristics is provided 
in Table 3.7.  As with the previous studies reviewed, common diseases included those of the 
cardiovascular system.  In contrast, renal failure was the most frequently reported comorbidity, 
affecting almost half the study population (48.4%).  This may be reflective of the point in time that 
the measurement was conducted and the acute nature of the participant’s presentation, in 
comparison to the participants in the other studies who were inpatients and any acute renal 
dysfunction may have already been corrected.  ADRs, based on the WHO definition8, were 
identified using medical records and interviews with the patient or relative.  A patient was 
classified as having an ADR if a known adverse effect of a medication was described, there was 
a temporal relationship, and other causes could be excluded.  Causality was determined using 
the Naranjo algorithm129 and preventability using Schumock and Thornton criteria145.  It was 
unclear who conducted the initial assessment but all patients who were suspected of having an 
ADR, and 10% of cases where there was said to be no ADR, were assessed by a clinical 
pharmacist.  The clinical pharmacist and researcher met to reach a consensus.   An ADR was 
reported in 15% of the population, a rate similar to that reported by Tangiisuran85 and McElnay89 
for inpatient ADR.  Medications prescribed for the management of cardiovascular disease were 
most commonly associated with an admission due to an ADR. 
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Table 3.7 Summary of population characteristics of Nair and colleagues study 
Development Validation 
Population and setting No. of patients (n),  
co-morbidities (%) 
No. of drugs Outcome 
(rate) (%) 
Drugs associated with primary 
outcome (%) Population and setting 
Age: 80.1±7.7 years 
Location: Acute hospital (Australia) 
Year: 2014-15 
Gender: F 52.2% Ethnicity: NR 
n = 768 
Renal failure (48.4) 
Anaemia (39) 
Vascular disease (36.8) 
Hyperlipidaemia (28.6) 
Diabetes (28.1) 
Mean: 10.8  
Range: NR 
SD: 5.2 
ADR (15) Antithrombotics (68) 
ACEIs or ARBs (54.7) 




n = 240 (30 suffered ADR) 
Number of drugs 9.9 ±   4.8 
Cohort similar to development 
cohort 
ACEIs: angiotensin converting enzyme inhibitors; ADR: adverse drug reaction; ARBs; angiotensin receptor blockers; F: female; NR: not reported; SD: standard deviation 
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Nair and colleagues68 reported on the validation of the model, however they did not proceed to 
the impact and implementation stages that are recommended in the development of a quality risk 
prediction model.  Similar limitations were identified to those described for the models developed 
for inpatient use.  The recently published TRIPOD guidelines143 were applied to this study.  It was 
identified that only one third (10/31) of the recommended reporting criteria for the development of 
a risk prediction were fully met (Table 3.8).  The reporting of missing data and the calculation of 
sample size were not considered.  A large proportion of patients were excluded which may have 
resulted in sampling bias, and potentially missing those that suffered the most severe ADRs as 
they were too ill to consent.  Events per variable (EPV) were not reported but could be calculated: 
14 variables were considered and 115 events were identified and so the study failed to meet the 




Table 3.8 TRIPOD checklist: prediction model development as applied to the PADR-EC model 
Section/Topic Checklist Item Checklist item completed 
Title and abstract 
Title 
Identify the study as developing and/or validating a multivariable 
prediction model, the target population, and the outcome to be 
predicted. 
Partly 
Study developing and/or validating multivariable model – No 
Target population – Yes 
Outcome to be predicted - Yes 
Abstract 
Provide a summary of objectives, study design, setting, participants, 
sample size, predictors, outcome, statistical analysis, results, and 
conclusions. 
Partly 
Objectives – No 
Study design – Yes 
Setting – Yes – broad i.e. hospital 
Participants – yes – broad i.e. over 65years 
Sample size – yes 
Predictors – yes 
Outcome – yes 
Statistical analysis – no 
Results – yes – frequency ADR, outcome of logistic regression and preventability 
reported 




Explain the medical context (including whether diagnostic or 
prognostic) and the rationale for developing or validating the 
multivariable prediction model, including references to existing 
models. 
Partly 
Medical context – yes, does not explicitly state that it is prognostic. 
Rationale – yes 
Reference to existing models -  only 2 of 4 
Specify the objectives, including whether the study describes the 
development or validation of the model or both. 
No 
Objectives – no, broad aim of developing and validating a model 
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Table 3.8 cont. TRIPOD checklist: prediction model development as applied to the PADR-EC model 
Section/Topic Checklist Item Checklist item completed 
Methods 
Source of data 
Describe the study design or source of data (e.g., randomized trial, 
cohort, or registry data), separately for the development and 
validation data sets, if applicable. 
Yes 
Source data described – yes  
Cohort study 
Reported separately for development and validation 
Specify the key study dates, including start of accrual; end of 
accrual; and, if applicable, end of follow-up.  
Yes 
Start and end of accrual – yes (Development = 12months, Validation = 4months) 
Participants 
Specify key elements of the study setting (e.g., primary care, 
secondary care, general population) including number and location 
of centres. 
Partly 
Study setting – yes, secondary care acute medical wards for development and 
validation.  Number of wards not stated. 
Describe eligibility criteria for participants.  
Yes 
≥65 years, unplanned emergency admission to medical wards. Excluded if refused 
participation, unable to be interviewed, medical notes unavailable. 
Give details of treatments received, if relevant.  NA 
Outcome 
Clearly define the outcome that is predicted by the prediction 
model, including how and when assessed.  
Partly  
Outcome clearly defined – yes, ADR (WHO definition). Assessed by researcher 
(unknown qualifications). Medical record review and patient/relative interview.  
ADR positive if known side-effect based on Australian Medicines Handbook, temporal 
relationship, after investigation other causes excluded.  
Causality based on Naranjo. Only definite and probable included.  
Report any actions to blind assessment of the outcome to be 
predicted.  
No 
No blinding. Primary researcher collected data, screened for ADRs.  Prospective 
study so variables selected prior to knowing outcome. Independent blinded senior 




Table 3.8 cont. TRIPOD checklist: prediction model development as applied to the PADR-EC model 
Section/Topic Checklist Item Checklist item completed 
Predictors 
Clearly define all predictors used in developing or validating the 
multivariable prediction model, including how and when they were 
measured. 
Yes 
Medicines prior to admission – WHO ATC 
Number of medicine – number of active ingredients 
Clinical diagnosis – International Classification of Primary Care 
Co-morbidity – Charleson Comorbidity Index 
Renal failure – eGFR <60ml/min 
Liver disease – raised ALT (twice normal range) or documented liver disease 
Anaemia – Hb<120 female, <130 male 
Comorbidities defined as present if documented in medical records. 
Functionality – Barthel 
PIMS – Beers 
Recent changes to drugs – addition, deletion or change of dose in past 3 months, 
excluding PRN. (from interview) 
Report any actions to blind assessment of predictors for the 
outcome and other predictors.  
None 
Sample size Explain how the study size was arrived at. 
No 
Not explained – convenience sample. No mention of need to have minimum EPV. 
Missing data 
Describe how missing data were handled (e.g., complete-case 
analysis, single imputation, multiple imputation) with details of any 
imputation method.  
No 
Missing data outlined in table 2. Described the characteristics but unclear if from 





Table 3.8 cont. TRIPOD checklist: prediction model development as applied to the PADR-EC model 




Describe how predictors were handled in the analyses.  
Yes 
Variables identified using univariate analysis (Chi square or Fisher’s exact test) were 
taken forward for binary logistic regression p<0.20 
Multicollinearity between independent categorical variables assessed using phi 
coefficient. Two variables with phi ≥0.3 were trialled separately in model and one with 
highest predictive ability was retained.  
Specify type of model, all model-building procedures (including any 
predictor selection), and method for internal validation. 
Partly 
As per GerontoNet – stepwise logistic regression.  Added and retained variables if 
p≤0.1. Method of elimination and retention unclear. Score developed as per 
GerontoNet – OR 1.00-1.49 =1, 1.5-2.49 = 2, 2.5-3.49 = 3 etc.  
No internal validation. 
Specify all measures used to assess model performance and, if 
relevant, to compare multiple models.  
Partly 
AUROC 





Table 3.8 cont. TRIPOD checklist: prediction model development as applied to the PADR-EC model 
Section/Topic Checklist Item Checklist item completed 
Results 
Participants 
Describe the flow of participants through the study, including the 
number of participants with and without the outcome and, if 
applicable, a summary of the follow-up time. A diagram may be 
helpful.  
Partly - development 
1271 screened, 768 took part. 115 had ADR (Definite/Probable). 653 no ADR. 
Proportion doubtful/possible not reported. 
Partly – validation 
518 screened, 123 not willing, 155 too ill. 240 took part. 30 had ADR 
(definite/probable). 210 no ADR. Proportion of doubtful/possible not reported.  
Describe the characteristics of the participants (basic 
demographics, clinical features, available predictors), including the 





Specify the number of participants and outcome events in each 
analysis.  
Yes  
Development 768 participants, 115 ADR 
Validation 240 participants, 30 ADR 
If done, report the unadjusted association between each candidate 
predictor and outcome. 
No 
Adjusted OR reported for each candidate predictor and outcome. 
Model 
specification 
Present the full prediction model to allow predictions for individuals 
(i.e., all regression coefficients, and model intercept or baseline 
survival at a given time point). 
No 
Regression coefficients and model intercept not reported.   
Explain how to use the prediction model. No 
Model 
performance 
Report performance measures (with CIs) for the prediction model. 
Partly 
Only reported OR (95% CI) for variables included in model, AUROC and sensitivity 
and specificity at given cut point. 




Table 3.8 cont. TRIPOD checklist: prediction model development as applied to the PADR-EC model 
Section/Topic Checklist Item Checklist item completed 
Discussion 
Limitations 
Discuss any limitations of the study (such as non-representative 
sample, few events per predictor, missing data).  
Partly 
Did not validate in community population. 
Drug changes in past 3 months may have been inaccurate.  
Variables from patient interviews may be subject to recall bias 
Most unwell (and so at risk) patients may not be included as couldn’t get consent.  
Limitations do not discuss missing data, events per variables, clinical judgement 
variations on complex outcome.  
Interpretation 
Give an overall interpretation of the results, considering objectives, 




Discuss the potential clinical use of the model and implications for 





Provide information about the availability of supplementary 
resources, such as study protocol, Web calculator, and data sets.  
No 
Funding 





Nair68 produced a model which included six variables as outlined in Table 3.9; the predictive ability 
of this model was no better than the models identified in the systematic review, AUROC 0.70 
(95% CI 0.65-0.75), sensitivity 72.2% and specificity 58%.  External validation produced an 
AUROC 0.67 (95% CI 0.56-0.78), sensitivity and specificity 63%.  The methods followed by Nair 
and colleagues68 replicated that of Onder and colleagues114 so it is perhaps unsurprising that the 
models perform similarly.  
Table 3.9 Summary of PADR-EC model and scoring 
Significant variables (multivariate 
analysis) OR (95% CI) Score Validation 
Drug changes in the preceding 3 months 1.54 (1.00-2.37) 2 External (n=240) 
Sensitivity 63% 
Specificity 63% 
AUROC 0.67 (95% CI 
0.56-0.78) 
Renal failure (eGFR<60ml/min) 1.97 (1.22-3.17) 2 
Dementia 2.44 (1.17-5.10) 2 
Number of antihypertensives   
1-2 3.00 (1.22-7.38) 3 
≥3 4.75 (1.89-11.93) 5 
Anticholinergics 2.09 (1.16-3.75) 2 
AUROC: area under the receiver operator curve; CI: confidence interval; eGFR: estimated glomerular filtration rate; 
OR: odds ratio 
 
In addition to clinical and medication variables that the previous studies considered, Nair68 
included PIMS (according to Beers57), any recent changes to medications and groups of 
medications e.g. multiple antihypertensives. Univariate analysis also assessed associations 
between variable and outcome for: admission in preceding month or 3 months, use of dosing 
administration aid, use of generics, use of alcohol, smokers, presence of ADR within 3months, 
regular pharmacy visits, HMR in preceding 3months, assistance required with >1 activities of daily 
living (ADL).  Many of these variables were not considered in the previous model development 
and, of these, drug changes in the previous 3 months was the only one that was retained in the 
final model.  Whilst it is commendable to incorporate these previously “untested” variables, the 
authors failed to consider variables relating to the important concept of frailty in this population.  
None of the existing models have considered this and none have developed a model with good 
enough accuracy for use in clinical practice.  The addition of frailty to a future model, measured 
using an easy to conduct assessment such as hand grip strength, may provide a level of accuracy 




Risk stratification is attractive, especially in older patients where the population is growing, placing 
an increased demand on the healthcare service - a service which is woefully underprepared for 
the projected global growth.146  Models must be of high quality for clinicians to have confidence 
in their ability to predict risk with adequate sensitivity and specificity, especially in the case of ADR 
risk prediction models, a poorly researched area of risk prediction.  Five ADR risk prediction 
models were identified with poor to modest performance, raising questions about their overall 
quality.  Further work needs to be conducted on these existing models to develop a robust ADR 
risk prediction model which is externally validated, with practical design and good performance.  
Issues highlighted in this review were primarily in the study design and the approach used for 
evaluation: low sample size, lack of an independent validation sample, and little attention to 
recommended lists for assessing assumptions.   
Four of the models were developed to address medication harm in the inpatient setting.  The 
development of more models within this setting continues as outlined by the SENATOR Project, 
a pan-Europe collaboration which aims to develop computer software that will optimize 
medications and non-pharmacological interventions in multimorbid older adults.147  Whilst this 
may be an important line of enquiry, identifying those at risk in the community or at the point of 
discharge from hospital may have more impact.148  Transferring a patient between care settings 
is associated with a high-risk of harm, partly due to changes in patients’ clinical status, 
medications and functionality, and the failure to effectively communicate such changes.  The NHS 
National Reporting and Learning System recorded approximately 10,000 reports of patient safety 
incidents relating to discharge in one year (October 2012 – September 2013), with the most 
severe outcomes being death and avoidable re-admission to hospital.149  The ability to identify 
those at risk of medication harm at this stage in the patient journey and focusing on costly 
medication related hospital re-admissions2 could assist in the targeting of interventions and the 




3.8 Re-framing medication related harm – a potential conceptual 
framework 
3.8.1 The need to move risk prediction research forward 
The literature highlights many variables which are significantly associated with medication related 
harm with a large focus upon clinical variables, and individual or classes of medicines.  Except 
for the number of medicines, the significance of most associations decreases or disappears when 
combined in a multivariate model, indicating potential multicollinearity between these previously 
studied variables.  Furthermore, as outlined in the systematic review, when developed into a 
predictive model, only a moderate predictive ability is demonstrated.  This research finding is 
supported by observations in clinical practice where not all older adults taking multiple medicines, 
with complex comorbidities, experience MRH.  The focus of MRH research needs to move beyond 
the clinical and medicine-related variables and adopt a more holistic approach incorporating the 
psychological and social systems which influence medicines use.   
It is notable from the literature that whilst a few studies have considered functional or social 
variables, for example independence in activities of daily living or alcohol consumption, the 
variables which influence how medicines are used have not been explored fully.  These variables 
may include social support mechanisms, or factors influencing adherence to treatments such as 
depression.  Perhaps it is only those who have risks, or deficits, across multiple systems (clinical, 
medicines and/or psychosocial) that are increasingly vulnerable to MRH.  Parallels may be drawn 
between this theory and the concept of frailty.  Scarcely considered in the context of MRH risk 
prediction research, frailty, said to be “the most problematic expression of population ageing”, is 
recognised to increase an individual’s risk of experiencing adverse health outcomes when 
exposed to an external stressor.150  When this external stressor is a medicine, the outcome may 
be medication related harm.   
Multiple models have been developed to measure frailty however, the phenotype model151 and 
frailty index (FI)152 dominate the literature.  Two distinct instruments, the phenotype model 
focusses upon pre-defined signs and symptoms, in comparison to the FI which calculates the 
number of deficits accumulated from an unspecified set of criteria relating to disease and 
function.153 Based on the principle “the more individuals have wrong with them, the higher the 
likelihood they will be frail”154, it seems that there is a limit to the number of deficits.  The maximum 
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FI compatible with life is 0.67.  Clegg and colleagues155 derived an electronic FI (eFI) for use in 
the community setting.  In this study, the severity of frailty was categorised as patients with an 
eFI score of 0-0.12 were fit; >0.12-0.24 were mildly frail; >0.24-036 moderately frail and > 0.36 
as severely frail.  Estimated prevalence for each of these categories was 50, 35, 12 and 3%, 
respectively. 
Cullinan and colleagues156 recently tested the hypothesis that there is a relationship between 
frailty and potentially inappropriate prescribing (PIP) and ADR risk.  They concluded that a patient 
with a frailty index (FI) of ≥0.16 is more than twice as likely to experience an ADR, stating that a 
FI could be a useful clinical indicator.  The concept of frailty warrants further exploration in order 
to identifying potential variables associated with MRH. 
 
3.8.2 Frailty and medication related harm 
The physiological adaptions that occur with ageing and disease, and the resulting impact on the 
basic pharmacokinetics and pharmacodynamics of medicines, has been extensively described in 
the literature.102  However, it is likely that the physiological changes only partly explain the risk of 
MRH in older adults as social and psychological factors may also contribute.  This bears 
congruence with Rockwood and colleagues’157 proposal that a definition of frailty should 
encompass not only medical but psychological and social factors too.  Another similarity is the 
dynamic nature of MRH risk and frailty.  As with frailty, a reduction in deficits are likely to be 
equally as important as the accumulation of deficits when considering the future risk of MRH and 
appreciating that risk can increase and decrease with time.  Nicholson and colleagues158 recently 
emphasised that whilst existing frailty models focus upon deficits, considering what a patient can 
do should not be overlooked.  This salutogenic approach, meaning an approach which focuses 
upon factors which support health rather than purely focus upon disease159, recognises the 
relevance of coping strategies and the resilience of older patients when challenged.158   Figure 
3.2 attempts to explain the complex interplay between the physiological and psychosocial 





Figure 3.2 Proposed model outlining the relationship between age, disease, psychosocial issues and MRH 
  
A simplistic linear visualisation of the journey from a medicine being prescribed, to the potential 
use by the patient (adherence or non-adherence), and the consequence of this action being a 
therapeutic effect, an adverse effect or no effect is presented, Figure 3.2.  The journey is of course 
far more complex.  The physiological and psychosocial systems which influence the action and 
the consequence of medicines use must be considered.  Failure to consider these systems at the 
point of prescribing a medicine may result in MRH e.g. a patient with age-related renal impairment 
who is prescribed a medicine that is largely dependent upon renal excretion, such as gentamicin, 
is likely to experience increased plasma concentrations, resulting in MRH if a dose adjustment is 
not made at the point of prescribing.  Similarly, a patient who is dependent upon a multi-
compartment compliance aid (MCA) (colloquially referred to as a dosette box) for support with the 
administration of their medicine and is prescribed a medicine which cannot be added to the MCA 
(e.g. warfarin due to the variability in dosing), may experience MRH due to the omission of the 
medicine.  These examples illustrate the potential relationship between the action of prescribing 
a medicine and the physiological and psychosocial systems which influence the outcome (efficacy 
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or adverse effects).  Further exploration of this relationship is beyond the scope of this thesis 
which will focus on the post-prescribing period.    
When considering the physiological system, it is necessary to discuss the concept of physiological 
reserve.  An innate excess capacity of organs and biological systems, it is essential in maintaining 
physiological homeostasis.  It is however limited, and may be overwhelmed by a substantial insult.  
Whilst physical, nutritional or lifestyle interventions for example may improve or preserve function, 
over the course of a lifetime the physiological reserve of an individual will decline.  Different, but 
often linked, mechanisms i.e. ageing and/or disease (Figure 3.2) impact on the loss of reserve, 
the rate and chronology of which is subject to individual variation.  A depletion of this reserve may 
increase the likelihood of adverse events, as seen in frailty.  
With regards to MRH, adequate function of the physiological system will theoretically result in the 
expected therapeutic effect of a medicine when administered at a therapeutic dose.  In contrast, 
a significant overdose of a medicine is likely to overwhelm the physiological reserve of any 
individual regardless of excess capacity.  When a medicine is administered at an acceptable 
therapeutic dose to an individual with a depleted physiological reserve, the risk of harm due to 
the medicine is likely to increase, but will be dependent upon several factors including the drug 
pharmacology, the extent to which the physiological reserve is depleted, and which organs and 
biological systems are involved.  An individual may tolerate a complex medicine regimen whilst 
there is a depleted, yet sufficient, physiological reserve, however the balance between tolerating 
the medicines and harm is likely to be very delicate.  Any further insult, be it major or minor, to 
the physiological system may be enough to topple the balance, resulting in harm.  This could, for 
example, be in the form of an acute infection, the addition or removal of a drug, or simply 
continued ageing.  It may also be due to a reduction in the functional capacity of the psychosocial 
system.   
The reserve, or excess capacity, within the psychosocial system is influenced by a wide range of 
factors some of which include functional ability, social support, cognition, mood or financial 
circumstances and, as outlined in Figure 3.2, the function of the physiological system.  As an 
example, poor health due to disease resulting in impaired physiological function can reduce mood, 
and thus psychosocial reserve, and vice versa.  As with physiological reserve, an individual may 
tolerate a complex medicine regimen even when the psychosocial reserve is depleted, however 
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a minor insult may result in significant harm. The fragility of this balance may be likened to the 
vulnerability of a frail older person to even minor insults as outlined by Clegg and colleagues150  
whereby the initiation of a new drug for example may result in a disproportionate level of harm.  
In addition to the influence of the physiological and psychosocial systems, it would also seem 
plausible that the consequence of a previous action feeds back to impact directly on future actions 
and also on the capacity of the physiological and psychosocial systems.  For example, a patient 
with depleted physiological and psychosocial systems due to severe chronic obstructive 
pulmonary disease experiences oral thrush secondary to an inhaled corticosteroid.  As a result 
they become non-adherent to their inhaler which results in a further decline in respiratory function 
and a reduction in mood which in turn influences future actions with detrimental consequences.  
A further complexity is polypharmacy.  Where a patient is prescribed multiple medicines, 
elucidating the causal factor becomes increasingly challenging, as highlighted by the many 
interacting pathways in Figure 3.3.   
 
Figure 3.3 Interaction between systems, action and consequences in a patient prescribed multiple medicines 
 
In such a complex system, it is difficult to conclusively associate a specific medicine with an 
observed harm.  This represents a significant challenge when conducting MRH risk research as 
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the misappropriation of blame may occur.  Such misclassification of events will influence the level 
of significance of the associations of variables and MRH, and thus the accuracy of the predictive 
model in which they are incorporated. 
It is likely that multiple factors; medicine related, physiological and psychosocial, contribute to 
MRH but the extent to which is debatable.  With increasing age comes increasing heterogeneity, 
making the identification of universal MRH risk prediction variables even more challenging.  
 
3.8.3 Medication related harm, a geriatric syndrome? 
A concept which successfully identifies global risk factors in an older population is that of geriatric 
syndromes.  Consisting of delirium, falls, frailty, dizziness, syncope, and urinary incontinence, 
Inouye and colleagues160 define the concept of geriatric syndromes and their multifactorial nature 
and shared risk factors.  Like frailty, they argue that geriatric syndromes defy traditional medical 
practice due to the requirement to look beyond the biological model and consider social, spiritual 
and financial domains.  The numerous potential pathways leading to the manifestation of a 
geriatric syndrome, and the interaction between these pathways, is complex and cannot be 
compartmentalised, for example to a single body system.  It may be argued that this is similar to 
MRH where, as already described, multiple causes contribute to an outcome.  
The reported shared risk factors of geriatric syndromes include; old age, cognitive impairment, 
functional impairment and impaired mobility.  Inouye and colleagues propose a combined 
conceptual model whereby geriatric syndromes lead to frailty which in turn, through shared risk 





Figure 3.4 Conceptual model developed by Inouye and colleagues demonstrating shared risk factors 
potentially leading to geriatric syndromes and frailty 
 
It is proposed that given the commonality that exists between geriatric syndromes (and thus frailty) 
and MRH, that MRH may be considered a geriatric syndrome.  Where previous studies have 
demonstrated an association between polypharmacy and geriatric syndromes161, here it is 
proposed that it is MRH that is the geriatric syndrome rather than polypharmacy.  In order to 
investigate this hypothesis it is necessary to explore associations between the frailty risk factors 
and MRH, with the aim of identifying key risk prediction variables for MRH.  Only then can the 
development of a predictive model for MRH with greater accuracy than those already identified in 
the literature be attempted.  
 
3.8.4 Outcome of MRH 
Over and above the severity of MRH, the level of physiological and psychosocial reserve may 
influence the type of healthcare utilised as a consequence of harm.  The salutogenic approach 
described earlier supports the theory that the same insult experienced by different individuals may 
have a different outcome, depending upon their coping strategies (which are related to their 
physiological and psychosocial reserve).  A relatively minor insult in the form of harm from a new 
medicine may result in the self-management of harm in one individual, but may require healthcare 





Figure 3.5 Case example illustrating that the same insult (medicines) to different individuals may have a 
different outcome 
 
Therefore, whilst the level of healthcare utilisation secondary to MRH is of interest, it should be 
kept in mind that a particular type of MRH is unlikely to predict the type of healthcare utilisation 
sought.  The exception may be in the most severe form of MRH where physiological and 
psychosocial systems are completely overwhelmed and hospitalisation is required.   
 
3.9 Summary 
This work highlights that although numerous factors have been associated with MRH, we may 
need to consider the occurrence of MRH more in line with frailty and/or geriatric syndromes.  The 
proposed conceptual framework (Figure 3.3) will be referred to in Chapter 4 and Chapter 5 as a 




Chapter 4 Prospective cohort study 
4.1 Introduction 
Hospitalisation due to MRH reflects significant morbidity and is costly to the NHS.  A recent 
systematic review of studies conducted in the acute care setting and published between 2003 – 
2013 investigated ADRs causing admission of patients aged 65 years old or over.  Across the 14 
studies included in the review, a median prevalence of ADR related hospitalisation was 10% (95% 
CI: 7.2%–12.8%).122  Whilst there are many studies reporting hospitalisation secondary to ADRs, 
few have explored the incidence of MRH during the post-discharge period.  A review of European 
ADR observational studies published from January 2000 onwards, found only 5 papers reporting 
the ADR rate in the outpatient setting - none of which focussed on older adults.11  Another review, 
using an outcome definition of post-discharge drug related problems, Garcia-Caballos and 
colleagues’24 concentrated on studies with a population age of over 60 years old.  The reported 
incidence of post-discharge MRH ranged from 18.4-37.5% and, where reported, a third were 
preventable26.  No study exploring post-discharge MRH in a frail older population has been 
conducted in the UK.   
At a time when patients are at an increased risk of adverse outcomes23, an understanding of the 
incidence, severity and causality of MRH during the post-discharge period may help to guide 
medicine optimisation strategies in older adults.  As outlined in Chapter 3, there are many studies 
which have investigated inpatient ADRs and ADEs in an attempt to develop models to predict 
those most at risk of harm18,85,88,89.  One study focussed on the risk of hospital admission due to 
ADRs.68  The poor to moderate accuracy of these models is perhaps the result of concentrating 
on clinical and medicine related variables.  Whilst important variables when considering harm 
from medicines, the conceptual framework presented in Chapter 3 (Figure 3.3) suggests that they 
are not fully representative of the multiple and diverse range of variables that can influence an 
individual’s risk of adverse outcomes.  Likened to frailty, and geriatric syndromes, it is proposed 
that MRH does not have a clearly defined cause but is influenced by physiological, psychological 
and social parameters.  These parameters are likely to interact synergistically and so exploring 
psychosocial variables in addition to physiological variables is important in order to advance our 
ability in identifying those at risk of MRH.  Furthermore, the frequency and type of healthcare 
accessed in relation to MRH is likely to be influenced by these variables too. 
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Older adults are four times as likely to be hospitalised due to an ADR compared to younger 
people39 but the healthcare utilisation associated with post-discharge MRH is unknown.  It is likely 
that whilst hospitalisation is the most costly outcome of MRH, and therefore worthwhile 
investigating, the frequency of community based care associated with MRH will be high.   
Little is known about post-discharge MRH in older adults, although it is suspected to commonly 
occur and have significant impact on the healthcare system.  The ability to identify those at risk 
of post-discharge harm could improve the efficiency of the healthcare provided to this population, 
but needs to consider factors outside the traditional clinical or medicines-related domains.  
 
4.2 Aim and objectives 
The aim of this observational study was to explore MRH experienced by older adults following 
discharge from an acute inpatient episode in a UK hospital.  The objectives were:  
1. Assess the frequency, causality, severity and preventability of MRH during the 8-weeks 
post-discharge from hospital.  
2. Determine the frequency of healthcare episodes related to post-discharge MRH. 
3. Describe the medicines most commonly causing MRH. 
 
4.3 Methods 
4.3.1 Research setting 
This research was undertaken over a 24-month period (December 2013 – December 2015) on 
the acute older persons’ unit (OPU) at St. Thomas’ Hospital, part of GSTFT.  GSTFT is a large 
inner-city London hospital trust, with over 1200 hospital beds, offering emergency and specialist 
care to the local boroughs of Lambeth and Southwark (44% of inpatients) and beyond (38% and 
18% of inpatients are from the rest of London and UK respectively).  Lambeth and Southwark are 
amongst the most deprived local authorities within the UK, ranking 14th and 25th out of 326 areas 
on the Index of Multiple Deprivation.  Approximately a third of over 60 year olds live in income 





The OPU accounts for approximately a third (36.7%) of general medical beds at St. Thomas’ 
Hospital and consists of three wards (84 beds).  Upon admission to the hospital, patients are 
triaged by a specialist geriatric multidisciplinary team.  This team allocates OPU beds on the basis 
of availability and need.  A review of patient need is conducted by the specialist team around nine 
domains, outlined in Table 4.1.  Therefore, patients admitted to the OPU are selected on the basis 
of multimorbidity and frailty, both factors likely to increase the incidence of MRH.  For example, 
most patients admitted to the OPU will have “deficits” in at least four domains described.  
Table 4.1 Referral criteria for admission to OPU 
Domain Rationale for selection for a specialist OPU 
Age Normally over 70 years old (younger if medically old/frail e.g. due to stroke or 
Parkinson’s Disease.  Majority are over 80 years old. 
Cognitive function Dementia or delirium - high priority. 
Continence Incontinence and/or difficulties with elimination in general e.g. constipation, 
urinary retention. 
Mobility Poor mobility - higher priority to those with a sudden decline and probable 
potential for reversibility. 
Falls risk Falls of unknown cause requiring investigations and observations.  
Pressure care/complex 
wounds 
Multiple causes, indicative of increased nursing care and nutritional needs. 
Nutrition Poor swallow resulting in high-risk of aspiration, malnourished and become 
very frail when they are ill. 
Complex medical issues Often incurable, degenerative conditions such as chronic obstructive 
pulmonary disease or heart failure. 




4.3.2.1 Inclusion criteria 
Patients had to be over the age of 65 years at the time of recruitment and registered with a GP 
within Lambeth, Southwark or Westminster Clinical Commissioning Groups (CCGs).  These 
localities were selected as they included the majority of patients admitted to the OPU whilst 
keeping the geographical spread of GP practices manageable for the follow up data collection 
phase.  The locality of the patient’s GP practice was obtained from the patient’s electronic records 
and confirmed with the patient during recruitment to the study.  
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4.3.2.2 Exclusion criteria 
Patients were excluded from the study if they did not consent to participate in the study; lacked 
capacity and did not have a personal consultee; were transferred to another acute healthcare 
trust (excluding transfer to an intermediate care facility) or; had a short life expectancy and were 
therefore unlikely to survive to the end of study eight week follow up period.   
Capacity, in accordance with the Mental Capacity Act 2005163, was assessed by the research 
nurse or research pharmacist who had undertaken capacity and consent training.  It was 
recognised that seeking consent from this population may present some issues: many older 
patients suffer fluctuating or temporary loss of capacity upon admission to hospital due to delirium; 
some older patients may lack capacity for the duration of the study; gaining consent may be 
unsettling, creating confusion as they will not experience change in their clinical care.  Previous 
studies in this area have not consented participants however they have not studied primary care 
utilisation or self-reported medication related problems.164  It is important that primary care 
utilisation is investigated as this outcome measure has rarely been studied in the field of 
medication harm in older adults and is likely to be contribute to increased workloads and pressure 
on services.  
Patients with a short life expectancy were identified as those who had been place on the AMBER 
Care Pathway.  Recommended by the Department of Health, and developed at GSTFT, this care 
bundle is designed to improve the quality of care of patients where recovery is uncertain and, 
although they are still receiving active treatment, they are at risk of dying in the next 4-8 weeks.165 
 
4.3.3 Patient recruitment 
The patient recruitment and data collection process are outlined in Figure 4.1.  Patients medically 
fit for discharge from the OPU were screened against the inclusion criteria and, where eligible, 
were invited to participate in the study by the research nurse or pharmacist.  The principles of the 
Declaration of Helsinki were upheld, and patients were provided with verbal and written study 
information and allowed a minimum of 24 hours to decide if they wished to participate.  Written 
consent (or assent) was obtained from all participants.  Where a patient lacked capacity to 
consent, their next of kin was asked to act as a personal consultee and to support their relative 
taking part in the study.  It was important to include those who lacked capacity, as failure to do so 
 102 
 
could exclude those who are potentially most likely to experience MRH i.e. those most vulnerable 
due to frailty and/or cognitive impairment.  Where a potential participant lacked capacity and the 
next of kin was unavailable, they were excluded from the study.  Patients who consented to be 
included in the study were assigned a Unique Patient Identifier Number (UPIN) which was used 
throughout the data analysis to maintain patient confidentiality.   
 
4.3.4 Data collection process 
A standardised CRF was designed by the principal researcher to capture all relevant data.  Up to 
three data sources (the clinical records, the patients/carers and the direct care team) were used 
to generate the most accurate patient data. 
Baseline admission and follow up data were collected by the principal researcher, research nurse 
or pharmacist using the CRF.  Details of the baseline data collected are described later in this 
chapter and are summarised in Figure 4.1. 
The follow up data collection process (Figure 4.1) was conducted 8 weeks after discharge from 
hospital by the principal researcher and included a review of up to three sources: 1. Patient 










4.3.5 Standardisation of data to be collected 
The possible data to be collected and the outcomes to be assessed, were identified by the 
principal researcher and verified by an expert panel following the steps outlined in Figure 4.2. 
 
 
Figure 4.2 Process of identification and selection of data to be collected and agreement on definition of 
outcome 
 
Following a comprehensive review of the literature by the principal researcher, including a 
systematic review to identify existing MRH risk prediction models, a conceptual framework was 
developed as described in Chapter 3 (Figure 3.3).   In summary, where previous studies have 
focussed on clinical and medicine related risk variables, it is proposed that both physiological and 
psychosocial variables are equally important when considering the risk of an older person 
experiencing MRH.  This is consistent with the key domains that are believed to contribute to 
frailty.157  The link between frailty and harm from medicines is supported by Cullinan and 
colleagues156 where, in a study of 711 older inpatients, it was concluded that those with a FI of 
≥0.16 were twice as likely to experience an ADR.   
From the literature, a list of potential variables, including previously studied MRH risk variables 
and variables associated with frailty, was generated (Appendix C).  The list was emailed to an 
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expert panel two weeks prior to meeting to determine the data to be captured.  The panel of local 
and international experts consisted of: 
• 2 professors of geriatric medicine (UK and Netherlands) 
• 2 consultant geriatricians (UK) 
• 1 professor of clinical pharmacy and therapeutics (UK) 
• 2 clinical pharmacists specialising in older people (UK) 
The expert panel reviewed all variables for their clinical relevance and consistency with the 
literature.  They considered and agreed for each potential MRH risk variable: the importance 
(essential, desirable, not important); the timing and frequency of collection (for example, on 
admission or discharge); the source of the data; if there was an existing measure used in practice 
for example, the Barthel Index as a measurement of activities of daily living; whether the potential 
MRH risk variable had been included in an existing MRH risk prediction model; and ultimately if 
the variable should be included.  Variables deemed non-significant following assessment by 
univariate analysis in previous studies were not immediately discounted; their significance was 
reviewed by the expert panel.  This is recognised practice and is especially important if the dataset 
is small or the variable rare.109  Agreement on the potential MRH risk variables to be collected 
was reached through discussion.  Basic demographic data to be collected was agreed.   
 
4.3.6 Baseline data 
Data collected for all patients included demographic (e.g. age, gender, ethnicity), clinical (e.g. 
presenting complaint, discharge diagnosis, co-morbidities, renal and hepatic function, 
biochemistry), medicines (e.g. name, dose, frequency and use of a compliance aid), length of 
stay and social information (e.g. care package provision, support with medicines and living 
arrangements).   
Where possible, validated instruments, used routinely on the OPU were used to collect data such 
as nutritional status, functional ability, cognitive function and depression and anxiety as outlined 
in Table 4.2.   The utilisation of instruments used in routine care should improve the transferability 
of any future risk prediction model developed.  The assessments were conducted by the research 
nurse/pharmacist and, where appropriate, the OPU nurse caring for the patient.  Training was 
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provided to ensure consistency of assessment.  Questions in the abbreviated mental test score 
(AMTS), patient health questionnaire (PHQ-2) and general anxiety disorder score (GAD-2) were 
asked as written to reduce any subjectivity.        
Table 4.2 Validated assessments used in data collection 
Variable of interest Validated assessment Who conducted assessment 
Nutritional status MUST166 Research nurse/pharmacist 
Function ability Barthel ADL121 Research nurse/pharmacist/OPU nurse 
Frailty measure Hand grip167 Research nurse/pharmacist 
Cognitive function AMTS168 Research nurse/pharmacist 
Depression  PHQ-2 questionnaire169 Research nurse/pharmacist 
Anxiety GAD-2 questionnaire170 Research nurse/pharmacist 
ADL: Activities of Daily Living; AMTS: Abbreviated Mental Test Score; GAD-2: General Anxiety Disorder-2; MUST: 
Malnutrition Universal Screening Tool; OPU: Older Persons Unit; PHQ-2: Patient Health Questionnaire-2 
 
4.3.6.1 Nutritional status 
Many validated and widely used tools are available for the screening of malnutrition in clinical 
practice including, the Subjective Global Assessment (SGA)171, Mini-Nutritional Assessment 
(MNA)172 and Nutrition Risk Screening (NRS)173 and the Malnutrition Universal Screening Tool 
(‘MUST’)166.  The SGA, MNA and NRS all require the patient’s weight, which can be difficult to 
obtain in the busy clinical environment, the ‘MUST’ does not.  It is also the nutritional screening 
tool recommended by the British Association for Enteral and Parenteral Nutrition (BAPEN) and 
used on the OPU at St. Thomas’ Hospital and so was used for this study.  The score ranges from 
0-2, with 0 indicating low, one medium and two a high malnutrition risk.  All patients scoring 2 are 
referred to the dietician for assessment and treatment.  
 
4.3.6.2 Functional ability 
The modified Barthel ADL index is a 10 item (20 point) score used to measure the performance 
of activities of daily living.(13)  Originally developed to measure rehabilitation progress, it is 
commonly used to assess disability in the acute clinical environment.174   Studies investigating its 
reliability when used in the older population are limited and a systematic review concluded that 
it’s accuracy may be reduced in those with cognitive impairment when assessment via physician 
interview and nurse observation are compared.174  The studies however are too few and small to 
draw robust conclusions.  When compared to the Katz ADL it was suggested to be the more 
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appropriate index for the acute care setting175 and is the measurement of ADL used on the OPU 
at St. Thomas’ and also for this study. 
 
4.3.6.3 Cognitive function assessment 
An extensive range of cognitive function assessment tools are described in the literature including 
the MMSE, Mini Cog and the 6-item cognitive impairment test (CIT) for example, each measuring 
different aspects of cognitive impairment and each with advantages and disadvantages.176 The 
abbreviated mental test (AMTS) measures cognition on a scale of 0 (poor) to 10 (excellent), where 
a score of <8 is suggestive of cognitive impairment.168  It was chosen as the method for assessing 
cognition in this study due to its brevity, taking approximately 2 minutes to complete, no 
requirement for any props or writing by the patient and reported sensitivity (91%) and specificity 
(82%) using a cut off <8 when compared to MMSE.177  The assessment was conducted as close 
to discharge as possible to reduce the impact of acute illness on cognitive function.   
 
4.3.6.4 Depression and anxiety assessments 
PHQ-2 and GAD-2 are recommended by NICE for the screening of populations at high-risk of 
depression or those with chronic ill health178 and the screening of anxiety respectively.179  Both 
were derived from longer diagnostic tools; PHQ-9 for depressive disorders and GAD-7 for anxiety 
disorders.  They each consist of two questions that focus on the core symptoms of the disorders 
and enquire about the frequency of these symptoms over the previous two weeks.  Respondents 
have 4 options; “not at all”, “several days”, “more than half the days”, “nearly every day”, scoring 
0, 1, 2, 3 respectively.  The total scores for the PHQ-2 and GAD-2 can therefore range from 0-6, 
the higher the score the greater the likelihood of suffering the relevant disorder.169,170  Widely 
reviewed and commonly used in the community setting, the PHQ-2’s accuracy in the acute care 
setting, and in particular its use in older adults requires further investigation.180  Similarly, the 
GAD-2 has demonstrated validity in a community based older population but further validation 
studies are required.181,182 For the purpose of this study however, the brevity, endorsement by 




4.3.6.5 Hand grip 
Hand grip strength has been identified as a quick, easy and reproducible measure of muscle 
strength and has been recommended in the screening process of sarcopenia, a syndrome 
characterised by progressive loss of skeletal mass and strength and often present in frail older 
adults.183,184  It was measured using the JAMAR Hydraulic Hand Dynamometer by the research 
nurse or pharmacist who were trained using the Southampton Protocol for Adult Grip Strength 
Measurement.  This protocol formed part of a review paper that identified the JAMAR Hydraulic 
Hand Dynamometer as the most widely used instrument for measuring grip strength with excellent 
inter-rater reliability.167,185  
  
4.3.6.6 Co-morbidities and diagnoses 
Comorbidity has long been recognised as an important consideration in medical statistics.186  This 
importance has arguably grown as an increasing proportion of the population are living with 
multiple long term conditions44 and comorbidities may impact upon the outcome of interest.  
Designed as a measure of prognostic co-morbidity for longitudinal studies in 1987, the CCI187 is 
widely used in clinical research and was used as the measure of comorbidity in this study.  It 
consists of 19 conditions each weighted according to its ability to predict 1 year mortality.  
Weightings range from 1 (e.g. myocardial infarction) to 6 (e.g. metastatic cancer).  The sum of 
the weightings for the conditions identified in the patient are calculated.  The higher the score the 
greater the comorbidity and predicted 1 year mortality: score 0, 12% 1 year mortality; 1–2, 26%; 
3–4, 52%; and ≥5, 85%. The CCI has been criticised for the fact that it does not consider the 
severity of several conditions in its weighting system.  For example, a patient with mild heart 
failure will be attributed the same score as a patient with severe heart failure and so risks missing 
the extent of this as a potential predictor of mortality.188  However, with good test-retest and inter-
rater reliability, good predictive validity demonstrated for many outcomes189, clearly defined 
conditions190 many of which have been associated with ADR related hospitalisation191, it was 
identified as an appropriate measure.  Data required to complete the CCI was obtained from the 
patient’s medical records and through discussion with the direct medical team and the patient or 
carer during the admission.   
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Discharge diagnoses were obtained from the Electronic Discharge Letter (EDL).  All diagnoses, 
not just primary diagnosis, were included in the analysis.  It is recognised that following the 
introduction of Payment by Results by the Department of Health, England, whereby hospital trusts 
are paid by healthcare commissioners for each patient seen based upon the complexity of the 
case192, there may be a temptation to “engage in opportunistic behaviour” or “gaming”193 of the 
system and so overstate the complexity of the diagnosis.  A recent study quantifying the 
prevalence of frailty in English hospital would suggest that this is not the case.  They found that 
the coexistence of multiple frailty syndromes was uncommonly coded.194  Due to the complexity 
of the patients recruited to this study, where many conditions are linked and impact upon one 
another, it was necessary to use all discharge diagnoses and not just the primary diagnosis. 
 
4.3.6.7 Biochemical parameters 
The association of biochemical parameters and ADRs has been identified in several studies.19,89  
The results of tests conducted as part of routine clinical care were recorded on admission and 
discharge, where admission results were those taken within 48 hours of admission and discharge 
results were those taken as close to discharge as possible.  Where a test was not conducted or 
a result not available the data were recorded as missing.  The following parameters were 
collected, where available, for every patient: 
• Full blood count (white cell count, haemoglobin, platelets, neutrophils, lymphocytes) 
• Inflammatory markers (C reactive protein) 
• Electrolytes and renal (sodium, potassium, urea, creatinine, eGFR) 
• Liver (alanine transaminase, alkaline phosphates, bilirubin) 




The total number of medicines taken at the time of admission and on discharge were recorded, 
including name, dose and frequency.  It was also recorded if an MCA filled by a healthcare 
professional was used by the patient.  To obtain the most accurate list of medicines, admission 
medicines were recorded after the completion of medicines reconciliation by the ward pharmacist.  
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Medicines reconciliation is a process where a patient’s pre-admission medicines are identified 
and compared with the medicines they are currently prescribed and any unintended discrepancies 
rectified within 24-hours of admission.  This includes the use of OTC medicines.72  Medicines at 
discharge were recorded from the ward pharmacist approved EDL.  All medicines were coded by 
the research pharmacist using the World Health Organisation Anatomical Therapeutic 
Classification (WHO-ATC) code.  A seven character internationally recognised coding system, 
the WHO-ATC classifies a drug at five levels as described in Table 4.3.    
Table 4.3 WHO-ATC drug classification system (using diuretics as an example) 
Level Group Code Description 
1st Anatomical main group C Cardiovascular 
2nd Therapeutic main group C03 Diuretics 
3rd  Therapeutic/pharmacological subgroup C03C High-ceiling diuretics 
4th Chemical/therapeutic/pharmacological subgroup C03CA Sulphonamides 
5th Chemical substance C03CA01 Furosemide 
 
4.3.7 Main outcome measure 
The primary outcome of the study was to determine the incidence of MRH occurring during the 
eight-week period following discharge from the OPU.  The definition of MRH is outlined later in 
this chapter. Causality, preventability and severity were also determined and will also be defined. 
The secondary outcome was to measure the healthcare utilisation due to MRH during the follow-
up period.  This was measured with the aim of quantifying the number of healthcare episodes that 
were due to MRH.  Furthermore, the proportion of preventable MRH related healthcare episodes 
was also calculated to allow identification of potentially unnecessary healthcare utilisation.  A 
count of accident and emergency (A&E) attendance, hospital admission, GP consultation, contact 
with out of hours services and visits to a community pharmacist for advice or treatment regarding 
MRH was used to determine healthcare utilisation.  Patients could have multiple healthcare 
episodes with the same or different services for a single episode of MRH e.g. a patient may at 
first seek advice from their GP but is ultimately admitted to hospital.  This would count as two 
episodes of healthcare.  Where a patient attended A&E and was admitted directly to the hospital 




4.3.7.1 Definition of primary outcome measure 
As reported by Leendertse and colleagues34, when researching harm due to medicines, the 
definition of the outcome measure impacts on the prevalence of harm reported.  Frequently, and 
incorrectly, ADE and ADR are used interchangeably.  ADE describes harm from a medicine and 
includes errors in prescribing, dispensing and administration.6,7  ADR refers to harm when a 
medicine is used at an established dose for an appropriate indication.8  
Three common definitions of adverse drug events, adverse drug reactions and medication related 
problems (Table 4.4)6–8,195–200 were presented to the previously described expert panel.  Based 





Table 4.4 Definitions of medicines related harm 
Term Definition Sub-classification 
Adverse Drug Events 
(ADE) (Bates et al.)6 
“An injury resulting from medical 
intervention relating to the drug”6 
1. ADRs 
2. Medication errors 
3. Therapeutic failures 






“A response to a drug that is noxious and 
unintended and occurs at doses 
normally used in man for the 
prophylaxis, diagnosis or therapy of 
disease or for the modification of 
physiological function.”8 
Type A: Augmented 
Type B: Bizarre  
Type C: Chronic 
Type D: Delayed 
Type E: End of use 
Type F: Failure195–199 
Medication (Drug) 
Related Problems 
(Strand et al.)200 
“Drug related problem is an event or 
circumstance involving drug treatment 
that actually or potentially interferes with 
the patient’s experiencing an optimum 
outcome of medical care”200 
1. Untreated Indication  
2. Improper Drug Selection 
3. Subtherapeutic Dosage 
4. Failure to Receive Drugs 
5. Overdosage  
6. Adverse Drug Reaction 
7. Drug Interaction 
8. Drug Use without Indication200 
 
The definitions provided for ADE and ADR were rejected by the panel as being too broad in the 
case of ADE and too narrow in the case of ADR.  The agreed definition of the primary outcome 
measure was derived from the Strand and colleagues definition of medication related problems.200  
It was selected on the basis that it more accurately reflects the presentation of MRH in older adults 
in clinical practice.  When investigating a complex older population, harm from medicines is likely 
to involve ADRs and difficulties with accessing or using medicines.  This is captured in the 
definition of the primary outcome of this study, medication related harm (MRH), which focussed 
on harm due to: 
- “Failure to receive drugs - The patient has a medical problem that is the result of his or her not 
receiving a drug (e.g. for pharmaceutical, psychological, sociological or economic reasons)”, 
including failure in the supply chain and problems with adherence. 
- “Adverse drug reaction - The patient has a medical problem that is the result of an ADR” defined 
as “a response to a drug that is noxious and unintended and occurs at doses normally used in 




Similar to the outcome measure presented by Hallas and colleagues130, abnormal laboratory 
results and non-adherence without clinical symptoms were not included in this study.  This is in 
contrast to Gandhi and colleagues201 who considered some abnormal laboratory values to be 
ADEs even if there was no symptomatic problem.  It is acknowledged that asymptomatic abnormal 
laboratory values have the potential to cause harm, however it would be only be due to clinical 
need that bloods were conducted and the abnormal values identified.    
 
4.3.7.2 Outcome data 
It is recognised that the reporting of medication harm, more specifically ADRs, is poor amongst 
healthcare professionals and patients.6,202,203  The consequence of this under-reporting is 
reflected in studies investigating ADRs and ADEs where medical chart review yields a higher 
prevalence than spontaneous reporting or database screening methods.34  Ruiz and colleagues 
found only 34.6% of all ADRs identified in a prospective cohort study were later identifiable 
retrospectively using the ICD coding from the hospital discharge report.164  Furthermore, incidents 
were not always recorded in the patient notes, especially in the outpatient setting, and so it was 
concluded that eliciting information from the patient themselves is important.22   
Using only self-reporting techniques however, may result in data skewed towards minor, 
unconfirmed reports with multiple proposed “culprit” medicines, whilst using only healthcare 
professional reports may miss the less severe MRH events.204  
Gandhi and colleagues used telephone interviews to follow patients up and compared the overlap 
with computer systems, self-reporting by healthcare professionals, and chart review.  Patient 
interview identified 92% of ADEs in the outpatient setting in comparison to 28% by chart review.  
Overlap occurred in only 19% of cases reviewed and so the use of multiple methods appears to 
be complimentary and useful in determining the true event rate.201     
To overcome the limitations of each data source described in the literature and capture a true 
incidence and range of severity of MRH, multiple approaches were used to determine MRH in 
this study: patient self-reporting, computer system review, healthcare professional identification 
and medical chart review. 
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4.3.7.3 Patient interview (self-reported MRH) 
Eight weeks after discharge the patient and/or carers were contacted via telephone by the 
principal researcher.  A minimum of three (and maximum of 20) attempts at contact were made 
within the ten-week post-discharge period after which, if contact was unsuccessful, the patient 
was deemed lost to follow up for the self-reported MRH part of the study.  A two-week window 
was incorporated to allow for individuals who were, for example, on holiday.    
A standardised questionnaire was used to conduct a semi-structured interview with the patient 
and/or carer.  They were asked about their general health and healthcare utilisation over the 8 
weeks after discharge (pharmacist and GP contact, Out of Hours contact, hospital attendance/re-
admission) and whether they had recognised any unwanted side effects from their medicines.  
Patient adherence to their discharge medicines was measured using the Morisky Adherence 
Rating Score (MARS)205 (Table 4.5).  Consisting of four questions, each answered yes or no, 
MARS measures the likelihood of an individual being adherent to their medicines on a scale of 0-
4.  The higher the score, the more likely the patient is adherent. 
Table 4.5 Morisky Adherence Rating Score questions and scoring system 
Question Response (score) 
Do you ever forget to take your medicine? Yes (0) / No (1) 
Are you careless at times about taking your medicine? Yes (0) / No (1) 
When you feel better do you sometimes stop taking your medicine? Yes (0) / No (1) 
Sometimes if you feel worse when you take your medicine, do you stop taking 
it? 
Yes (0) / No (1) 
 
4.3.7.4 GP records review (Primary Care MRH) 
Using a standardised data collection form, the principal researcher reviewed the patient’s GP 
records for the eight-week follow up period to determine whether the patient had experienced any 
MRH and had, as a consequence, required additional healthcare.  Dates of issue and re-ordering 





4.3.7.5 Re-admission review (Secondary Care MRH) 
To identify if a patient had been re-admitted during the 8-week follow up period, daily reviews of 
hospital admissions were undertaken by the research nurse or pharmacist.  In the event of a re-
admission the research nurse/pharmacist collected baseline re-admission data (which included 
the same data as the original baseline data) using the standardised data collection form.  The 
principal researcher interviewed the patient and/or carer to determine any non-adherence using 
the MARS and reviewed the patient’s medical notes and blood results, in conjunction with the 
admitting Consultant, to determine if the re-admission was due to MRH.  In the event that 
agreement could not be reached between the Consultant and the pharmacist, the case was 
presented by the research pharmacist to the study End Point Committee (EPC) for discussion 
and a final decision.  The EPC consisted of a Consultant geriatrician and Professor of Clinical 
Pharmacy and Therapeutics.  
 
4.3.8 Determining MRH 
A two-step process was applied to identify and confirm cases of MRH (Figure 4.3).  The first step, 
the initial assessment, was conducted by the principal researcher (and consultant physician 
where relevant).  The second step, the final classification of MRH was made by the study EPC. 
 




4.3.8.1 Initial assessment of MRH outcomes 
Key information required to support the principal researcher (and Consultant physicians where 
relevant) in determining the likelihood that the patient had experienced MRH included current 
medicines, assessment of medicines adherence (using MARS), history of presenting complaint, 
ADR profile of the prescribed medicines, relevant comorbidities and appropriate clinical 
observations and investigations.   
Table 4.6 provides details of how the outcome of the initial assessment was recorded.  Further 
details outlining the definitions of causality, severity and preventability are described below.  
Table 4.6 Key questions and answer options used to record MRH 
Question Options 
1. Do you think this patient has suffered 
medication related harm? 
Definite, probable, possible, doubtful 
2. How confident are you in this judgement? Little or no confidence, slight to moderate 
confidence, <50% confidence but a close call, 
>50% confidence but a close call, strong 
confidence, virtually certain 
3. If the patient has suffered medication related 
harm, what was the main cause? 
- What medicines were implicated? 
- What was the clinical event? 
ADR, non-adherence, other, unable to determine 
 
- Free text entered by the research pharmacist 
- Free text entered by the research pharmacist 
4. If the patient has suffered medication related 
harm, was it preventable? 
Definitely, possible, not preventable, unable to 
determine 
5. If the patient has suffered medication related 
harm, what was the severity? 
Fatal, life threatening, serious, significant 
 
4.3.8.2 Causality 
Where an ADR was suspected, the Naranjo algorithm129 was utilised to support the causality 
assessment.  Reproducible assessment of causality is important when studying ADRs to produce 
consistent measurement of the outcome of interest.  A systematic review identified 34 
assessments using three main methods, expert judgement, probabilistic approaches and, most 
commonly, algorithms.206  Each method has advantages and disadvantages and all require some 
level of clinical judgement potentially limiting their reproducibility.  As there is no universally 
accepted assessment this study followed the algorithm based approach, in conjunction with 
expert opinion.  The Naranjo algorithm was selected based on its use in previous studies 
investigating in-hospital ADRs and hospitalisation secondary to ADRs.2,14  Published in 1981, the 
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Naranjo algorithm was developed with the aim of reducing inter-rater variability when assigning 
causality to potential ADRs, and so improving pharmacovigilance.  In a study of 6 raters (2 
physicians and 4 pharmacists) inter-rater reliability was reported to improve from Kappa=0.21-
0.40 to Kappa=0.69-0.86 when the algorithm was applied to a set of 63 patient cases.129  
Consisting of 10 weighted questions (see Table 4.7), causality is classed as definite (score ≥9), 
probable (score 5-8), possible (score 1-4) and doubtful (score ≤0).  The Naranjo algorithm rates 
causality conservatively as many of the questions are not relevant e.g. did the same reaction 
occur when a placebo was administered?  Furthermore, the often atypical and non-specific 
presentation of MRH in older adults and the multimorbidity frequently present makes it difficult to 
definitively attribute causality to a specific medicine(s).  Therefore, it was used as a guide to 
ensure a temporal association, previous reports of the reaction and other possible causes were 
all considered when determining MRH due to an ADR, in conjunction with expert opinion.  
Causality was categorised into four categories: definite, probable, possible and doubtful.     
Table 4.7 Naranjo algorithm questions and associated scores 
Question Yes No Don’t know 
1. Are there previous conclusive reports on this reaction? +1 0 0 
2. Did the adverse event appear after the suspected drug was 
administered? 
+2 -1 0 
3. Did the adverse reaction improve when the drug was discontinued 
or a specific antagonist was administered? 
+1 0 0 
4. Did the adverse reaction reappear when the drug was re-
administered? 
+2 -1 0 
5. Are there alternative causes (other than the drug) that could on 
their own have caused the reaction? 
-1 +2 0 
6. Did the reaction reappear when a placebo was given? -1 +1 0 
7. Was the drug detected in the blood (or other fluids) in 
concentrations known to be toxic? 
+1 0 0 
8. Was the reaction more severe when the dose was increased, or 
less severe when the dose was decreased? 
+1 0 0 
9. Did the patient have a similar reaction to the same or similar drugs 
in any previous exposure? 
+1 0 0 
10. Was the adverse event confirmed by any objective evidence? +1 0 0 
 
4.3.8.3 Severity  
The severity of MRH was graded using ratings defined by Morimoto and colleagues.22  The four 
categories were fatal, life threatening, serious and significant as described in more detail in Table 
4.8.   
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Table 4.8 Classification and definition of severity of MRH 
Severity Definition 
Fatal Patient died due to the incident 
Life threatening Requiring hospitalisation resulting in permanent defects or life-
threatening complications 
Serious Additional visit to clinic for treatment or additional medications, including 
dose reductions or cessation of therapy 
Significant Any significant event that is identified by the patient but not requiring a 
change in therapy 
 
4.3.8.4 Preventability 
It is widely accepted that medicines, even when used in accordance with present day knowledge 
of good medical practice, may cause harm that could not be prevented.  Whilst it is important to 
remain vigilant in order to limit the severity of such harm, efforts may be better spent focussing 
on preventable MRH.  It is therefore important when studying MRH that preventability is 
considered.  The most commonly used preventability criteria for ADR/ADE studies, derived by 
Hallas and colleagues.130 and outlined in Table 4.9, were applied to all cases of suspected MRH. 
Table 4.9 Classification and definition of preventability of MRH 
Classification Definition 
Definitely preventable Treatment inconsistent with current knowledge of good medical practice or 
was unrealistic taking circumstances into account. 
Possibly preventable Prescription was not erroneous but the event could have been avoided by 
an effort exceeding the obligatory demands. 
Not preventable Could not have been avoided by any reasonable means, or it was 
unpredictable during treatment fully in accordance with good medical 
practice. 
Unevaluable Rating could not be obtained or evidence was conflicting. 
 
 
4.3.9 Confirmation and classification of MRH 
For all patients, the outcomes recorded for each follow up stage (i.e. telephone interview, GP 
records review and re-admission review, where applicable) were reviewed by the principal 
researcher and a senior clinical academic pharmacist to determine the final outcome.  Likelihood, 
preventability, severity, main cause (i.e. ADR, non-adherence or both), the nature of the event 
and the medicine(s) involved were determined (Figure 4.3).  Any disagreement was resolved 
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through discussion.  This form of mixed methods, using healthcare professional reporting and 
identification of ADR by members of the research team and verification through a systematic 
medical review by a panel of experts, has been adopted in previous ADRs studies.122 The total 
number of events due to MRH were recorded. 
 
4.3.10 Healthcare utilisation 
The healthcare utilisation, that is the number of re-admissions, A&E attendances, access to out 
of hours services, GP or pharmacist contacts for each stage of the follow up were also reviewed 
by the principal researcher and senior clinical academic pharmacist.  Due to the complex 
presentation of this population it can often be difficult to determine one definite cause for 
healthcare utilisation therefore it was not possible to state that MRH caused the presentation but 
in all cases it contributed to it.  The agreed count of MRH related episode of care was recorded. 
 
4.3.11 Recording of data 
Screening, recruitment and follow up data logs were recorded using Microsoft Excel and were 
password protected.  The CRF was developed using Formic Solutions version 5.51 build 005 
computer software. Using this software data were scanned from the paper CRF into an electronic 
database which was cleaned and transferred into SPSS for analysis.  CRFs were stored in a 
locked cabinet, in an office with restricted access, for the duration of the study. 
 
4.3.12 Sample size 
A sample size of 1500 patients was calculated for the PRIME Study (see Chapter 2, Section 2.5).  
As this thesis was a sub-analysis of the St. Thomas’ cohort a separate sample size calculation 
was not conducted and the cohort investigated was therefore a convenience sample.  
 
4.3.13 Analysis 
Descriptive statistics were applied to describe the primary and secondary outcomes and the 
population characteristics.  Categorical data were presented as number (%) and numeric data as 
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mean (SD).  Non-normally distributed numeric data were presented as median (inter-quartile 
range (IQR)).  The analysis was undertaken using the SPSS software (version 24.0; SPSS, Inc., 
Chicago, IL, USA). 
 
4.3.14 Approvals and funding 
The study was approved by the National Research and Ethics Service, East of England (Norfolk; 
REC reference 13/EE/0075) (Appendix D) and was funded by the Guy’s and St. Thomas’ Charity 
(G100716) and the National Institute of Health Research (NIHR) – Research for Patient Benefit 
(RfPB) (PB-PG-0711-25094).  The study was adopted as a Clinical Research Network Portfolio 
study (Ageing and Primary Care).  Local Research and Development Departments approvals 





4.4.1 Patient recruitment 
Over the study period 8280 patients were discharged from the three wards of the OPU.  Of these, 
1122 patients were screened for participation in the study, of whom 857 met the criteria for 
inclusion and 421 patients were recruited to the study.  Not all patients were screened due to 
limited resources; screening was not possible at weekends or during public holidays, and staff 
had to prioritise re-admitted study patients due to short lengths of stay, resulting in reduced time 
for screening patients.  
Of the 701 patients not included, consent or assent was not given or could not be obtained in 436 
(62%).  The remaining patients were outside of the designated GP catchment area (n=153), had 
a short life expectancy (n=95), were under 65 years old and were admitted to the OPU due to bed 
pressures (n=13) or were not ready for discharge (n=4). Twenty-five patients were later 
withdrawn: 17 had already taken part in the study and had been re-admitted after the 8-week 
follow up period, three had not been discharged by the recruitment closure date, three died before 
they were discharged, and two of the patient’s GPs were found to be outside the designated 
catchment area for follow up (Figure 4.4). 










The demographics of the study cohort compared to the general OPU population and those 
patients screened for inclusion are outlined Table 4.10.  There were some variations in 
demographics between the three groups.  A larger proportion of females were recruited to the 
study (64.7%) than were screened for the study (61.2%) or discharged from OPU in general 
(59.8%).   
Table 4.10 Description of OPU, screened and study populations 




All OPU discharges 
(2014-16) (n=8280) 
Gender (female) (%) 256 (64.7) 687 (61.2) 4954 (59.8) 
Age > 85 years (%) 175 (44.1) 502 (44.8) 3787 (45.7) 
Ethnicity (white) (%) 352 (88.9) - 6586 (79.5) 
OPU: Older Persons’ Unit 
 
The study cohort was predominantly white, reflecting the cohort of very old inner Londoners, and 
not as diverse as the overall patient population.  According to the 2011 Census, less than half the 
all-age population (approx. 45%) of Lambeth would described themselves as White British.46  The 
ethnicity of the older population in London however appears to be less varied.  Data published by 
the Greater London Authority for 2015 estimated that approximately 70% of residents in Lambeth, 
Southwark and Westminster aged 65-90 years old were described as White.207  The older 
population discharged from the OPU in 2014-16 are even more ethnically homogeneous (79.5% 
White) and the study cohort even more so still.  Only 11.1% of study participants were not White 
which may be reflective of language barriers limiting recruitment to those who have English as a 
first language.  
A similar proportion of patients over the age of 85 were recruited to the study (44.1%), as were 
screened (44.8%) and discharged from the OPU generally (45.7%).  The mean age of patients 
recruited to the study was 83 years old (65-102 years, SD 7.0), see Figure 4.5.  Patients over the 
age of 80 years old formed almost 69% of the study population, with the majority (52%) aged 
between 80-90 years old.  This age distribution is reflective of the selection criteria, outlined 
earlier, for admission to the OPU.  Importantly, it also characterises a frequently underrepresented 





Figure 4.5 Age distribution of study population 
 
Further baseline demographics of the study cohort are outlined in Table 4.11 and are grouped 
loosely around four domains of the Comprehensive Geriatric Assessment (medical, mental 
health, functional capacity and social circumstances).209  In summary, the cohort may be 
described as multimorbid, and although cognitively intact, they have impaired functional capacity 
and most are dependent upon formal care.  The overall demographics are suggestive of a frail 




Table 4.11 Baseline demographics, including clinical, frailty, social parameters of study participants (n=396) 
Variable Number of patients (%) 
Demographics  
Female 256 (64.7) 
Mean Age (years) (SD) 83.3 (7.0) 
Ethnicity: White 352 (88.9) 
Medical   
Mean CCI (SD) 2.16 (1.63) 
Mean number of conditions (SD) 4.53 (1.87) 
Median eGFR (ml/min/1.73m2) (IQR) 64 (45, 82) 
Mean number of discharge medicines (SD) 10.07 (4.37) 
Median length of stay (IQR) 10 (6, 17) 
MUST: 0 209 (55.0) † 
 1 72 (19.0) † 
 2 99 (26.1) † 
Mental Health  
Mean AMTS (SD) (range 0-10)a 8.29 (1.71) 
Mean PHQ-2 (SD) (range 0-6)b 1.74 (1.87) 
Mean GAD-2 (SD) (range 0-6)c 2.26 (2.04) 
Functional capacity  
Hand Grip: <20kg (Female) 225 (88.6) ^ 
 <30kg (Male) 128 (91.4) 
Falls: 0 119 (30.1) ˜ 
 1 91 (23.0) ˜ 
 2 185 (46.8) ˜ 
Mean Barthel Index (SD) (range 0-20) 13.24 (4.56) 
Social circumstances  
Living arrangements:   
Lives alone 262 (66.3) 
Lives with spouse/family/friend/carer 124 (31.4) 
Lives in an institution 9 (2.3) 
POC Frequency:  
0 146 (36.9) 
1-3 108 (27.3) 
>4 times per day (incl. 24 hr home care) 111 (28.0)  
AMTS: abbreviated mental test score; CCI: Charlson comorbidity index; eGFR: estimated glomerular filtration rate; 
GAD: generalised anxiety disorder; IQR: inter-quartile range; PHQ: Patient Health Questionnaire; POC: package of 
care; SD: Standard Deviation;  
a: higher score = better cognition; b: higher score = more likely depressed; c: higher score = more likely anxious; † 






The study cohort had a mean CCI of 2.16 (SD 1.63), equating to a 26% one year mortality rate.  
As described in more detail in Chapter 5, 37 patients died during the 8-week follow up period, 
suggesting a potentially higher mortality rate than is reflected by the mean CCI.  It should however 
be noted that after an acute event deaths are not evenly spread over 12 months.210  The number 
of conditions and discharge medicines may provide a better indication of the level of comorbidity 
in the study population, being 4.53 (SD 1.87) and 10 (SD 4.37) respectively.  Co-morbidities were 
dominated by diseases of the cardiovascular system; most commonly hypertension (diagnosed 
in 61.4% of the study population), atrial fibrillation (26.3%) and hyperlipidaemia (22.7%).  
Connective tissue disorders (including rheumatoid arthritis, osteoarthritis and systemic lupus 
erythematous), obstructive lung disease and diabetes were also common and were diagnosed in 
29.8%, 28.5% and 27.3% of the study population respectively. The median renal function, 
measured by eGFR, was 64 ml/min (IQR 45,82), with under half (44%) of all patients being 
described as renally impaired (eGFR <60ml/min).  Nutritional impairment was identified in 45% of 
the cohort as determined by a MUST score of ≥1.211  The most frequent discharge diagnosis, 
based on body system, were those relating to the musculoskeletal system (including falls, 
fractures and reduced mobility) (25.8%), the respiratory system (including COPD, pneumonia and 
pulmonary emoboli) (23.8%) and the cardiovascular system (including heart failure, atrial 
fibrillation and postural hypotension) (17.4%).  
 
4.4.2.2 Mental Health 
The majority (74%) of patients were cognitively intact with an AMTS ≥8 (mean 8.29 (SD 1.71)).  
Anxiety and depression levels were low, mean GAD-2 2.26 (SD 2.04) and mean PHQ-2 1.71 (SD 
1.87), both below the recommended screening cut-off of 3.169,170 
 
4.4.2.3 Functional capacity 
There was impairment in all measures of functional capacity.  The mean hand grip stratified by 
gender was; females 12.21kg (5.79), and males 19.93kg (7.28).  89% females and 91% males 
would be described as sarcopenic using the cut offs recommended by the European Working 
Group on Sarcopenia in Older People (EWGSOP)184, as outlined in Table 4.11.  
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4.4.2.4 Social circumstances 
Almost 80% lived in privately owned or rented accommodation, with most living alone (66%).  Only 
eight patients were nursing home residents.  Social support, in the form of a package of care, was 
provided to more than half of the study population (55%), and ranged from once daily visits to 24-
hour live in care.  
 
4.4.2.5 Medicines 
The mean number of medicines on admission was 8.8 (SD 4.40, range 0-25) and increased to 
10.1 (SD 4.37, range 0-26) on discharge.  Approximately 61% of patients were discharged home 
with more medicines and almost all patients were discharge with a change to their admission 
medicines, 384 (96.9%).  This includes any medicines stopped or started but does not include 
changes in doses.  New medicines were started in 355 (89.6%) patients; the number of new 
medicines ranged from 0-16 per patient.   
Just over a quarter of the study population reported a previous ADR (102 patient (25.8%)). 
Approximately a third (33.2%) of patients, when asked, reported some degree of non-adherence 
illustrated by a MARS of less than four.   
Support with medicines was common with 226/268 (84.3%) reporting help with medicines in the 
form of obtaining a supply 219/268 (81.7%) and/or administration 122/268 (45.9%).  Help was 
most frequently provided through formal routes i.e. the pharmacy or formal carers arranging the 
supply of medicines (132/219 (60.3%)) and formal carers supporting administration of medicines 
(64/122 (52.5 %)).  MCAs were used by 172 (45.9%) patients.  Almost all patients 390 (98.7%) 
used only one community pharmacy to access their medicines. 
A total of 3986 medicines were prescribed on discharge.  The most commonly prescribed group 
of medicines, based on the WHO-ATC anatomical group classifications were medicines used to 
treat disorders of the alimentary tract and metabolism (25.8%), followed by cardiovascular system 
(20%) and nervous system (16.2%).  Alimentary tract and metabolism medicines commonly 
included; laxatives (e.g. senna and macrgols), proton pump inhibitors (e.g. omeprazole), oral 
hypoglycaemic agents (e.g. metformin and gliclazide) and calcium and vitamin D supplements.  
The frequency of prescribing medicines used to treat gastric acid related disorders was higher 
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than the proportion of patients diagnosed with such conditions.  It is likely that this reflects 
prophylactic prescribing to reduce the risk of gastrointestinal bleeding in those taking medicines 
such as antithrombotics (e.g. aspirin, clopidogrel, rivaroxaban) or prednisolone, which accounted 
for 8% of all prescribed medicines.  Of all prescribed medicines, paracetamol was the most 
common, received by 60% of the study population at discharge.      
 
4.4.3 Incidence of MRH 
Of the 396 patients completing the 8-week follow up, 128 (32.3%) were unavailable for telephone 
interview and 10 patients did not have their GP review completed due to incorrect GP details.  In 
all patients, at least one of the follow up sources was available i.e. telephone interview, GP 
records review or re-admission review.  Three sources were available for 84 patients (21.2%), 2 
sources for 284 (62.6%) patients and 66 (16.7%) patients had only 1 follow up source available.   
Within the study cohort 158 of 396 (39.9%) patients experienced MRH within the 8-weeks follow 
up period, rated as possible, probable or definite; 113 experienced only 1 MRH event (71.5% of 
all MRH events); 34 (21.5%) experienced 2 MRH events; and 11 (7.0%) experienced 3 or more 
MRH events.  In total 217 MRH events were identified.   The rate of MRH is described in Table 
4.12. 
Table 4.12 Rates of MRH during 8-weeks follow up 
 Number (%) Event rate per 100 patients  
Total number of patients with MRH 




















Preventability of MRH 
Definitely or possibly preventable 
Not preventable 










The number of events based on severity and preventability of MRH are also outlined in Table 
4.12.  A total of 6 events were classified as life-threatening or fatal and will be discussed in more 
detail later in this chapter.  Over half of all events were deemed preventable (58.1%); 26 were 
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definitely preventable, 100 possibly preventable.  Due to conflicting information, it was not 
possible to evaluate the preventability of 1 event.  
Approximately two thirds of MRH was due to ADRs (149 (68.7%)), 48 (22.2%) due to non-
adherence, and 20 (9.2%) due to a combination of ADR and non-adherence.  Examples of each 
are provided in Figure 4.6. 
 
Case 1: ADR 
Likelihood MRH: definite, Severity: serious, Preventable: definitely 
93 year old male.  Lives with niece.  Past history of IHD, CCF, hypertension and BPH.  After showering, 
central heavy chest pain. Took 2 puffs of GTN spray, felt dizzy so went downstairs.  Niece found patient 
unresponsive in chair. Ambulance service stood patient up and witnessed 2nd episode of 
unresponsiveness lasting 3 minutes. No confusion, tongue biting or urinary incontinence.  Similar episode 
in March 2013 due to oral ISMN which was then stopped but GTN spray was not reconciled in drug history 
and so patient continued to use.  Diagnosed with syncopal episode after using GTN spray. 
Case 2: Non-adherence  
Likelihood MRH: definite, Severity: serious, Preventable: definitely 
88 year old female.  Lives alone, daily carer, supportive family.  Past history of heart failure, COPD and 
dementia.  Presented with increased shortness of breath and bilateral leg swelling.  Discharged 7 days 
previously with increased bumetanide dose.  At home carer administered medicines from old MCA 
containing lower dose of bumetanide. Symptoms responded well to increased diuretics.  Diagnosed with 
worsening heart failure due to administration of incorrect dose of bumetanide. 
Case 3: ADR and non-adherence 
Likelihood MRH: definite, Severity: serious, Preventable: possibly 
90 year old female.  Lives alone, family provide care.  Past history of AF, diabetes, PVD, reduced mobility, 
intermittent constipation, grade 3 pressure sore (ankle and buttock), recent #NOF.  Daughter requested 
GP visit.  Mum complaining of nausea and constipation.  No urinary symptoms, negative MSU.  Prescribed 
buprenorphine patch and dihydrocodeine from hospital (discharged 6 days previously) following #NOF.  
Has Laxido but does not take it.  Diagnosed with constipation secondary to opioids and non-adherence 
to laxatives.  
IHD: ischaemic heart disease; CCF: congestive cardiac failure; BPH: benign prostate hypertrophy; GTN: glyceryl 
trinitrate; ISMN: isosorbide mononitrate; COPD: chronic obstructive pulmonary disease; AF: atrial fibrillation; MSU: 
midstream urine; PVD: peripheral vascular disease; #NOF: fractured neck of femur 




4.4.3.1 Type of MRH 
The most frequently affected body system due to MRH was the alimentary system 68 (31.3%), 
followed by the central nervous 34 (15.7%) and haematological 20 (9.2%) systems.  A summary 
of all MRH events, the body system affected and examples of the medicines involved is provided 
in Table 4.13.  Constipation (n=25), falls (n=17), diarrhoea (15) and bleeding (15) were the most 




Table 4.13 MRH event by body system and examples of commonly involved medicines (n=217) 
System (%) MRH event Examples of medicines 
commonly involved 
Autoimmune (0.9) Flare of phemphigiod (1), immunosuppression (1) Prednisolone 
CNS  
(15.7) 
Behaviour change (1), black out (1), confusion (4), 
dizziness (3), drowsiness (2), hallucinations (2), 
headache (1), insomnia (2), low mood (1), 
nightmares (1), uncontrolled pain (11), sedation (1), 





AF (1), exacerbation HF (5), hypotension (2), 
peripheral oedema (2), postural hypotension (4), 





Alopecia (1), puritis (2), rash (5), urticaria (1), 









Fall (17) Codeine, lorazepam, 
ramipril 
Alimentary (31.3) Abdominal cramps (1), black stools (4), constipation 
(25), diarrhoea (15), dry mouth (5), dysphagia (1), 
hepatotoxicity (1), nausea (6), overflow diarrhoea (1), 
stomach pain (1), taste disturbance (2), vomiting (5), 





Polyuria (1), urinary incontinence (1), urinary 
retention (2) 
Furosemide, tiotropium 






C. difficile (2), conjunctivitis (1), oral thrush (6), 




Fatigue (2), hip fracture (1), weakness (1),  Carboplatin, prednisolone 
Renal  
(4.1) 
AKI (5), hyperkalaemia (2), hypokalaemia (2) Furosemide  
Respiratory  
(4.6) 
Cough (1), SOB (9) Salbutamol  
AF: atrial fibrillation; AKI: acute kidney injury: CNS: central nervous system; CVS: cardiovascular system; 





4.4.3.2 Medicines associated with MRH 
A total of 339 individual prescriptions were involved in 217 MRH events.  In many cases, there 
was more than one prescribed medicine with a potential causal link to MRH.  The prevalence of 
polypharmacy and the frequency of use of medicines with similar therapeutic outcomes e.g. ACE 
inhibitors, beta-blockers and diuretics will all reduce blood pressure, or similar side effect profiles 
e.g. morphine, agents used to treat neuropathic pain and drugs used to treat urinary incontinence 
may all cause constipation, made it very challenging to attribute the event to one medicine. Table 
4.14 summarises the medicines involved in MRH, sub-divided into MRH due to ADR or non-
adherence. 
Based on the WHO-ATC classification system, medicines acting on the nervous system were 
most frequently involved in MRH contributing a quarter (25.1%) of all medicines causing harm, 
followed by those acting on the cardiovascular system (20.1%), and the alimentary tract and 
metabolism (18.9%).  Opioids, which included morphine, oxycodone, codeine, dihydrocodeine, 
buprenorphine and tramadol, dominated the nervous system category.  When considering ADRs 
only, furosemide was the most frequent causative medicine, causing 15 ADRs.  This was followed 
by rivaroxaban (n=11), bisoprolol (n=10) and codeine (n=9).  The most common causative 
medicine for MRH due to non-adherence was senna (n=11), followed by macrogols, furosemide 




Table 4.14 Frequency of medicines involved in MRH 








Acid related disorders (5)  ADR: Omeprazole (4) 
Non-ad: Ranitidine (1) 
Constipation (38) ADR: Laxatives (13), Sodium docusate (1) 
Non-ad: Laxatives (23), Phosphate enema (2), 
glycerol suppositories (1) 
Functional GI disorders (1) Non-ad: Metoclopramide (1) 
Diabetes (16) ADR: Insulins (4), Oral hypoglycaemics (4) 
Non-ad: Insulins (4), Oral hypoglycaemics (4) 
Mineral supplements (2) ADR: Calcium and vitamin D (2) 
Anti-infectives 
(30) (8.9%) 
Systemic antibacterials (30) ADR: Penicillins (14), Others (15) 
Non-ad: Penicillins (1) 
Blood and blood 
forming organs 
(38) (11.2%) 
Iron preparations (8) ADR: Ferrous fumarate (3), Ferrous sulphate (5) 
Antithrombotics (30) ADR: Rivaroxaban (11), Dalteparin (4) 
Aspirin (6), Clopidogrel (2), Warfarin (6) 




Antihypertensives (30) ADR: Ramipril (8), Losartan (2), Doxazosin (1), 
Bisoprolol (10), Nifedipine (1), Diltiazem (2) 
Non-ad: Ramipril (2), Bisoprolol (4) 
Cardiac stimulants (3) ADR: Digoxin (2) 
Non-ad: Midodrine (1) 
Vasodilators (6) ADR: GTN spray (1), ISMN (1), Nicorandil (2) 
Non-ad: GTN spray (1), naftidofuryl (1) 
Diuretics (29) ADR: bumetanide (1), furosemide (15), 
spironolactone (3) 
Non-ad: bumetanide (2), furosemide (5), 
metolazone (1), spironolactone (2) 
Nervous system 
(85) (25.1%) 
Analgesics (55) ADR: opioids (41), ketamine (1) 
Non-ad: opioids (9), paracetamol (4) 
Antiepileptics (7) ADR: gabapentin (2), pregabalin (4) 
Non-ad: sodium valoproate (1) 
Antidementia (3) ADR: memantine (3) 
Antidepressants (11)  ADR: amitriptyline (3), mirtazapine (4), citalopram 
(2), sertraline (2) 
Hypnotics and anxiolytics (7) ADR: diazepam (1), lorazepam (2), zolpidem (1), 
zopiclone (2) 
Non-ad: temazepam (1) 
Other (2) ADR: aripiprazole (1) 




Obstructive airways disease 
(28) 
ADR: Symbicort (1), Seretide (2), tiotropium (3), 
beclomethasone (1), theophylline (3) 
Non-ad: Symbicort (3), Seretide (2), salbutamol 




Table 4.13 cont. Frequency of medicines involved in MRH 









ADR: Pemetrexed (2), Carboplatin (4) 
Dermatologicals (4) Non-ad: mometasone (2), emollients (2) 
Urologicals (9) ADR: tamsulosin (4), urinary frequency (4) 
Non-ad: tamsulosin (1) 
Anti-inflammatory (1) ADR: ibuprofen (1) 
Systemic hormones (6) ADR: prednisolone (4), carbimazole (1) 
Non-ad: prednisolone (1) 
ADR: adverse drug reaction; Non-ad; non-adherence; GI: gastrointestinal 
 
4.4.4 Causality assessment 
All MRH events were assessed for a causal relationship between the suspected medicine(s) and 
event.  The assessment ratings were: 44% possible, 31% probable and 24% definite (Figure 4.7).  
Although the majority were rated probable and definite, it is important to also consider those rated 
possible.   In such cases, there is a link between the event and the medicine but other conditions 
or medicines may be implicated and so it is not possible to definitively state that a medicine was 
the sole cause of the event.  The majority of definite events (87%) resulted in serious harm of 
which approximately two thirds (67%) were deemed preventable.     
 
 
Figure 4.7 Frequency of likelihood, severity and preventability of all MRH events 
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4.4.5 Severity of MRH  
Most events were categorised as serious 185 (85.3%), followed by significant 26 (12.0%), fatal 
4 (1.8%) and life threatening 2 (0.9%).  The four fatal MRH events were caused by both ADRs 
(n=3) and non-adherence (n=1).     
The relationship between medicine class and severity of events is shown in Figure 4.8 
 
 
Figure 4.8 Severity of events by class of medicine 
 
Almost all episodes of MRH attributed to cardiovascular medicines resulted in serious harm 
whereby an additional clinic visit or treatment alteration was required.  This encapsulates the 
challenge presented to clinicians managing the delicate equilibrium of risk and benefit when 
prescribing the guideline recommended medicines for the secondary prevention of cardiovascular 
disease in a frail older population.   
The outcome of MRH events due to antithrombotic agents is the only medicine class that spreads 
across all severity grades.  At one end of the severity spectrum, this was attributed to the relatively 
minor, and expected, bleeding and bruising that are common with this class of medicines but do 
not require any treatment.  At the other extreme, the clinical pharmacology of these medicines 

























Significant 8 4 4 8 1 0 0 2 1 2 6
Serious 37 58 26 19 67 16 8 19 26 7 12
Life threat 0 0 0 2 0 0 0 0 0 0 0






























serum concentrations resulting in catastrophic outcomes for the patient. This is seen in the life-
threatening haematological events observed where major bleeding was secondary to 
antithrombotic treatment, and the fatal CNS event was due to non-adherence to warfarin. This is 
also reflected in Figure 4.9 which illustrates the severity of MRH events by body system. 
 
 
Figure 4.9 Severity of MRH events by body system affected 
 
It can also be seen from Figure 4.8 and Figure 4.9 that the high frequency of MRH events affecting 
the CNS and alimentary tract correspond to the common use of analgesics and those medicines 
used to treat conditions of the alimentary tract.  In the study population, constipation was 
frequently reported secondary to non-adherence to laxatives or the side effect of opioids.  
Uncontrolled pain, confusion or dizziness were common and often due to either non-adherence 









GU Haem Inf MSK Resp Renal Fall
Significant 0 2 1 2 0 13 0 4 1 2 0 0 1
Serious 1 31 16 9 9 55 4 14 11 1 10 9 15
Life threat 0 0 0 0 0 0 0 2 0 0 0 0 0





























More events were considered preventable 126 (58.1%), than not preventable 90 (41.5%).  It 
was not possible to evaluate the preventability of one event (a fall), due to conflicting 
information from the GP records and hospital re-admission.  All events categorised as not 
preventable were ADRs (or ADR combined with non-adherence).  This is expected as non-
adherence is largely regarded as preventable.  
 
 
Figure 4.10 Preventability of events by body system affected (n=216) 
 
Most of the events affecting the endocrine, respiratory and renal system were considered 
preventable and were due to non-adherence to insulin or oral anti-diabetics; non-adherence to 
inhalers such as salbutamol or Seretide; and acute kidney injury secondary to furosemide.  In 
comparison, three quarters of events affecting the haematological system were considered not 
preventable.  Bleeding was the cause of all non-preventable haematological system MRH 
events.  A recognised side effect of antithrombotic agents, it may be that bleeding is perceived 
to be an accepted consequence of prescribing such medicines and the benefit of treatment 
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4.4.7 Healthcare utilisation 
There were 250 episodes of care associated with the 217 MRH events (see Table 4.15) in 158 
patients, equating to 1.6 episodes of care per patient.  Although most healthcare utilisation 
involved a visit to the GP (n=147 (58.8%)), about a third (29.6%) of all episodes of care were re-
admissions to hospital.    
Table 4.15 Type of healthcare utilisation due to MRH  
Healthcare type Total (%) 
GP 147 (58.8) 
Re-admission 74 (29.6) 
Out of hours 28 (11.2) 
A&E 1 (0.4) 
 
The most severe MRH events, fatal and life-threatening, all resulted in re-admission to hospital 
(n=5).  Serious events were managed through a range of healthcare resources; in the community 
(i.e. by the GP or nurse) (n=119), hospital attendance (re-admission and A&E) (n=75) or by the 
patient/carer themselves (n=1).  This is perhaps reflective of the broad categorisation of “serious” 
where the main reason for allocating events to this category was a change in therapy.  
 
4.4.7.1 Re-admissions 
During the 8-week follow up period there were 222 episodes of re-admission involving 156 
patients (39.4%).  Patients were re-admitted between one and five times, with most re-admitted 
once (27.8%), Table 4.16.   
Table 4.16 Re-admission frequency and proportion of MRH re-admission 
Re-admission episode Number of patients (n; %)  MRH related re-admission (n) 
1 110 (27.8) 53 
2 31 (7.8) 14 
3 12 (3.0) 6 
4 1 (0.2) 1 
5 2 (0.5) 0 





Reflecting upon national data, which uses a standard of 28-days re-admission, this re-
admission rate was higher than anticipated.  National data (2011-12), from the NHS Digital 
Indicator Portal, reports the rate of GSTFT emergency readmissions to hospital of adults aged 
over 75 years within 28 days of discharge as 18.23% (95% CI 17.26-19.24).  This is higher than 
the national figure of 15.29% (95% CI 15.22-15.36%).212  To provide a more valid comparison 
the proportion of patients re-admitted within 28-days was calculated as 28.5%, over 10% higher 
than the national data.  Time to re-admission was skewed towards the first 28 days (mean time 
to re-admission 19.5 days [CI 95% 17.0 – 22.0 days]).   
Of the 156 patients re-admitted during the 8-week follow up, 67 (43%) experienced MRH, 
equating to 74 MRH re-admissions and 79 events.  Multiple events were experienced by four 
patients during a single re-admission episode; one patient experienced four MRH events and 
three patients experienced two events.   
Table 4.17 provides a summary of MRH events where the patient was re-admitted.  The 
likelihood, main cause (that is ADR, non-adherence or both) and preventability of the MRH 
event are provided.  Approximately three quarters (74.3%) were preventable MRH events.  All 
cases where non-adherence was the main cause of MRH were preventable (one episode could 
not be evaluated).   
Table 4.17 Summary of MRH events in re-admitted patients 
Likelihood MRH Main Cause of MRH Preventable MRH (n) (%) 
Definite (22) ADR = 12 8 (66.7) 
Non-adherence = 6 6 (100.0) 
ADR and non-adherence = 4 4 (100.0) 
Probable (25) ADR = 19 10 (52.6) 
Non-adherence = 3 3 (100.0) 
ADR and non-adherence = 3 3 (100.0) 
Possible (32) ADR = 21 12 (57.1) 
Non-adherence = 8 7 (87.5)* 
ADR and non-adherence = 3 2 (66.7) 






This study has shown that approximately two in every five frail older patients discharged from 
hospital following an episode of acute care will experience MRH and more than half of these 
events are preventable.   Treatment modification was required in the majority of cases (88%) as 
signified by a severity rating of serious or above.  Given the reported preventability of MRH in this 
study (58.1% of MRH were deemed preventable), these results suggest that there is a significant 
level of avoidable healthcare expenditure due to MRH.  Indeed, hospital admission, the most 
costly type of healthcare utilisation, accounted for approximately one third of care episodes 
associated with MRH.   
 
4.5.1 MRH incidence in a frail population 
The study population was drawn from the OPU at St. Thomas’ Hospital where admission to the 
unit is based on bed availability and patient need.  The criteria used to assess need intentionally 
selects the most vulnerable patients and so it is unsurprising that the patient demographics 
described the majority of the study population as aged over 80 years old and multimorbid with 
high levels of dependence.  Considering hand grip in isolation would suggest that the study 
population is sarcopenic, and may be frail.  A degree of caution should be applied when 
interpreting these results.  Hand grip strength can be influenced by cognitive impairment limiting 
an individual’s ability to follow instructions or conditions such as rheumatoid arthritis 
compromising physical ability.  Cognitive impairment was not widespread in the study population 
however connective tissue disorder, which includes rheumatoid arthritis, was present in almost a 
third of the cohort.  Overall, the demographics reflect a group of complex older adults who are 
frequently excluded from clinical trials and so there is a paucity of evidence to support the risk 
versus benefit judgements that are required when prescribing medicines. 
Harm from medicines in older adults however is extensively reported, with significant variability in 
incidence, 6.5-39%, due to heterogeneity in populations, outcome definitions and study design, 
as outlined in Chapter 1 and Chapter 3.  Much of the published research has focussed upon 
identifying older adults at greatest risk of inpatient ADRs/ADEs but few have explored harm post-
discharge11,24 in frail older populations.  The incidence of post-discharge MRH ranges from 18.4-
37.5%.24  Gray and colleagues25 reported a 20% post-discharge ADE incidence in older patients 
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receiving home health services.  Home health is an agency based system which provides multi-
disciplinary services based on patient needs following hospital discharge.  Patients are likely to 
be housebound, have functional limitations and take several medicines; that is, they are likely to 
be frail.  The reported ADE rate is less than identified in this study and whilst study demographics 
appear comparable, several groups of patients were excluded from the Gray study including, 
those who had suffered a thrombotic event in the previous 2 months, dementia patients with no 
carer and those who had a delay between discharge and initiation of the home health service.  
These excluded patients are likely to be the most at risk of MRH for several reasons.  For example, 
patients who have suffered a recent thrombotic event are normally initiated on antithrombotic 
therapy, a group of medicines which were frequently associated with MRH in this, and other88 
studies.  Their physiological reserve is likely to be reduced and their psychosocial resilience 
diminished after the acute insult.  Considering the conceptual framework outlined earlier, deficits 
across multiple areas (for example levels of independence, mood) in combination with exposure 
to a high-risk medicine will increase the likelihood of experiencing MRH.   
With few exclusion criteria, and recruitment from the OPU, the study population is likely to 
represent a highly vulnerable group of older patients.  Similar to the home health service, 
community based support teams are deployed across the GSTFT localities with the aim of 
admission avoidance.  Should a patient present to hospital, a service embedded within the 
emergency department screens for “frailty at the front door”213,214 to ensure that an accurate 
problems list is created and appropriate actions taken, which often results in the avoidance of 
unnecessary admissions.  Patients who are admitted to GSTFT are therefore potentially more 
unwell than those recruited in other studies.  In these patients a small insult may overwhelm 
already depleted physiological and psychosocial reserves so that admission is required to provide 
the level of care needed.  This elevated level of vulnerability may also explain the higher MRH 
rate reported in this study and the high re-admission rate.  Most re-admissions occurred within 
the first week of discharge which is consistent with other ADR studies26.   This is also consistent 
with the slow time to recovery witnessed in frail older adults after an acute insult150 such as a 
hospital admission, and so they are more vulnerable during the post-discharge period.  Few 
studies have focussed on this high-risk stage of the patient journey215, and none have included 




4.5.2 Assessment of MRH in a frail population 
4.5.2.1 Data sources 
Identifying and confirming MRH in a complex older population is challenging and the methods 
employed in the identification, classification and confirmation of MRH in this study must be 
considered when comparing the incidence rates.  Often presenting with atypical symptoms or 
geriatric syndromes, on a background of multiple comorbidities and polypharmacy, it can 
sometimes be impossible to disentangle the causal pathways.  Unique in its approach, this study 
used up to three data sources to confirm MRH: GP records, patient interview and re-admission 
review, allowing every patient to be followed up and a detailed case history to be constructed, 
reviewed and associations agreed.  This method also resulted in no loss to follow up and enabled 
more robust identification of MRH in a complex population, and so may partly explain the higher 
incidence.  Furthermore, many studies investigating MRH are limited as they regularly use 
existing databases or clinical records to retrospectively identify events18,33, or use only a single 
source for follow up25,26.    Often, they are reliant upon a clinician for the accurate identification of 
MRH, attribution of harm to specific medicines and documentation in the patient’s records.  It is 
recognised that clinicians may fail to identify clinical presentations due to ADRs and, in some 
instances, rather than remove the culprit medicine, a new medicine is prescribed to treat the side 
effects.  Known as the prescribing cascade216 this results in polypharmacy, which adds to the 
complexity of identifying MRH.   
 
4.5.2.2 Causality assessment 
The use of algorithms to assign causality to a specific medicine is common practice in ADR 
studies18,25,85, although such approaches have limitations, especially when applied to an older, 
medically complex population.  To mitigate against these limitations, in this study, the Naranjo 
algorithm129 was used as a guide as scores would have been influenced by the inability to re-
challenge a suspect ADR (one of the Naranjo assessment criteria) and almost all patients had a 
potential “other cause” that could have led to the reaction.   
Given the demographics of the study population and the aforementioned difficulty in identifying 
true causality, it is not surprising that in this study only a quarter of all MRH events were classed 
as definite.  This result is comparable to Tangiisuran85, who conducted a prospective study of 
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inpatient ADRs in an older population, but is much higher than other post-discharge MRH studies 
where between 3-6% of events were considered definite25,26.  The method of follow up employed 
contributes significantly to the difference seen.  Patient self-reporting via telephone interview was 
the only source of follow up used in the previous post-discharge studies compared to multiple 
sources, including patients and clinicians, in this study.  Patients may fail to recognise symptoms 
as MRH or not report relatively minor side effects considering them to be an expected 
consequence of taking medicines.  Tangiisuran’s study took place in the inpatient setting where 
clinicians could be consulted at the time of the event and there was greater access to clinical 
investigations, allowing more confidence in the final confirmation of ADR. 
The complexity of such presentations emphasises the need to consider not only the definite 
events but also the probable and possible categories, which is common practice in research of 
this nature.18,25,85  In doing so, the risk of event misclassification and the potential impact of this 
when investigating statistical associations between risk variables and MRH needs to be 
acknowledged.  In an attempt to limit such misclassifications and ensure consistency in 
categorisation of harm, this study applied a multiple stage review process where every case was 
reviewed by both the research pharmacist and a senior clinical academic.   
Overall, the incidence of MRH was higher than previously reported which may be explained by 
the level of frailty of the study population, the extended outcome definition to incorporate non-
adherence and the robust follow up method.  This result is consistent with the theory proposed in 
the conceptual framework that heightened vulnerability increases the likelihood of MRH.  The 
method employed is reflective of the challenges in assigning causality which is frequently 
multifactorial. 
  
4.5.3 Medicines involved in MRH 
Medicines acting on the nervous system were most frequently involved in MRH contributing to a 
quarter (25.1%) of all medicines causing harm, followed by those acting on the cardiovascular 
system (20.1%), and the alimentary tract and metabolism (18.9%).  As these were the three most 
commonly prescribed groups of medicines, the frequency of harm may reflect the frequency of 
exposure.  However, medicines acting on the nervous and cardiovascular systems are recurrently 
reported in the literature as causing ADRs and ADEs in older adults.25,85,88  This may be due to 
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altered pharmacodynamics in older populations increasing their susceptibility to the adverse 
effects of agents acting on the nervous system.  With regard to cardiovascular agents, often 
multiple medicines with similar side effect profiles are prescribed, for example antihypertensives, 
and so the propensity for harm is increased.  Furthermore, these medicines may interact with pre-
existing geriatric syndromes, such as falls.  Medicines acting on the alimentary tract and 
metabolism, was dominated by laxatives but also included medicines used in the management of 
diabetes which are also commonly reported as causing harm in older adults85.  Although MRH 
resulting from the use of laxatives is less well reported, the high incidence of harm associated 
with these medicines in this study is probably due to the definition of MRH used, which included 
harm due to failure to receive a medicine.  Most of the reported harm relating to laxatives was 
constipation secondary to non-adherence, either alone or in conjunction with an ADR from 
another prescribed medicine e.g. codeine.  
Reflecting on the medicines most frequently involved in MRH (those acting on the nervous 
system, cardiovascular system and alimentary tract), it is unsurprising that the alimentary tract 
and nervous systems were the most commonly affected body systems.  This is consistent with 
other studies investigating both inpatient and outpatient ADEs/ADRs in older adults18,25,85,88.  
Constipation and falls accounted for a fifth of all MRH in this study, conditions that are considered 
geriatric syndromes and are known to affect many frail older adults.  As a consequence, it was 
sometimes challenging to definitively discriminate between whether the clinical presentation of a 
fall or constipation was the manifestation of frailty or due to MRH.  In the majority of cases the 
medicine probably augmented an underlying vulnerability.   
 
4.5.4 Defining harm from medicines in a frail older population 
It was important for this study to consider a wider definition of MRH as many previous studies 
have concentrated on ADRs alone.  Although potentially easier to measure using an algorithm 
based approach, ADRs are only one of the medication related problems experienced by older 
adults at discharge.  Over the past 50 years adherence to long term therapies has remained at 
around 50%65 and is associated with poor health outcomes.  In the USA, 33-69% of all medicine 
related hospital admissions are due to poor adherence to treatment.66  Often not considered as a 
potential cause of the clinical presentation, it is important to investigate this arguably avoidable 
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source of MRH. As demonstrated in the current study, the medicine not being available to the 
patient was a problem, as the harm experienced by around a third of patients was associated, at 
least in part, with not receiving their prescribed medicines.  Non-adherence in older adults is often 
thought to be unintentional: forgetting due to poor memory, or difficulty in opening packets due to 
impaired manual dexterity.  It is however more complicated and research highlights that 
approximately 50% of non-adherence in older adults is intentional.71  Six factors influencing 
adherence to therapy have been proposed by Mukhtar and colleagues, based on Leventhal’s 
Common-Sense Model of Self-Regulation.  These are: illness beliefs, perceived risks (e.g. 
adverse effects), benefits and necessity of treatments, the patient-practitioner relationship, inter-
current physical and mental illness, financial constraints and pharmaceutical/pharmacological 
issues (polypharmacy/regimen complexity).69  The potential interplay between physiological and 
psychosocial systems and the consequential action of the patient, as described in the conceptual 
framework proposed earlier, is evident in these factors.      
 
4.5.5 The influence of polypharmacy 
Polypharmacy was common in the study population where the mean number of medicines on 
admission was almost nine, increasing to ten at discharge.  This finding is consistent with previous 
research where it was found that 62.1% of the study sample had at least one or more additional 
medicines at discharge.217  Due to the ubiquity of polypharmacy in the study cohort it was not 
always possible to attribute MRH to a single medicine e.g. constipation in a patient prescribed 
oxycodone, ferrous sulphate, solifenacin, senna and macrogol but is non-adherent to the 
laxatives.  This highlights one of the challenges when conducting research in this area where 
patient presentation is often complex and requires a different approach to that of the traditional 
“single body system”, guideline driven, medicine.  Undeniably, however, guideline based 
prescribing can result in significant polypharmacy and exposes a patient to the risk of drug-drug 
interactions218,219 and is the most consistently reported single predictor of MRH.   
Over recent years, polypharmacy has attracted growing interest, as highlighted by two recent 
publications: King’s Fund Polypharmacy and Medicines Optimisation document52 and the Scottish 
Polypharmacy Guidance54.  Both suggest targeting frail older patients for medicines reviews, 
recognising the excessive harm that can result through the use of inappropriate medicines in this 
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population.  Similar to the NICE multimorbidity guidelines220, the Scottish Polypharmacy Guidance 
offers pragmatic guidance on the process of medicines reviews, proposing seven steps which 
focus on the: 1. Aims; 2. Need; 3. Effectiveness; 4. Safety; 5. Cost effectiveness and; 6. 
Adherence/Patient centeredness of the medicines.  The impact of conducting such medicine 
reviews on the incidence of MRH and which patients would benefit most requires further 
investigation. 
 
4.5.6 Healthcare utilisation 
The healthcare utilisation resulting from MRH ranged from accessing the out of hours services to 
admission to hospital, although the most common resource used was the GP, with 147 (58.8%) 
consultations relating to MRH.  Healthcare utilisation was closely linked to the severity of MRH 
reported where serious events accounted for 85.3% of all MRH and, by definition, required 
treatment modification and so access to healthcare.  Few studies have investigated this aspect 
as most focus on re-admission only and report a re-admission rate between 40-64%32,33,221 over 
a wide-ranging follow up period of between 60-365 days from discharge.  A comparison of this 
current study with the study by Thomas32, who followed patients for 60 days after discharge, would 
seem the most valid as patients re-admitted 1 year after discharge are likely to represent a 
different population.  Thomas and colleagues reviewed MRH in a discharge cohort of 100 patients, 
representing a convenience sample from 1611 patients recruited to another study.  Patients were 
followed for 60 days after discharge and MRH, using the definition of DRP (including problems 
associated with adverse events, treatment effectiveness and treatment cost), was seen in 64% 
of patients.   Whilst this is higher than the incidence reported in this current study (29.6%) it can 
be explained by a number of crucial differences in study design.  The outcome definition used, 
DRP, is likely to report a high incidence of MRH due to its wide scope, patients followed were not 
clearly defined and were generally much younger than those seen in the GSTFT population, with 
a mean age of 56 years compared to 84 years old respectively.  Re-admission in our study 
population was higher than national data reports for GSTFT and will be explored in more detail in 





The generalisability of our findings to the general older population, often defined as >65 years 
old, may be limited as the study participants represented the frail oldest old.  Comparison with 
other studies to help assess generalisability of the findings was difficult as so few post-discharge 
MRH studies have been conducted and different definitions for outcome, preventability, severity 
are frequently used, if reported at all.  Considering severity for example, Forster and 
colleagues222, used a self-derived scale consisting of 6 categories: serious laboratory abnormality 
only; one day of symptoms; several days of symptoms; non-permanent disability, or death.  94% 
of patients suffered non-permanent disability or more than one day of symptoms in a study of 
post-discharge adverse events.  There were no deaths but permanent disability occurred in 3% 
of the population.  Abnormal laboratory results and 1 day of symptoms affected 4%.  Four fatalities 
were reported in this study which may reflect the level of frailty within the study population where 
a relatively minor insult can have disproportionate consequences.  
A relatively small number of patients were screened and subsequently recruited to the study in 
comparison to the total number of patients discharged from the unit.  Screening and recruitment 
were limited by manpower and access to patients.  The extensive follow up process, including 
review of re-admissions, patient phone calls and visits to GP surgeries were highly labour 
intensive, but provided a robust approach to MRH identification and categorisation.  The re-
admission of patients frequently diverted research staff from recruiting patients, as a result, the 
study population may not be representative of the OPU population in general as reflected in the 
demographics where a greater proportion of white females were recruited to the study than were 
discharge from the unit during the same time period.  This may be due to non-white patients being 
unable to speak English, requiring an interpreter for recruitment.  
Further recruitment bias may be suspected when considering the mean depression and anxiety 
scores.  These suggest low levels of anxiety and depression in the study population which is 
inconsistent with the reported prevalence of these conditions in the older population.223  
Recruitment bias is likely to have contributed to this as they represent a group which can be hard 
to recruit.224 
Confirmation and classification of the final outcomes were conducted by members of the research 
team (the EPC) who were not blinded to the study aim and therefore bias may have been 
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introduced.  In the case of re-admissions, clinicians independent of the study group assigned 
causality, severity and preventability to the event alongside the principal researcher.  This 
approach is likely to reduce any bias and, although data were not collected at the time, very few 
case outcomes were significantly changed when reviewed by the EPC.  Most changes to 
classification were in relation to the classification of likelihood, for example from possible to 
probable and vice versa, to align with the study definition.  As already discussed, the assignment 
of causality in this population is challenging and all definite, probable and possible events were 
classified as MRH therefore the impact of any bias on the results is likely to be minimal.   
Healthcare utilisation was not a measure of MRH causing healthcare utilisation, but a measure of 
the number of care episodes that were associated with MRH.  That is, a patient may have 
presented for another reason and MRH was subsequently identified but was not the cause of the 
presentation.  It is therefore not possible to conclude that all these episodes of care were 
additional, although are likely to be directly attributable to the episode of MRH.  In future, it would 
be helpful to categorise patients based on healthcare utilisation due to MRH, although in this 
complex population it is common for more than one event to lead to a presentation and so this 
may be challenging. 
 
4.6 Conclusion 
The incidence of MRH in this study was higher than previously reported.  Study definitions and 
design are likely to have contributed to some of this variation however the study population is 
unique and is likely to be the main cause.  The patients in this study represent a complex frail 
older population who are at high-risk of experiencing adverse outcomes.  This supports the theory 
proposed in the conceptual framework in Chapter 3 (Figure 3.3) that, similar to frailty, multiple 
deficits across physiological and psychological systems results in a disproportionate level of harm 
when exposed to an insult.  In this study, the insult is in the form of a medicine.  This theory and 
the statistical significance of associations between physiological and psychosocial variables and 




Chapter 5 Exploration of variables associated with MRH 
5.1 Introduction 
As identified from the broader literature (Chapter 1), and confirmed in the systematic review 
(Chapter 3), previous studies investigating MRH in older adults have focussed on the influence 
that comorbidities and medicine related variables have on the risk of experiencing MRH.  Few 
studies have considered the impact of psychological and social variables.  The conceptual 
framework outlined in Chapter 3 (Figure 3.3) describes the important contribution that such 
variables could make when identifying frail patients.  The framework highlighted the similarities 
between frailty, geriatric syndromes and MRH, namely that they are multifactorial in nature with 
multiple causal pathways.  Given these commonalities, and the limited research exploring the 
influence of psychosocial variables on MRH, further study of this area is warranted and will be 
presented in this chapter.     
Around 40% (n=156) of patients in this study were re-admitted during the 8-week follow up period, 
with approximately half of these re-admissions (47%) being potentially related to MRH.  Almost 
three quarters (74.3%) of the MRH re-admissions were considered preventable.  Re-admission 
is the costliest outcome of MRH, with penalties levied on the hospitals when they occur within 28-
days of discharge.  The ability to identify those at greatest risk of MRH re-admission, to target 
interventions, would therefore allow a more efficient delivery of healthcare as well as the 
avoidance of distress by the patient.  Nair and colleagues developed a model to predict the risk 
of admission due to MRH in community based patients.  The model had only modest performance, 
as described in more detail in Chapter 3, and didn’t consider psychosocial variables.  
Furthermore, risk factors for re-admission may be different to those associated with admission 
due to the increased vulnerability in the immediate post-discharge period23.  To better understand 
the variables that predict MRH re-admission, this chapter will further explore the associations 





5.2 Aim and objectives 
This chapter aims to explore the relationships between physiological and psychosocial variables 
and the risk of post-discharge MRH.  It will do so by addressing the following objectives: 
1. Measure and compare the associations of variables studied in previous MRH prediction 
model research with MRH in this study population.   
2. Explore the relationship between re-admission with MRH and physiological and 
psychosocial variables.  
3. Explore the potential of frailty indicators, proposed for use in the acute care setting, to 
improve prediction of MRH re-admission.  
 
5.3 Methods 
The dataset described in Chapter 4 was further interrogated with the aim of identifying 
relationships between MRH and selected variables.  Full methods detailing the data collection, 
identification and classification of MRH are described in Chapter 4, a summary of which is 
provided below.   
Three distinct analyses were conducted:  
1. A comparison of patients who experienced MRH to those who did not through exploration 
of the relationships between independent variables and MRH using binary logistic 
regression.  In the discussion section of this chapter, the results from this analysis are 
compared with variables reported in the studies identified in the systematic review (see 
Chapter 3) 
2. Survival analysis with the identification of variables associated with MRH re-admission 
3. A comparison of patients re-admitted with and without MRH.  
 





5.3.1 Summary of prospective cohort study methods 
Patients discharged from the OPU at GSTFT over 24 consecutive months were invited to 
participate in the study.  Data were collected prospectively and is summarised in three key stages: 
1. baseline data collection, including demographic, clinical, medicines and social data; 2. follow-
up data collection, where any MRH associated healthcare utilisation was identified; 3. 
confirmation and classification of MRH, where causality, likelihood, preventability and severity 
were confirmed.  Full details are described in the methods section of Chapter 4.   
 
5.3.2 Variable selection 
There is no defined method for the selection of variables for exploratory analysis.  Previous 
studies have utilised data-driven techniques68 however they have failed to develop risk prediction 
models with adequate accuracy for use in clinical practice.  Therefore, variables considered for 
this analysis were derived from the literature and refined by expert consideration (the supervisory 
team).   
The studies identified by the systematic review were revisited in order to identify potential 
variables for further analysis in this study population.  These studies identified a large number of 
variables, mainly focussing on clinical and medicine related factors.  Between nine and sixty 
seven variables were reported, with Nair68 reporting the most and Trivalle88 the least.  Across 
these studies several common variables were associated with MRH following univariate analysis, 
however there were also many where the association with MRH was inconclusive, or no link was 
found.  Examples of the variables for each of these groups is provided in Table 5.1.  Due to this 
variance, statistical significance from any single dataset alone could not be used to select suitable 
variables for further study.  Variables were therefore selected, following discussion by the 
supervisory team, based upon their face validity and repeated occurrence across the systematic 
review studies. The selection processes deliberately included variables from a range of groupings 
(patient characteristics, comorbidities, clinical, social and medicines) and with varying consistency 
of association as outlined in Table 5.1.  The variables included for example age, gender, ethnicity, 
CCI, eGFR, length of stay ≥12 days, albumin <35g/l, Barthel Index, number of medicines and the 




Table 5.1 Summary of the relationship between selected variables and MRH following univariate analysis 






















 No. of medicines <0.001$ <0.001 <0.001^ 0.05◦ 
































0.308* <0.001* 0.03 0.01# 






















 Age 0.62 0.15¥ - 0.07† 
Gender 0.855 - No value given 0.42 
ADL disability 
 








ADL: activities of daily living; ADR: adverse drug reaction: eGFR: estimated glomerular filtration rate; $ ≥8 medicines; ^ at 
multivariate level; ◦ ≥9 medicines; - not reported/measured in study; * ≥4 co-morbidities; #≥7 co-morbidities; ¥≥80 years; 
†≥85 years 
 
An important aspect of this exploratory analysis was to investigate the influence of psychosocial 
variables on the likelihood of MRH.  In the conceptual framework proposed in Chapter 3 (Figure 
3.3) similarities between the cumulative deficits model of frailty (or FI)154 and MRH were 
described, whereby physiological, psychological and social variables were thought to contribute 
to the likelihood of an individual experiencing an adverse outcome. Therefore, a review of the FI 
literature was conducted in order to facilitate the selection of psychosocial variables for analysis.    
Requiring data for a minimum of 30 variables, the practical feasibility of the FI in the acute care 
setting has been questioned.  The need for an operationalised measure of frailty in the acute care 
setting was recognised by Soong and colleagues who recently derived a set of frailty indicators 
appropriate for use in the acute care setting.225  They conducted a literature review to identify 
studies that developed or validated frailty assessments in the acute care setting.  From the review, 
31 indicators were identified and were grouped into five categories: social demographics, 
phenotype model, high intensity service usage, accumulated deficits model and bio-
gerontological model. As described by Soong, these indicators were reviewed over two rounds, 
by an expert panel using a modified Delphi technique.  Expert panel members were selected 
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nationally on the basis that they were research-active, or providing frailty care, or were involved 
in charities associated with frailty.  The panel consisted of physicians (Consultant Geriatricians 
and Psychiatrists and, GPs), nurses, pharmacists, physiotherapists, dieticians, psychologists, 
social care managers (a Chief Executive of social care, and a care home manager), academics 
and specialists from the charity sector.  They were asked to rate the 31 variables, using a five 
point Likert Scale ranging from “not useful at all” to “very useful”.  Using a cut-off 80% agreement 
(“useful or “very useful”) for inclusion in the final list resulted in the selection of 12 frailty indicators 
(see Table 5.2).  The variables agreed by the consensus panel focused largely on accumulated 
deficits and high intensity service usage.  The authors recognised that whilst these may not fully 
reflect the current definitions of frailty, they cover a range of physiological and psychosocial 
variables, and are potentially indicative of variables that are easily accessible and useful in the 
acute care setting.  Therefore, where the data were available, these variables were incorporated 
into the analysis in this study.  Data pertaining to pressure ulcer risk and multiple hospital 
admission episodes was not available in the study dataset.  The measure used for each variable 
is outlined in Table 5.2, with greater detail provided in the methods section of Chapter 4.   
 
Table 5.2 Recognised frailty indicators and the measurement used in the current study 
Frailty variable Measure used 
(current study) 
Classification % agreement 
(n=41) 
Falls >1 (12 months) Accumulated deficits 95.1 (39) 
Impaired cognition AMTS <8 Accumulated deficits 95.1 (39) 
Nutritional status MUST ≥1 Accumulated deficits 92.7 (38) 
Functional dependence Barthel Accumulated deficits 90.2 (37) 
Multiple morbidity CCI Accumulated deficits 90.2 (37) 
Impaired mobility Barthel  Accumulated deficits 87.8 (36) 
Multiple hospital admissions Unavailable High intensity service use 87.8 (36) 
Large package of care at home ≥4 visits/day High intensity service use 85.4 (35) 
Care home resident Yes/no High intensity service use 82.9 (34) 
Polypharmacy No. of discharge 
medicines 
Accumulated deficits 82.9 (34) 
Incontinence Barthel (bowel and 
bladder) 
Accumulated deficits 80.5 (33) 
Pressure ulcer risk Unavailable Accumulated deficits 80.5 (33) 
Adapted from Soong et. al225 




In addition, hand grip was included in the variables selected for my analysis.  Including this 
variable allowed further exploration of the relationship between markers of frailty and MRH. This 
is because it is a quick and reproducible measure of sarcopenia184, which is often present in frail 
older adults, and a component of the phenotype model of frailty151.  
 
5.3.3 Comparison of patients with MRH and without 
To further understand the factors that influence MRH in the study population, binary logistic 
regression was applied to the dataset.  A commonly used statistical method in prognostic 
research, binary logistic regression facilitates the identification of statistically significant 
associations between the outcome of interest and the independent variable(s).109  The 
associations were compared with selected variables explored in the studies identified by the 
systematic review. 
 
5.3.4 Survival analysis with the identification of variables associated with MRH re-
admission 
MRH re-admission was defined as those who were re-admitted with MRH during their 8-week 
follow up period.  Survival analysis was used to explore the relationship between physiological 
and psychosocial variables and MRH re-admission, with the time to event measure being the time 
elapsed between the date of discharge to the date of hospital re-admission.  
 
5.3.4.1 Survival analysis 
Previous risk prediction model studies have failed to consider that by the end of the study period 
many patients will not have experienced MRH, however this does not mean that they would not 
go on to experience MRH.  They also do not consider competing events e.g. a patient dying during 
the study period.  In this study, 60% of the population did not experience MRH, and around 10% 
(n=37) died during the study follow up period.  Survival analysis allows such events to be taken 
into account through a process known as censoring, and so improves the reliability of any 
conclusions drawn from the data.  Survival analysis was therefore used to identify variables 
associated with MRH re-admission, compared to no MRH occurring.   
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Patients who experienced a fall were allocated to one of two groups; those experiencing up to 1 
fall and those with more than 1 fall in the preceding 12 months, based on the distinction used in 
clinical practice that a patient who has more than one fall in 12 months is in need of a detailed 
assessment.226  Based upon accepted clinical measures, an AMTS of <8 was used to define 
cognitive impairment.177  After discussion with the lead Geriatrician for the Department of Ageing 
and Health at GSTFT, the package of care was categorised as a light care package, a heavy care 
package or institutional care.  A light care package was defined as 0-3 visits a day, a heavy care 
package was four or more visits a day and included 24-hour home care, and institutional care 
was 24-hour care within a nursing or residential home or bed based rehabilitation units.  The 
definitions of the other variables investigated are described in detail in Chapter 4.   
 
5.3.4.2 Comparison of those re-admitted with MRH and those re-admitted without MRH 
It is recognised that the previous analyses comparing those re-admitted with MRH and those not 
re-admitted may have identified variables that are predictive of re-admission in general, rather 
than re-admission with MRH.  Therefore, a comparison of those re-admitted with MRH and those 
re-admitted without MRH was conducted with a focus on the variables identified by Soong and 
colleagues225 
 
5.3.4.3 Healthcare utilisation secondary to serious MRH 
As outlined in Chapter 3 (Figure 3.5), the same MRH may result in various levels of healthcare 
utilisation in different individuals.  In this thesis, it has been proposed that this is due to variations 
in physiological and psychosocial reserve.  Case examples, drawn from the dataset described in 
Chapter 4, are used to illustrate this hypothesis.  
 
5.3.5 Analysis 
Statistics were applied to describe population characteristics, the frequency of MRH re-admission 
and to identify differences between those who experienced MRH and those who did not.  
Categorical data were presented as numbers (%) and numeric data were presented as a mean 
(SD).  Non-normally distributed numeric data were presented as median (inter-quartile range).  
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Binary logistic regression was used to assess the risk of MRH in relation to a particular 
independent variable for all study patients, and for the sub-analysis of all re-admitted patients.      
The relationships between independent variables and MRH re-admission were identified using 
survival analysis.  Kaplan-Meier was conducted for categorical data, with the difference between 
two groups assessed using the logrank test.  Kaplan-Meier plots were presented with the 
corresponding p-value for the logrank test to determine significance.  Cox regression models were 
used for continuous data, and the results were reported as hazard ratios with the corresponding 
95% confidence intervals and p values.  Variables significantly associated with MRH re-admission 
(p<0.05) were entered into a Cox regression model to assess for multicollinearity. 
The analysis was performed using SPSS software (version 24.0; SPSS, Inc., Chicago, IL, USA). 
 
5.4 Results 
5.4.1 Comparison of patients with MRH and without 
The characteristics of those patients who experienced MRH and those who did not are presented 
in Table 5.3.  Univariate analysis comparing the two groups revealed a number of variables 
significantly associated with MRH (set at an a priori of p=0.05) (Table 5.4).  
The two groups were well matched for gender, age, ethnicity and a range of clinical, medicine 
related and functional variables (Table 5.3).  Almost all study participants were probably frail 
based on the measurement of hand grip strength alone, using the recognised cut offs (male 
<30kg; female <20kg)184, and therefore comparison of frail and non-frail was not possible. 
However, when analysed on a continuous scale, lower hand grip strength (men only) was 
associated with an increased risk of MRH.  Patients who experienced MRH were also prescribed 
significantly more medicines on discharge (mean number of medicines: MRH 11.2 (SD 4.3), no 
MRH 9.3 (SD 4.3).  A MUST score equal to one was also significantly associated with MRH.  
Patients who experienced MRH were more likely to live alone (69% vs 58.2%) but this difference 




Table 5.3 Comparison of patient characteristics in patients with MRH and without 
Characteristic Number of patients (%)  
MRH (n=158) No MRH (n=238) Total (n=396) 
Demographics    
Gender (female) 109 (69) 147 (62) 256 (65) 
Age (years)^ 84 (6.7) 83 (7.2) 83 (7.0) 
Ethnicity (white) 143 (91) 209 (88) 352 (89) 
Clinical    
CCI^ 2.3 (1.6) 2.1 (1.7) 2.1 (1.6) 
eGFR (ml/min/1.73m2)˜ 53 (31-79) 60 (37-80) 57 (35-79) 
Length of stay˜ 11 (7-18) 10 (6-16) 10 (6-17) 
Died 12 (7.6) 25 (10.6) 37 (9.3) 
AMTS^ (range 0-10) 8.5 (1.6) 8.2 (1.8) 8.3 (1.7) 
MUST†    
0  77 (49) 132 (59)  209 (55) 
1 38 (25) 34 (16)* 72 (19) 
2 40 (26) 59 (26) 99 (26) 
Comorbidities    
Hypertension 103 (65) 140 (59) 243 (61) 
Connective tissue disease 46 (29) 72 (30) 118 (30) 
Diabetes 50 (32) 58 (24) 108 (27) 
Atrial fibrillation 49 (31) 55 (23) 104 (26) 
Hyperlipidaemia 34 (22) 56 (24) 90 (23) 
IHD 23 (15) 33 (14) 56 (14) 
Anaemia 21 (13) 20 (8) 41 (10) 
Medicine related    
No. admission medicines^ 9.3 (4.2) 8.4 (4.5) 8.8 (4.4) 
No. discharge medicines^ 11.2 (4.3) 9.3 (4.3)* 10.1 (4.4) 
Previous ADR 45 (28.5) 57 (24.0) 102 (25.8) 
MCA† 68 (49.6) 104 (43.7) 172 (45.9) 
Regular pharmacist† 156 (99.4) 234 (98.3) 390 (98.7) 
Frailty measures    
Hand Grip^    
Female (kg)† 12.8 (5.8) 11.8 (5.8) 12.2 (5.8) 
Male (kg) 17.7 (8.5) 21.2 (6.3)* 19.9 (7.3) 
Falls (>1 in 12months)† 71 (45.2) 114 (47.9) 185 (46.8) 
Dependency in ADLs    
Barthel Index^ (range 0-20) 13.0 (4.8) 13.4 (4.4) 13.2 (4.6) 
Social circumstances    
Lives alone 109 (69.0) 138 (58.2) 247 (62.5) 
^ Mean (SD); ˜ Median (IQR); † missing data: MUST n=380, MCA n=395, community pharmacist n=395, hand 
grip n=254, falls n=395; *p<0.05 
ADLs: activities of daily living; ADR: adverse drug reaction; AMTS: abbreviated mental test score; CCI: Charlson 
comorbidity index; eGFR: estimated glomerular filtration rate; IHD: ischaemic heart disease; MCA: multi-




Table 5.4 Univariate analysis of potential predictor variables for MRH (based on binary logistic 
regression) 
Variables Odds ratio (95% CI) p 
Demographics   
Gender (female) 1.38 (0.90 – 2.11) 0.14 
Age 1.03 (1.00 – 1.06) 0.08 
Ethnicity   
White 1.00  
Non-white 0.76 (0.39 – 1.46) 0.41 
Clinical   
CCI 1.06 (0.94 – 1.20) 0.35 
eGFR (ml/min/1.73m2) 0.995 (0.99 – 1.00) 0.07 
Length of stay ≥ 12 days 1.27 (0.85 – 1.91) 0.25 
Albumin <35g/l 1.02 (0.63 – 1.68) 0.92 
AMTS 1.11 (0.98 – 1.25) 0.10 
MUST: 0 1.00  
 1 1.92 (1.12 – 3.29) 0.02 
 2 1.16 (0.71 – 1.90) 0.55 
Co-morbidities   
Atrial fibrillation 1.50 (0.95 – 2.35) 0.08 
CCF 1.26 (0.74 – 2.16) 0.40 
Diabetes 1.44 (0.92 – 2.25) 0.11 
Hypertension 1.31 (0.86 – 1.99) 0.20 
Hyperlipidaemia 0.89 (0.55 – 1.45) 0.64 
IHD 1.06 (0.60 – 1.88) 0.85 
Liver disease 2.56 (0.60 – 10.87) 0.20 
Medicine related   
No. admission medicines 1.04 (1.00 – 1.09) 0.07 
No. discharge medicines 1.10 (1.05 – 1.16) <0.0001 
Previous ADR 1.22 (0.80 – 2.00) 0.31 
MCA 0.98 (0.66 – 1.48) 0.94 
Antithrombotic at discharge 1.71 (1.12 – 2.60) 0.01 
Antidiabetic at discharge 1.28 (0.78 – 2.08) 0.33 
Antihypertensive at discharge 1.55 (1.03 – 2.33) 0.04 
Frailty measures   
Hand Grip   
Female (kg) 1.02 (0.98 – 1.07) 0.31 
Male (kg) 0.93 (0.89 – 0.98) 0.008 
Falls 0 1.00  
 1 0.70 (0.40 – 1.22) 0.20 
 >1 0.76 (0.48 – 1.21) 0.25 
Dependency in ADLs   





Table 5.4 cont. Univariate analysis of potential predictor variables for MRH (based on binary logistic 
regression) 
Variables Odds ratio (95% CI) p 
Social circumstances   
Care frequency   
0 1.00  
1 – 3 times per day 1.50 (0.90 – 2.48) 0.13 
4 – 6 times per day 1.58 (0.96 – 2.62) 0.08 
24 hr care in institution 0.65 (0.27 – 1.55) 0.33 
Lives alone 1.28 (0.83 – 1.97) 0.29 
ADLs: activities of daily living; ADR: adverse drug reaction; AMTS: abbreviated mental test score; CCF: 
congestive cardiac failure; CCI: Charlson comorbidity index; eGFR: estimated glomerular filtration rate; IHD: 
ischaemic heart disease; MCA: multi-compartment compliance aid; MUST: malnutrition universal screening tool 
 
Being prescribed antithrombotics (which included antiplatelets and anticoagulants) at discharge 
was significantly associated with MRH.  It is unclear if this association was due to the high-risk 
nature of these medicines and their propensity to cause distressing side effects such as bruising 
or bleeding, or the clinical indication for which they were prescribed.  More patients with MRH had 
atrial fibrillation (31%) than those in the no MRH group (23%), but this difference was not 
statistically significant (p = 0.08).  Based on the recommendations of NICE227 (which advocates 
the use of CHA2DS2-VASc score228 to estimate stroke risk in patients with non-valvular AF), it is 
likely, due to their age alone being a substantial risk factor (most were ≥75 years old), that the 
majority of the study population with AF were receiving antithrombotic treatment.  Multi-collinearity 
between these variables is therefore probable, however this was not tested for.   
Care frequency was not significantly associated with MRH however the result tended towards 
greater support needs at home, as suggested by the need for a four times a day or more care 
package, being associated with the risk of MRH.  Interestingly, this relationship was not seen with 




5.4.2 Re-admissions  
Over one third (n=156 (39.4%)) of patients were re-admitted during the 8-week follow up.  The 
baseline demographics for re-admitted patients and the whole study population is provided in 
Table 5.5.  Age, gender and ethnicity were similar but overall re-admitted patients were more frail.  
Re-admitted patients had a higher CCI (2.3 (SD 1.6) compared to 2.1 (SD 1.6)), were prescribed 
on average 1 more discharge medicine, and were more likely to use an MCA to assist in the 
management of their medicines.  They had a higher level of dependency in ADLs (mean Barthel 
Index 12.6 (SD 4.3) compared to 13.2 (SD4.6)) and greater levels of sarcopenia in both sexes 
but especially in men (mean hand grip: female 11.9 (SD 5.9) kg, male 18.3 (SD 6.9) kg compared 
to female 12.2 (SD 5.8) kg, male 19.9 (7.3) kg).  Over two thirds (68%) of the patients who died 
during the 8-week follow up were re-admitted.  
Table 5.5 Baseline demographics of re-admitted patients and not re-admitted patients 





All study patients 
(n=396) 
Demographics    
Gender (female) 99 (63) 157 (65) 256 (65) 
Age (years)^ 83 (7.2) 84 (6.9) 83 (7.0) 
Ethnicity (white) 140 (90) 213 (89) 352 (89) 
Clinical    
CCI^ 2.3 (1.6) 2.1 (1.7) 2.1 (1.6) 
AMTS^ (range 0-10) 8.3 (1.7) 8.3 (1.8) 8.3 (1.7) 
MUST†    
0  82 (55) 127 (53) 209 (55) 
1 29 (19) 43 (18) 72 (19) 
2 38 (26) 61 (25) 99 (26) 
Medicine related    
No. discharge medicines^ 11.1 (4.4) 9.4 (4.2) 10.1 (4.4) 
MCA† 80 (51.3) 92 (38.8) 172 (45.9) 
Frailty measures    
Hand Grip^    
Female (kg) 11.9 (5.9) 12.3 (5.8) 12.2 (5.8) 
Male (kg) 18.3 (6.9) 21.0 (7.3) 19.9 (7.3) 
Falls (>1 in 12months)† 80 (51.3) 105 (43.8) 185 (46.8) 
Dependency in ADLs    
Barthel Index^ (range 0-20) 12.6 (4.3) 13.6 (4.7) 13.2 (4.6) 
^ Mean (SD); †missing data: MUST n=380, MCA n=395, falls n=395 
AMTS: abbreviated mental test score; CCI: Charlson comorbidity index; MCA: multi-compartment compliance 




The distribution of time to re-admission of the study population is presented in Figure 5.1.  Almost 
half (49%) of re-admissions occurred within the first 14 days, which is similar to that of the OPU 
population in general.  
 
Figure 5.1 Distribution of re-admission of the study population (n=156) 
 
5.4.2.1 Comparison of patients with MRH re-admission to those without  
Of the 396 patients included in the study, 67 were readmitted with MRH.  Survival analysis 
revealed a mean time to event of 48.9 days (SE 0.84; 95% CI 47.3-50.6).  Table 5.6 summarises 
the relationship between the independent variables and MRH re-admission.  Significant 
associations were found with variables across a range of categories.  Using an MCA, number of 
medicines, CCI and depression were all found to be statistically significant following survival 
analysis.  The significance of falls and care frequency was borderline.  Kaplan-Meier curves are 




Table 5.6 Analysis of variables for MRH re-admission (based on survival analysis) 
Variable Statistical association 
Kaplan-Meier chi square p 
New medicine 0.091 0.762 
MCA 9.762 0.002 
Falls 0-1,>1 3.571 0.059 
AMTS<8 0.348 0.555 
Care package 5.934 0.051 
Previous ADR 0.889 0.346 
Ethnicity 0.697 0.404 
Gender 0.330 0.566 
Cox regression Hazard Ratio (HR) (95% CI) p 
Number of drugs 1.101 (1.05-1.154) <0.01 
MUST 1.083 (0.821-1.426) 0.573 
Barthel 0.973 (0.925-1.024) 0.299 
CCI 1.142 (1.012-1.29) 0.032 
Mobility 0.916 (0.752-1.115) 0.381 
Age 0.995 (0.962-1.03) 0.779 
Length of stay 0.995 (0.976-1.014) 0.589 
Depression 1.044 (1.007-1.082) 0.019 
Anxiety 0.970 (0.861-1.093) 0.614 
ADR: adverse drug reaction; AMTS: abbreviated mental test score; CCI: Charlson comorbidity index; 






Figure 5.2 Kaplan-Meier curves showing relationship between MRH re-admission and any new drug (5.2a), 




Figure 5.3 Kaplan-Meier curves showing relationship between MRH re-admission and falls (0-1 or >1 in 12 




Figure 5.4 Kaplan-Meier curves showing relationship between MRH re-admission and use of an MCA 
(dosette box) (5.4a) and intensity of home support (light = 0-3 times/day, heavy = >4 times/day and 




Figure 5.5 Kaplan-Meier curves showing relationship between MRH re-admission and gender (5.5a), and 




Multicollinearity is expected to exist between these variables and so must be tested for, e.g. the 
more comorbidities diagnosed (as represented by CCI) the more medicines prescribed.  To test 
for multicollinearity, statistically significant variables, and those approaching significance, were 
included in a multivariate model (see Table 5.7).  The number of medicines was the only variable 
that retained significance.  Falls and depression, whilst tending towards an association with MRH, 
were not statistically significant, and adjusting for age and gender made minimal difference to the 
model.     
Table 5.7 Multivariate Cox regression model of independent variables (adjusted for age and gender) 
Factor HR Lower CI Upper CI p 
Number of medicines 1.08 1.025 1.138 0.004 
MCA 1.535 0.908 2.593 0.11 
CCI 1.074 0.932 1.239 0.323 
Falls 1.556 0.936 2.587 0.088 
POC light 
   
0.226 
POC NH 0.377 0.089 1.586 0.183 
POC heavy 1.267 0.748 2.145 0.378 
Depression 1.039 0.996 1.083 0.077 
CCI: Charlson comorbidity index; CI: confidence interval; HR: hazard ratio; NH: institutional care; MCA: multi-
compartment compliance aid; POC: package of care 
 
5.4.2.2 Comparison of patients re-admitted with and without MRH 
To further explore the relationship between MRH and frailty, a comparison of MRH re-admission 
(n=67) and non-MRH re-admission (n=89) and the associations with frailty indicators was 
conducted.  As shown in Figure 5.6, at univariate analysis, CCI and the number of medicines 
were associated with an increased risk of MRH re-admission, (p<0.05), OR 1.227 (95% CI 0.998-
1.508, p0.053) and OR 1.082 (95% CI 1.005-1.166, p0.037), respectively.  As previously 
mentioned, these are likely to be correlated but this was not tested.  As only 2 patients from 
institutional care were re-admitted, and neither instance was due to MRH, this group could not be 
included in the analysis.  All other frailty indicators did not demonstrate a significant association 





Figure 5.6 Comparison of MRH re-admission and non-MRH re-admission 
 
5.4.3 Severity of MRH and healthcare utilisation 
In this study, a severity rating of “serious” was defined as ‘an additional visit to clinic for treatment 
or additional medications, including dose reductions or cessation of therapy’.22  Due to the scope 
of this definition all re-admissions were classed as at least serious MRH, however not all serious 
MRH had to result in re-admission.  The same serious MRH may also be managed through self-
care at home or a GP consultation.  The concept that different types of healthcare utilisation may 
be sought by different individuals, in response to the same severity of MRH, was introduced in 
Chapter 3 (Figure 3.5).  This action is likely to be influenced by both their physiological and 
psychosocial reserve.  Figure 5.7 describes three cases of serious MRH where the patient 
developed constipation as a result of an ADR, or a combination of ADR and non-adherence.  The 




 Case 1: Serious – self-management 
MRH event: constipation (ADR and non-adherence) 
92 year old female.  Lives with daughter, no formal care package.  Past history of OA, CKD, colorectal 
Ca, hyperlipidaemia, hypertension.  Previous allergies/ADR: Rash from ACE inhibitors.  Discharged from 
hospital following pubic rami fracture.  Co-codamol 30/500mg QDS initiated as inpatient and continued 
on discharge.  Macrogol 1 BD and senna 15mg ON PRN also prescribed but patient was non-adherent.  
Developed constipation so commenced laxatives and normal bowel movements were resolved.  
 
Case 2: Serious – GP managed 
MRH event: constipation (ADR) 
79 year old female.  Lives alone, no care package.  Past history of COPD, AF, hypertension, IHD (previous 
MI), depression.  Previous allergies/ADR: cough with ramipril.  Co-codamol 8/500mg 2 QDS initiated to 
treat back pain.  After 7 days contacted GP because she was constipated.  GP diagnosed constipation 
and advised to stop co-codamol.  Regular paracetamol, tramadol PRN were commenced for pain and 
senna and lactulose for constipation. 
 
Case 3: Serious – hospital admission 
MRH event: constipation (ADR and non-adherence) 
86 year old female.  Lives alone in “extra care” sheltered accommodation with QDS carers.  Past history 
of type 2 diabetes, hypertension, hyperlipidaemia, diastolic dysfunction, peripheral vascular disease, 
neuropathic pain, previous stroke (residual left hemiplegia), wheelchair bound, cataracts.  Previous 
allergies/ADR: Unknown nature of intolerance to beta-blockers, ramipril, co-proxamol and glibenclamide; 
rash with penicillins.  During index admission buprenorphine patch initiated in hospital for shoulder pain, 
and regular lactulose for constipation.  Patient was prescribed Senna PRN prior to admission and this 
was continued.  Buprenorphine dose increased in community due to uncontrolled pain.  Two weeks later 
presented to A&E with abdominal pain and was diagnosed with acute on chronic constipation.  Advised 
to take regular laxatives – macrgol commenced.  Re-presented four days later with ongoing lower 
abdominal pain, not eating or drinking and no bowel motions.  Due to reduced oral intake carers were 
concerned about continuing insulin and so sent patient to A&E.  Compliance with laxatives unclear – 
lactulose and senna issued by hospital (outside of MCA) following index admission but was not on GP 
records so further supply unlikely.  Re-admitted with constipation. 
 
ACE: angiotensin converting enzyme; ADR: adverse drug reaction; AF: atrial fibrillation; BD: twice per day; Ca: cancer; 
CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; IHD: ischaemic heart disease; MCA: 
multi-compartment compliance aid; MI: myocardial infarction; MRH: medication related harm; OA: osteoarthritis; ON: 
at night; PRN: when required; QDS: four times per day. 





Considering the cases outlined in Figure 5.7, it may be argued that the overall resilience (both 
physiological and psychosocial) declines as the level of healthcare utilisation increases.  Case 1, 
whilst being the oldest patient, had a relatively simple past medical history and living with her 
daughter provided a robust psychosocial system and as a result, she was able to self-manage 
the constipation.  By comparison, Cases 2 and 3 had more complex medical histories and were 
likely to have less physiological reserve.  In Case 2, social isolation and a history of depression 
were likely to limit the psychosocial resilience.  In combination, the limitations within both 
physiological and psychosocial systems lead to the patient requiring GP support to manage her 
constipation.  Finally, in Case 3 the patient suffered from multimorbidity and was heavily 
dependent upon formal care to support her ADLs and so had extensive levels of impairment in 
both physiological and psychosocial systems.  She was ultimately sent to hospital by her carers 
for the management of her constipation.   
 
5.5 Discussion 
This is the first study to explore previously validated variables alongside those where little prior 
research has been undertaken.  The analysis found associations between MRH and a range of 
variables from both physiological and psychosocial clusters but, apart from the number of 
medicines prescribed at discharge, none retained significance when included in a multivariate 
model.  This research programme has highlighted the heterogeneity of this population who 
present to the health services with not only a diverse range and combination of clinical conditions, 
but with extensive variability in their functional ability, and psychological and social support 
mechanism, which is likely to make the identification of a discrete number of highly predictive 
variables challenging.   
When comparing the findings of this research to previous findings a number of issues are worth 
considering. Firstly, patients are generally older and receive more prescribed medicines.  This is 
partly driven by increased life expectancy coupled with multimorbidity48 and the ensuing guideline-
based prescribing218,219, as evident from the number of medicines prescribed in earlier studies in 
the systematic review being less than this study cohort.  Secondly, despite the lack of significance 
at multivariate level, some interesting findings were noted which suggest that as well as the more 
traditional variables, such as number of medicines and specific medicines classes, the 
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psychosocial variables are likely to influence the occurrence of MRH.  These findings include use 
of a multi-compartment compliance aid, depression, malnutrition, low hand grip (men only) and 
having a large package of care at home being associated with post-discharge MRH.  The lack of 
demonstrated independent association can in part be explained by the relatively small sample 
studied, as well as the possible complexity of the relationship between variables.  Furthermore, 
whilst the variables explored in the psychosocial cluster explored some of the aspects of frailty it 
was by no means complete.  As our understanding of the variables that influence frailty 
progresses this will direct future work to ensure that the variables included represent a better 
understanding of the frailty domains.  
This study has confirmed the association between a range of variables and MRH at a univariate 
level.  The number of medicines demonstrated a significant association with MRH in all analyses, 
a finding consistent with the wider literature. This is unremarkable given that it would be 
anticipated that patients are more likely to experience MRH when they are prescribed more 
medicines.  Given the high prevalence of overall low reserve in the patient group, the number of 
medicines may represent both a greater clinical illness burden, and an increasing likelihood of 
exposure to a potential medication related insult, and consequentially an increased likelihood of 
experiencing MRH.  Interestingly, the effect size for the number of medicines reported across the 
literature varies, and is influenced by whether this variable is analysed as a continuous or 
dichotomised variable. The odds ratios (95% CI) for the number of medicines variable were: 1.10 
(1.05-1.16) compared to 3.30 (1.93-5.65) Tangiisuran85, 4.07 (2.93-5.65) Onder18, 1.9 (1.6-2.3) 
Trivalle88.  This variance may be due to the different primary outcome measures studied or the 
use of non-standard definitions which, as discussed in Chapter 3, is a challenge when interpreting 
research in this area.  However, it should also be noted, that both Tangiisuran85 and Onder18 
categorised the number of medicines based on an “optimal” cut-off point of ≥8 medicines.  Altman 
and Royston127,229 advise against adopting this technique of arbitrary dichotomisation due to the 
increased likelihood of a Type 1 error occurring thereby over-estimating the difference between 
the two groups.  Indeed, dichotomisation of the number of medicines variable using the cut-off 
point of ≥8 medicines in this study results in an odds ratio of 2.45 (95% CI 1.52-3.92, p<0.0001), 
more than doubling the effect size.  In the systematic review studies, many continuous variables 
were dichotomised or split into multiple categories e.g. number of comorbidities, renal function, 
age, antihypertensives, and so further comparison is of limited value. 
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Antithrombotics were significantly associated with MRH at a univariate level which is consistent 
with previous studies85,88 and is unsurprising given the high-risk nature of these medicines.  
Associated with serious and potentially distressing side effects, such as bruising and bleeding, 
patients are counselled on the importance of identifying and reporting these side effects, as they 
may be a sign of over treatment.  As a result, patients may be better educated about the risk 
profile of these drugs, increasing reporting and documentation of these ADRs in their medical 
notes.  A true increased risk of harm from medicines within this class however is likely, as 
demonstrated by a recent large prospective cohort study230.  It found that those over the age of 
75 years old admitted to hospital with their first transient ischaemic attack, ischaemic stroke or 
myocardial infarction and treated with antiplatelet therapy (mainly aspirin), without routine proton-
pump inhibitor (PPI) use had a significantly higher risk of major bleeding events than younger 
patients (HR 3·10, 95% CI 2·27-4·24; p<0·0001).  This risk was even higher for major upper 
gastrointestinal bleeds (HR 4·13, 2·60-6·57; p<0·0001), particularly if disabling or fatal (10·26, 
4·37-24·13; p<0·0001).230 
Being prescribed an antihypertensive has previously been identified as a risk factor for MRH and 
was confirmed in this current study.  A combination of antihypertensives, with different 
mechanisms of action, were frequently prescribed in the study population. This is unremarkable 
given the prevalence of hypertension in this population, and in line with national guidance. The 
use of multiple antihypertensives with similar therapeutic and adverse outcomes could overwhelm 
an already compromised system in a frail older population.  For example, an 86 year old female 
study participant was re-admitted to hospital following a two day history of urinary frequency, 
burning upon micturition, fevers and dizziness.  Amongst her comorbidities were severe aortic 
stenosis and ischaemic heart disease and, her prescription medicines included; losartan, 
diltiazem, nicorandil and isosorbide mononitrate.  Urinalysis tested positive for a urinary tract 
infection (UTI).  Upon admission her blood pressure was slightly elevated (155/72mmHg), 
however following administration of her medicines it dropped to 95/40mmHg and she described 
the same dizzy feeling as prior to admission.  She was diagnosed with a hypotensive episode 
secondary to antihypertensives on a background of a UTI and severe aortic stenosis.  Nair and 
colleagues68 also reported that the more antihypertensives prescribed the higher the risk of 
hospitalisation due to ADR but with a greater effect size OR 4.75 [95% CI 1.89-11.93, p0.001] 
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compared to the current study OR 1.55 [95% CI 1.03-2.33, p0.04]), most likely due to 
categorisation of the continuous variable. 
Comorbidity was significantly associated with MRH at a univariate analysis level but significance 
was not maintained in a multivariate model.  This is consistent with the findings of Nair68 and 
Trivalle88, however Onder18 reported significance at multivariate level and Tangiisuran85 found no 
association.  Some of the variation may be explained by: the different method of measurement 
used, for example this current study used the Charlson comorbidity index in comparison to the 
systematic review studies which used disease count; or the type of analysis used, different cut-
off points were used to dichotomise the number of comorbidities variable.  Unlike previous MRH 
risk prediction studies18,68, depression was found to be significant at a univariate level in this study, 
HR 1.04 (95% CI 1.01-1.08, p0.019).  The relationship between depression and MRH has been 
reported in the wider literature and is consistent with the findings of this study; Onder and 
colleagues231 in a study of 3134 older inpatients (mean age 72.0±14.1 years) found depressed 
patients (classified using the Geriatric Depression Score) had a higher risk of ADR than patients 
without depression, adjusted OR 1.58 (95% CI 1.14-2.20).  With regards to non-adherence, in a 
meta-analysis of the effects of depression on patient adherence, which identified 13 studies, those 
with depression were found to be three times more likely to be non-adherent to medical 
treatment232 and as demonstrated by this current study, non-adherence was responsible for 
approximately a third of all MRH.  The associations of liver disease and hyperlipidaemia with the 
risk of MRH remain unclear with the current study, along with some of the systematic review 
studies68,85, not reporting a significant relationship whilst others18,85 did, even at multivariate level.   
A unique aspect of this study was the exploration of variables which have either not previously 
been researched or only in a limited fashion, with regards to predicting MRH.  The use of a MCA 
was significantly associated with MRH re-admission at a univariate level, which is perhaps 
surprising as they are a commonly used intervention aimed at supporting medicines use, however 
recent research questions their value.  The REMIND study233 was a comparative-effectiveness 
randomised controlled trial of three adherence support devices, including a MCA, involving over 
50,000 patients in the United States.  Almost 18,000 patients prescribed between one and three 
medicines for cardiovascular disease, diabetes, non-depression related chronic disease or 
depression were randomised to receive a MCA and followed up for 12 months.  The authors found 
that adherence was not improved by any of the devices.  In addition, a study of 2060 adult MCA 
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users in Scotland, with a median age of 82 (IQR 70-87) years, found patients using a MCA had 
an increased likelihood of being prescribed a potentially inappropriate medicine234 and so could 
have an increased risk of experiencing MRH.  
The association of MRH and care package was significant at a univariate level and was more 
significant in individuals who had a large care package at home than for those individuals requiring 
round the clock care, for example in a nursing home.  Although individuals requiring institutional 
care are likely to have greater physiological deficits than those managed at home, it would seem 
that the resources available to them to withstand setbacks within institutional care reduces the 
risk of experiencing a re-admission with MRH.   
A MUST score of 1 was significantly associated with post-discharge MRH.  An interdependent 
relationship between ADRs and nutritional status has been described where ADRs, such as 
nausea or taste disturbances, may influence nutritional intake which may then impact on the risk 
of ADRs through altered drug pharmacokinetics235 e.g. compromised nutritional status can result 
in reduced hepatic protein synthesis, in particular albumin, thereby reducing the protein-binding 
capacity of the drug and increasing the concentration of free drug which increases the risk of 
toxicity.   
Hand grip has not been explored previously in the context of MRH and a low hand grip (males 
only) was found to be significantly associated with post-discharge MRH univariate level.  A 
measure frequently considered when assessing frailty, this association may be highlighting that 
frail individuals are at greater risk of MRH due to decreased homeostatic reserve and so they 
have limited reserve to cope with minor insult.   
Whilst many of the variables whose relationship with MRH had not previously been explored were 
significantly associated with MRH upon univariate analysis (MCA use, care package, MUST score 
and hand grip), none retained significance in a multivariate model which is likely due to 
multicollinearity.  
The inconsistencies across the studies between variables identified as being associated with 
MRH may be explained by the different study populations, the different clinical context (that is, 
post-acute illness in this study) and the considerable heterogeneity that exists in older 
populations.  The limited reporting of baseline characteristics restricts the ability to compare this 
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study population and the populations investigated in the development of the existing risk 
prediction models18,68,85,88,89, however where data were available it suggests that the current study 
population was more frail.  Only Onder18 reported CCI and it was lower than in this study 
population (1.46 (SD 1.75) versus 2.1 (SD 1.6) respectively).  Although the demographics of this 
study population were similar to the populations investigated by Tangiisuran85 and Trivalle88 (the 
majority of patients were over the age of 80 years old, white and female), this study population 
were more dependent in their activities of daily living with a mean Barthel Index score of 13 (SD 
4.6) compared to Tangiisuran85 who reported 19 (range 14-20).  More of this study population 
lived alone (62.5%) when compared to the population investigated by Tangiisuran (57%)85.    
Co-morbidities represented a spectrum of conditions in all studies, suggestive of multimorbidity 
in all the populations.  The older studies reported the lowest number of prescribed medicines, 
with Onder18 reporting the least, followed by Tangiisuran85 and Trivalle88.  More recent studies, 
including this study and the study by Nair68, both report a mean of over 10 medicines per patient.  
 Overall, where comparison of study populations was possible, the current study population 
appears to have more deficits across multiple domains than the systematic review study 
populations and so has a greater risk of MRH as reflected by the higher MRH incidence in this 
study and re-admission rate.   
The re-admission rate seen in this study, was found to be more than three times higher than that 
of the Older Persons Unit population in general; during the 28 days after discharge 28.3% of the 
study cohort was re-admitted compared to 8.4% of the OPU population.  The OPU figures 
represent a slightly different time period, during which a new admission avoidance service was 
introduced. This may have resulted in the more stable patients being treated at home: this would 
likely result in the mean readmission risk being higher in those who were admitted.  In addition, 
the new service may have directly reduced the number of OPU re-admissions, but it is unlikely 
that these possibilities fully explain the magnitude of observed difference in readmission rate. It 
is more likely that the study population is not representative of the OPU population. 




As previously discussed in Chapter 4, the complexity of this population makes determining the 
cause of MRH challenging.  Only a quarter (24%) of cases were classed as definitely due to MRH.  
This can result in some event misclassification and so the potential impact on the statistical 
associations between variables and MRH needs to be considered.   
Recruitment to the study was challenging, partly due to difficulties in consenting a frail older 
population, and so a small sample size limited some of the analysis.  For example, only 67 patients 
experienced MRH re-admission which should be recognised when interpreting the results as this 
presents an increased risk of Type II error during statistical analysis.  As a result, firm conclusions 
could not always be drawn from the data but the trends identified support the hypothesis of this 
exploratory study and warrant further investigation. 
To fully utilise the data available, dichotomisation, or categorisation of continuous variables, was 
avoided where possible.  Whilst this is a long-standing practice in risk prediction research, often 
justified by researchers as improving the clinical utility of risk prediction models, it is heavily 
criticised by statistical experts as it can result in over-optimism of effect size.   In the current study, 
AMTS score and number of falls were dichotomised, however AMTS was also analysed as a 
continuous variable with no noteworthy change in association.  It would be beneficial to analyse 
falls as a continuous variable; however the cut-off point utilised was reflective of that used in 
clinical practice in distinguishing between a one-time faller and a frequent faller, the latter being 
associated with frailty. 
Another challenge of research in this area is the vague reporting of episodes of MRH by patients 
and in medical notes, which make it difficult to determine the exact date that MRH commenced 
or was experienced.  Since a key component of survival analysis is an accurate event date, 
survival analysis could only be applied to re-admission data.     
The high re-admission rate of the study population in comparison to the general OPU may be 
suggestive of recruitment bias, whereby those who were less unwell were discharged quicker and 
therefore missed during recruitment.  The resultant study population was therefore more unwell, 
and more at risk of re-admission, thus limiting the generalisability of the findings.  This should not 
detract from the high re-admission rate and high overall incidence of MRH, which is important 
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with regards to service improvement, especially as this population reflects the advancing 
complexity of geriatric medicine.   
 
5.6 Conclusion 
This exploratory work has identified the complexity of the associations between variables and 
MRH, and the potential impact of psychosocial variables on MRH.  Psychosocial and frailty related 
variables, were associated with MRH risk, although statistical significance of each individual 
variable was not demonstrated in the multivariate model.  The heterogeneity of the population, 
due to advancing age236 and frailty, makes the identification of a small number of highly predictive 
variables challenging, and may limit the usefulness of pursuing the path of identifying a set of 
strongly predictive variables.  Furthermore, not only are an individual’s risk factors wide-ranging, 
they are also dynamic, improving or worsening at any given time point.  The clinical context of 
this study was one during which the patients conditions were likely unstable for most, with some 
recovering, some relapsing, and some having new conditions.  As described in the conceptual 
framework, when physiological and/or psychosocial reserves are limited, e.g. when the multiple 
deficits are combined, then the likelihood of harm increases.  In the context of MRH, multiple 
deficits increase the likelihood of a patient experiencing MRH, and the more medicines a patient 
is prescribed, the greater the chance of harm occurring.  With an aging population, it’s imperative 
that we better understand the complexity of MRH if we hope to reduce burden on the patient and 




Chapter 6 Discussion 
6.1 Principal findings 
This research set out to examine the possibility of identifying older patients at risk of MRH 
following an acute hospital episode.  The studies which form this thesis assessed the occurrence 
of MRH during the post-discharge period, and also focused on the identification of existing MRH 
risk prediction models and the exploration of variables associated with MRH.   
The systematic review identified five MRH risk prediction models for use in older adults, all 
focussing on ADRs, none of which were designed to assess the risk after an acute hospital 
episode.   A number of issues were identified relating to the quality of the existing studies and the 
accuracy of the models developed, preventing their adoption into routine practice.  Moreover, the 
models failed to address the complexity of the older population, and the breadth of variables 
required to capture such variation.  Work to date has focussed on more traditional variables 
relating to disease, its management and the associated risks e.g. number of co-morbidities, 
number of medicines and level of dependency for ADLs.  There is a lack of understanding of the 
role of psychosocial support received by older patients in mitigating the risk of harm from 
medicines.  
The prospective cohort study found that almost 40% of frail older patients discharged from 
hospital following an acute admission experienced at least one episode of MRH, the majority of 
which (88%) required treatment modification and were considered preventable (58%).  A 
significant level of healthcare utilisation relating to MRH was identified with 1.2 episodes of care 
per MRH event, most of which involved consultation with a GP (59%).  Re-admissions were 
common with two in five patients re-admitted within 8 weeks of discharge, 43% of which were due 
to MRH and three quarters were considered preventable.   
Further analysis confirmed the importance of the number of medicines and the risks associated 
with particular classes of medicines, e.g. antithrombotic agents, when identifying patients at high-
risk of MRH, but has also uncovered factors associated with risk which were previously thought 
to be supportive, e.g. the use of a MCA.  Hand grip (men only), a MUST score of 1, depression 
and comorbidity were also associated with MRH, however the only variable to demonstrate an 




The generalisability of the results from this research may be limited given the unique patient 
cohort who, due to recruitment from the specialist older persons unit only, represent a frail older 
population.  Whilst recognising this limitation it should be considered that the population studied 
is likely to reflect the future older patient discharged from hospital as healthcare services focus 
upon reducing the unnecessary admissions of older adults, and increasing care in the community, 
so limiting hospital admission to the most complex and frail.  A further limitation is the potential 
for event misclassification due to the difficulty of determining causality in such a complex 
population; this may have impacted on the strength of associations between certain variables and 
MRH.   
This study is one of only a few to explore the incidence of MRH in a population of older adults 
recently discharged from hospital, and highlights a significant problem both in terms of the extent 
of MRH, and the impact on patients and on healthcare provision.  Arguably this is a situation that 
is going to intensify as a multimorbid population ages, but in this study, and others2,14,85, it appears 
to be preventable in some cases, and so steps need to be taken to mitigate this risk.  It is difficult 
to compare the incidence of MRH reported in this study to previous research due to the small 
number of studies focussing on older adults during the post-discharge period, and the significant 
heterogeneity in study design which has resulted in a varied incidence (14-46%), as reported by 
Garcia-Caballos and colleagues in a review of the literature.24  That being said, the incidence in 
this study is higher than that reported in the wider MRH literature, and is similar to those post-
discharge studies where the incidence reported was at the higher end of the range.  This is most 
likely due to the level of frailty in the study population.  
Inconsistency was found across the literature regarding which variables are associated with MRH; 
the one exception being the number of medicines, where although the effect size varies 
depending upon the handling of the data during analysis, the association was strong and 
independent of other factors, as found in this study.  Hand grip and nutritional status, both 
considered to be markers of frailty, demonstrated significance at univariate level, and with very 
little previous research exploring their association with MRH, further investigation is required to 
confirm these findings. 
Where previous studies have focussed on co-morbidities and medicine related variables, this 
study highlighted the importance of considering a broader range of variables including those 
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relating to the support mechanisms around how the medicines were used outside of the hospital, 
and the robustness of systems aimed at optimising outcomes.  This broader consideration can 
be seen with the case of an 88 year old gentleman with atrial fibrillation, prescribed warfarin for 
the primary prevention of stroke but spending sub-optimal time in the therapeutic range.  Whilst 
his labile INR may have been the consequence of age-related  increased sensitivity to warfarin237, 
in this case the patient had difficulty remembering to take his warfarin, and so a system was 
devised between the patient and his regular carer to assist adherence.  This system worked well 
until the carer was admitted to hospital, resulting in a change to the support system and a 
subsequent re-admission for the gentleman with a cardio-embolic stroke and a sub-therapeutic 
INR following missed doses of warfarin.  The high-risk nature of the medicine in this case example 
is unquestionably important and illustrates the value of considering the more traditional risk 
variables, however it is proposed that the psychosocial elements of the case were fundamental 
in establishing a suitable equilibrium between risk and benefit.  Further exploration of 
psychosocial variables is therefore important to improve our understanding of their influence on 
MRH.  
The conceptual framework (Figure 3.3) developed within this research programme goes some 
way in capturing the relationship between physiological and psychosocial factors and their 
influence on MRH, but perhaps not in their entirety.  Elements of the psychosocial aspects such 
as mood and support were explored, and their influence upon MRH was upheld in part by some 
of the analysis, however further work is required to confirm these relationships.  The impact of 
socioeconomic status, for example, on the patient’s ability to avoid or cope with MRH also requires 
exploration.   
The conceptual framework does not capture the changing nature of an older person’s 
vulnerability.  The dynamism of the risks and protective systems is evident, as illustrated in the 
case earlier where social support appears to have been the keystone to modifying MRH risk.  In 
this study those within institutional care were less likely to experience MRH than those who were 
at home and heavily dependent upon a package of care.  Having a higher risk of MRH however 
may be an acceptable consequence for some patients if it enables “independent” living within 
their home environment.  Further development of the framework needs to capture the complexity 
of patient choice with regards to the risk of MRH and potential strategies for moderation.   
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The conceptual framework places MRH alongside other geriatric syndromes such as falls and 
incontinence, that is, MRH may be considered one of the “multifactorial health conditions that 
occur when the accumulated effects of impairments in multiple systems render (an older) person 
vulnerable to situational challenges.”238  In the same way that a fall may be the result of a specific 
overwhelming event such as a cardiac dysrhythmia, but is more commonly in older people the 
result of the combination of several factors such as cognitive impairment, gait dyspraxia and a 
new environment, MRH may also be the result of an specific overwhelming event such as 
prescription error but is more often the result of receiving a medicine for a reasonable indication, 
at a reasonable dose but by a patient with impaired physiological and/or psychosocial reserve to 
withstand a generally low risk but recognised adverse effect.  The diversity of systems involved 
explains, to some extent, the limited predictive ability of any individual risk variables researched 
in this study and the multicollinearity identified suggests complex interplay between the variables. 
The dynamic situation with altering vulnerability in both physiological (e.g. acute illness) and 
psychosocial (e.g. carer holiday) domains means that when trying to predict the likelihood of MRH 
considering the mere presence or absence of a risk factor may be too simplistic.  
 
6.2 Implications of this research 
This research has some key implications for the future management of MRH in relation to 
research, service development and education.  Firstly, from a research perspective, a better 
understanding of what is meant by MRH is required, starting with the definition applied.  In this 
study, MRH was a new term derived by a team of international experts as previous definitions 
were too narrow or too broad.  The development of a new term may be deemed unhelpful, 
however it aimed to capture two of the frequent types of harm seen in clinical practice, harm from 
an ADR and non-adherence to medicines.  Further work needs to be conducted to determine a 
term that is universally acceptable in both the academic and clinical arenas.   
 Consistent and robust measurement and classification of MRH is required to facilitate reliable 
identification and standardised documentation within the research and clinical environment.  At 
present causality assessments only focus upon ADRs and whilst they may reduce assessor 
disagreement, they are unable to quantify the contribution that a specific medicine made to the 
event or prove that there was a connection between the medicine and the event.239  Thus their 
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key role is to act as a guide to classifying the likelihood of a relationship between a medicine and 
an ADR.  Considering  MRH as a geriatric syndrome (for which polypharmacy is a significant risk 
factor but not the actual problem) may facilitate it’s formal classification as seen with the 
establishment of formal criteria to define other syndromes e.g. the use of the Diagnostic and 
Statistical Manuals for the classification of psychiatric disorders240, and so allow comparison of 
studies and pooling of results.  Standardisation of causality assessments, outcome definitions 
and preventability measures that have clinical utility are therefore required to facilitate high quality 
and valuable translational research of MRH in frail older adults. 
When considering MRH there is a need to embrace the environment in which the medicine is 
used and the factors which influence its use and the patient’s response.  This is likely to be 
complex, and where previous studies have mainly focussed on MRH within the hospital or causing 
hospitalisation, future research needs to be multi-sector with an emphasis upon the transitions of 
care, a particularly high-risk stage in care for older adults23,215.  The association of MRH with low 
hand grip, impaired nutritional status, depression, use of a MCA, multimorbidity and a high 
number of medicines suggests that patients with deficits across multiple domains are at an 
increased risk of experiencing MRH.  Further research is required to confirm these findings, and 
the study of potential interventions to reduce the risk of MRH should focus on the modification of 
these risks where possible.   
Secondly, from a service development and delivery perspective, the high incidence of MRH in 
frail older adults identified in this study suggests that it should be expected and considered as 
one of the differential diagnoses when an older adult taking medicines presents with a new 
symptom.  Two challenges are how to capture such data, and how to utilise it to inform and 
improve local practice.  As observed during the study, when patients were re-admitted with 
potential MRH the medicine would be altered, but it was infrequently documented as the cause 
or a contributor to the clinical condition of the patient.  ICD 10 codes are available for ADRs but 
they are many, 827 were identified in a systematic review of the medical literature, and there is 
great variability in their use241.  Consensus on the most appropriate codes to use, and the 
development of clinical standards incorporating recommendations for the accurate documentation 
of MRH, may facilitate future audits of practice and inform service improvement strategies.  
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Any service improvement strategy relating to MRH must recognise that it is a problem that 
transcends both health and social care services, and therefore interventions must reach beyond 
the limits of healthcare practices to incorporate social care.  The package of care was important 
not only with regards to the likelihood of a patient experiencing MRH, but also in how the patient 
responded to harm. The individuals responsible for the delivery of this care however receive very 
little training in the recognition or management of MRH.  Educating social care staff in the 
identification of those at risk, and providing a clear referral pathway may not prevent MRH, but 
could help in the early management of harm with a consequential reduction in severity. 
Where previous systems to identify and manage the risk of MRH have focused on prescribing 
criteria such as STOPP/START, thus providing a one-dimensional approach; new systems that 
consider the complexity of MRH and the importance of psychosocial variables in addition to the 
more traditional variables could better mitigate the risk of MRH.  Clinical pharmacists within 
general practice are ideally placed to advance the identification and management of risk through 
referrals from concerned patients, carers and health and social care workers; improved 
monitoring of medicines242 and;  the development of personalised care plans, an intervention 
which has demonstrated improved outcomes for patients with long term conditions243.  This form 
of individualised complex review, whilst time-consuming, considers the potential risk of MRH in a 
much broader context than looking at the medicines alone. This could help us move away from 
the MCA style blanket intervention, which from the findings of this study, and others233,234, does 
not universally support adherence and may, for some patients, increase the risk of MRH.  
However, for this to be achieved, MRH needs to be recognised as a priority and the resources 
necessary to develop and target interventions need to be made available. 
The MRH risk prediction model of the future needs to be a “live” system in order to capture a 
patient’s risk as it changes over time, and so minimise harm early through communication with 
multiple agencies across health and social care, and link to a referral system where red flags alert 
staff to potential MRH.  Advancement in information technology brings such interventions within 
reach and the outcomes of the SENATOR Project147, a pan-European collaboration which aims 
to develop and test a new software engine for the optimization of medical and non-drug therapy 
in older people with multimorbidity and polypharmacy, are eagerly anticipated.  The aim of this 
software is to provide non-specialist clinicians with evidence-based recommendations using a 
number of validated resources: STOPP/START (to identify potential inappropriate prescribing), 
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SafeScript (a database of drug-drug interactions), British National Formulary (a database of 
licensed indications), Cumulative Illness Rating Scale for Geriatrics (CIRS-G) to calculate the risk 
of death in the next year) and a tool to predict the risk of ADR.  The ADR risk prediction component 
will use either the GerontoNet model114, described earlier in this thesis in the systematic review, 
or a new prediction model developed by the research team, with selection based upon model 
accuracy.  The output of the software will be a bullet-point list of recommendations that the authors 
recognise will require clinical judgement, in conjunction with the patient, to determine the 
appropriate actions to take.  This software package commendably incorporates both process-
based interventions such as appropriate prescribing criteria, and a prediction model to identify 
those patients most at risk, in addition to targeting generalists who have the greatest contact with 
the high-risk older population but with minimal specialist training.  It is not yet known which ADR 
risk prediction model will be integrated into the software but should it be the GerontoNet model114 
then the psychosocial variables that may be an important component of identifying older adults 
at risk of MRH will be absent, bringing in to question the value of this system.  
When considering the implications of this research on education, geriatrics has not been a strong 
feature of medical or pharmacy training and a change in approach is required that extends beyond 
these two professions across the multidisciplinary team.  A qualitative analysis of 22 doctors in 
Ireland identified that a specific lack of geriatric pharmacotherapy training at an under and 
postgraduate level was a reason why potentially inappropriate prescribing occurs.244  Doctors 
were selected using a sampling matrix to ensure representativeness across grade (from 1st year 
qualified to consultant level); area of practice (10 were practicing in geriatrics and 12 in general 
medicines); and type of hospital where they work (large and small, public and voluntary/private 
hospitals).  They commented that although experiential learning is how they develop their 
prescribing skills, more specific structured training is also required as “there is no distinction made 
between older patients and the general adult population”.244  The Silver Book245, whilst focussing 
on urgent care needs of older adults, makes recommendations that are applicable outside of the 
emergency department, describing key skills and competencies, training and development for 
doctors, nurses, physiotherapists and occupational therapists.  The authors also recommend that 
additional training should extend to health care agencies, social services and community teams, 
and should preferably be undertaken jointly.  Positive outcomes have been reported from inter-
professional education (IPE)246 in the care of older people and so this would seem to be a valuable 
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approach.  The Older Persons’ Fellowship at King’s College London, sponsored by Health 
Education England, provides such a learning opportunity for senior nurses and allied health 
professionals working in older people’s services across England, with the aim of developing 
specialists and future leaders.  In accordance with the findings from this thesis that the risk factors 
for MRH extend beyond the patient’s comorbidities and medicines, education needs to extend 
beyond geriatric pharmacotherapy in order to equip health and social care professionals with the 
skills required to identify MRH and the associated potential risks.     
Unlike the medical and allied health professional, guidance for pharmacy education focussing on 
the care of older people appears to be lacking.  At an undergraduate level, pharmacy teaching 
often focuses on the single disease model with the development of clinical knowledge driven by 
guideline-based recommendations as opposed to the underpinning science.  In a complex older 
population where evidence-based medicine is limited, and multimorbidity common, making 
treatment recommendations is dependent upon the ability to work from first principles.  
Furthermore, the lack of education around the psychosocial influences on how medicines are 
used and the impact of an individual’s health beliefs on adherence and the risk of MRH need to 
be addressed.  At a postgraduate level, these skills need to be maintained, which some academic 
clinical pharmacy programmes achieve, however these tend to be aimed at hospital pharmacists.  
Community pharmacists, whose daily workload will frequently involve interactions with complex 
older adults and their carers through the supply of medicines for long-term conditions, are not 
adequately catered for. 
Clinical pharmacists in GP practices will need to be knowledgeable in the intricacies of geriatric 
pharmacy as a substantial proportion of their work is likely to focus on the review of complex and 
potentially frail older adults.  A useful professional curriculum developed by the Royal 
Pharmaceutical Society Faculty, with the support of the UK Clinical Pharmacist’s Association and 
endorsed by the British Geriatrics Society is available, but is aimed at those practicing at an 
advanced level, leaving a gap in the training of those beginning to consult within general practice.  
This research calls for consultant pharmacists with expertise in the care of older people, and an 
understanding of the complex interaction between health and social care, and physiological and 
psychosocial risk variables for MRH, to support and advise the development of a curriculum which 
incorporates the management of medicine in older adults at all stages of a pharmacist’s career.   
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The incidence of MRH and associated costs2,247, especially in the older population (which is the 
fastest growing segment of society248), would suggest that MRH should become one of the public 
health priorities for the country.  Adequate resources may then become available to tackle the 
challenge of polypharmacy, multimorbidity and the accompanying MRH from a research, service 
development and educational perspective.    
 
6.3 Future work 
This study identified a high incidence of MRH and several variables, some not previously 
investigated in relation to MRH, which potentially increase the likelihood of MRH in a frail older 
population following an acute hospital admission.  It also suggests that MRH risk needs to be 
considered in the context of impaired physiological and psychosocial systems. These findings 
need to be confirmed in a larger population where we need to ensure the adequate blinding of 
those classifying the final outcome, and the use of standardised definitions.   
Of primary importance with regards to future work in the area of MRH in older adults is the need 
to gain international consensus on clear definitions. This work would include definitions for the 
preventability and severity of harm due to medicines, and classification strategies that are 
reproducible and applicable across research and clinical practice.  There are many causality 
assessment tools available in the literature, each with advantages and disadvantages249 but none 
of which are validated in older adults or used routinely in clinical practice.  They are arguably not 
appropriate for modern clinical research, especially those measures which incorporate a 
medicines re-challenge or use of placebo, such as the Naranjo algorithm.  This algorithm also 
does not allow for drug-drug interactions to be the cause of ADRs which is problematic in an older 
population where polypharmacy is common, and the potential for drug-drug interactions high.  The 
involvement of subject area experts from healthcare, social care and research sectors, using a 
process such as a Delphi technique, may help to develop suitable definitions and assessment 
criteria and so increase the value of further research in the area.  
This study proposed MRH as a geriatric syndrome.  Merely exploratory in nature, it did not intend 
to demonstrate any cause and effect, and before causal pathways can be researched further, 
work is required to establish the associations between both psychosocial variables as well as 
those which are predictive of geriatric syndromes.  Further analysis of the data collected for this 
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study could have been conducted, however this would have been post-hoc “fishing” subject to 
over interpretation. A future research study should expand upon the hypothesis-generating work 
conducted here using a larger patient sample, and in a population with varying degrees of frailty, 
measured and sampled in a more robust manner.  
To further test the conceptual framework, expansion of the work conducted by Cullinan and 
colleagues156 to determine if a FI could identify those at risk of MRH in the outpatient setting is 
recommended.  The implementation of the electronic FI within general practice and the utilisation 
of clinical pharmacists in general practice to identify post-discharge MRH during medicines 
reviews could facilitate such a study.  The associations of the FI with MRH should be compared 
to routine clinical judgements of doctors and pharmacists in order to determine any superiority in 
terms of predictive ability.    
Research into appropriate interventions to reduce MRH should be attempted however it is 
important that the dynamic nature of frailty, and thus MRH, is considered as it is unlikely that a 
single intervention, at a single point in time will prove to be effective.  As the only consistent 
predictor of MRH, the starting point for interventional research may focus around managing 
polypharmacy and embracing comprehensive medicines reviews, which incorporate the concept 
of deprescribing, as part of individualised care planning.  The risk versus benefit of particular 
medicines for each patient is likely to change over time, and so an exploration of the most 
appropriate frequency for review is also required.   
Due to the lack of involvement of older adults in clinical trials, data pertaining to the benefit of 
commonly prescribed medicines is little known in this population.  Future studies using big data 
(such as HES data) may help to develop an understanding of the benefits by reporting numbers 
needed to treat (NNT), but understanding the risk benefit ratio is likely to be more challenging.  
The risk of harm from medicines in older adults needs to be considered at an individual patient 
level due to the complexity of MRH.  Therefore, if a true risk benefit analysis is to be undertaken 
then we need to focus on the likely benefits of treatment for that specific older patient, so that the 
risk can be judged against this.  Furthermore, for research at a population and individual patient 
level, appropriate outcome measures need to be defined; where increased survival may be 
perceived as an optimal outcome by a clinician, this may not be the priority of an older patient.  
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Adopting this patient focussed approach may ultimately reduce the number of medicines an older 
person is prescribed and so reduce the risk of MRH.   
As identified in previous work215, and observed in this study, poor communication across the 
healthcare interface can contribute to MRH and so reviewing the system-based challenges which 
hinder good communication between care settings and care teams is required.  Where 
appropriate, this may involve supporting the patient to become the custodian of information about 
their medicines through use of, for example, a medication passport250.  It will be necessary 
however to recognise that the patient themselves may not always be the most appropriate 
recipient of information.  As was identified in this study, patients are often not responsible for their 
medicines. Identification of the most suitable person to communicate with regarding medicines-
related information is important, especially at a time of great change such as hospital discharge.  
A recent study found that informal caregiver integration during the discharge planning of older 
adults reduced hospital re-admission.251  
Finally, an exploration of the potential utilisation of future technologies may transform the way in 
which medicines and their associated risks are managed.  We are now living in the connected 
age where the internet of things, (the interconnection via the internet of computing devices 
embedded in everyday objects thus allowing them to send and receive data and therefore be 
controlled remotely), is rapidly expanding.  Industry leaders, such as Nokia, have identified the 
potential financial gains to be made from the healthcare market and support the development of 
assisted living technologies.  An example of a connected assisted living device is the Pivotell 
compliance aid which can dispense pills up to 24 times a day and notify a designated contact via 
email, or text, if a scheduled dose has not been removed252.  Experts in the care of older people 
may immediately see potential flaws with such a system.  It is therefore crucial that they engage 
with technology developers to facilitate maximum gains for the patient and health and social care 
systems from industry investments, and to ensure such interventions are adequately researched 






Deficits in both physiological and psychosocial systems are contributors to the likelihood of MRH, 
as are the protective mechanisms which are employed by care givers, health professionals and 
the patient themselves.  As a consequence, significant variability exists within this population and 
the clinical nuances of age heterogeneity may not permit the use of risk prediction in this 
population.  The House of Lords criticised the preparedness of the health service to cope with an 
ageing population.44  To address this criticism, instead of striving to develop predictive models, 
the emphasis should be placed upon identifying those who are vulnerable to adverse events and 
developing individual treatment plans which not only meet the inter-individual variability but the 
intra-individual variability of risk that is presented over time.  Focussing on medicines related 
harm, and changing the approach taken to the prescribing and review of medicines is required.  
This study confirms the potential harm that medicines can cause in older patients and therefore 
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Appendix C. List of potential variables for collection 
Risk Factor 














Essential  Desirable 
Not 
required 
Adm D/C Other  (✓/) 
Medications   
Prescription Only Medications (POMs)              
Over the Counter Medications (OTC)              
When required medications (PRNs)              
Once only medications (STAT)              
Fluids              
Blood products              
Medication Name              
Dose              
Frequency              
Number of doses per day              
Route of admin              
Duration (Acute/Chronic)              
Change in medication              
Medication Classification              
Total number of medications              
Use of compliance aid              
Regular community pharmacist              
Who administers meds              
Patient/carer knowledge of the medication              
Problems with medications - missed doses, side effects, 
running out 




Patient thinks drug was responsible for admission              


















Essential  Desirable 
Not 
required 
Adm D/C Other  (✓/) 
Appropriate monitoring of medications e.g. warfarin at 
anticoag clinic           
  
Number of prescribers (i.e. cross specialities)              
Social   
Marital status              
Living arrangements (i.e. alone, with spouse, with family, 
RH, NH)          
    
Smoking status              
Alcohol consumption              
Home nursing care              
Monthly income              
Volunteer work              
Attendence at daycare centre              
Number of times patient able to leave the house in the 
past 3 months as a result of their own efforts 
         
    
Education (primary, secondary, tertiary)              
ADL - need for assistance with one or more tasks: eating, 
dressing bathing transferring, toileting 
         
    
Family support              
Care package              
Biochemistry  
Hb              
RBC              
PCV              
MCV              
MCH              
MCHC              


















Essential  Desirable 
Not 
required 
Adm D/C Other  (✓/) 
WCC              
Neutrophils              
Lymphocytes              
Monocytes              
Eosinophils              
Basophils              
Platelets              
MPV              
Troponin              
CRP              
Creatinine              
Urea              
Potassium              
Sodium              
eGFR              
ALT              
AST              
ALP              
TBIL              
GGT              
Albumin              
INR              
APTT              
Vit B12              
Folate              
Iron              


















Essential  Desirable 
Not 
required 
Adm D/C Other  (✓/) 
LDL              
HDL              
Blood glucose              
HbA1C              
Measured serum drug concentration              
Medical  
Presenting complaint              
Diagnosis on admission              
Diagnosis on discharge             
Cause of hospitalisation (ADE v non-ADE)             
Number of acute medical problems             
Number of past medical problems             
Co-morbidities             
Number of co-morbidities             
Number of hospital admissions in past 12 months 
 
           
Number of different visits to clinic in past 12 months 
 
           
Number of different visits to hospital (outpatients) in last 
12 months  
           
Last doctor attended (GP or hospital doctor)             
Number of visits to GP in past year             
Length of hospital stay             
Self-reported health over last year             
Weight/height ratio             
Nutrition             


















Essential  Desirable 
Not 
required 
Adm D/C Other  (✓/) 
Recent nausea/vomiting/diarrhoea             
Temperature             
Pulse             
Blood pressure             
Hearing eyesight             
Mental/cognitive status             
Renal failure             
Indicators of physical function             
Falls             
Ischaemic heart disease             
Diabetes             
Infections             
Acute stroke             
Liver disease             
Congestive cardiac failure             
Angina              
COPD             
Hyperlipidaemia             
Other  
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